

Cancer

PRESENTED BY AMERICA'S BIOPHARMACEUTICAL RESEARCH COMPANIES

Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer

Few things cause patients more fear and apprehension than a cancer diagnosis. But today—because of early detection and a steady stream of new and improved treatments—cancer increasingly can be managed and even beaten. President Obama has called for a cancer cure in our lifetime, patients and their families are looking for more and better treatments, and America's pharmaceutical research and biotechnology companies are responding.


Biopharmaceutical researchers are now working on 887 medicines for cancer. Many are high-tech weapons to fight the disease, while some involve innovative research into using existing medicines in new ways.

The medicines in development—all in either clinical trials or under Food and Drug Administration review—include among others 98 for lung cancer, the leading cause of cancer death in the United States, and 91 for breast cancer, which is expected to strike more than 200,000 American women each year. The medicines in development also include 80 for prostate cancer, which is expected to kill more than 32,000 American men each year, and 55 for colorectal cancer, the third most common cancer in both men and women in this country.

A deep commitment to patients and research is at the core of the remarkable progress made in fighting cancer that has led to declines in cancer deaths. According to the National Cancer Institute, cancer deaths in the United States decreased 1.6 percent per year from 2001-2006. Meanwhile, the number of cancer survivors living in the United States has increased from 3 million in 1971 to 11.7 million in 2007. The increase in survivors is attributed in large measure to earlier diagnosis and detection and better treatments and follow-up care.

America's pharmaceutical research companies are working on many new cutting edge approaches to fight cancer. They include:

- A medicine that interferes with the metabolism of cancer cells by depriving them of energy from glucose.
- A medicine designed to induce a powerful immune response to melanoma.
- A potential first-line treatment (meaning it's given to patients before any other treatment) and first-in-class

MEDICINES IN DEVELOPMENT FOR CANCER*

*Some medicines are listed in more than one category.

medicine designed to target specific cancer cells and kill them, then activate the patient's general immune system to destroy any remaining cancer cells.

- A therapy that uses new nanotechnology that enhances the delivery of medicine to the patient, overcoming obstacles in existing treatments.

Despite progress, cancer remains the second leading cause of death by disease in the United States, exceeded only by heart disease. In 2010, some 569,490 Americans were expected to die of cancer—more than 1,500 people a day. The hundreds of new medicines to treat cancer now being developed by the biopharmaceutical research industry demonstrate our commitment to meeting patient needs. They are our best hope for lessening the burden of cancer to patients, their families and society.

John Castellani
President and CEO
PhRMA

Medicines in Development for Cancer

BLADDER CANCER

| Product Name | Sponsor | Indication | Development Status* |
|--|--|---|--|
| Abraxane [®] albumin-bound paclitaxel | Celgene <i>Summit, NJ</i> | (see also lung, ovarian, pancreatic, skin) | Phase II (908) 673-9000 |
| AEZS-108 | AEterna-Zentaris <i>Warren, NJ</i> | (see also prostate) | Phase I/II (908) 626-5428 |
| apaziquone | Allergan <i>Irvine, CA</i> Spectrum Pharmaceuticals <i>Irvine, CA</i> | non-invasive bladder cancer (Fast Track) | Phase III (949) 788-6700 |
| BC-819 | BioCancell Therapeutics <i>Jerusalem, Israel</i> | (see also ovarian, pancreatic) | Phase II www.biocancell.com |
| CDX-1307 | Celldex Therapeutics <i>Needham, MA</i> | first-line bladder cancer | Phase II (781) 433-0771 |
| Chemophase [™] hyaluronidase | Halozyne Therapeutics <i>San Diego, CA</i> | superficial bladder cancer | Phase I/II completed (858) 794-8889 |
| EN3348 | Endo Pharmaceuticals <i>Chadds Ford, PA</i> | (Fast Track) | Phase III (610) 558-9800 |
| Erbix [®] cetuximab | Bristol-Myers Squibb <i>Princeton, NJ</i> Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i> | (see also breast, head/neck, lung) | Phase II (212) 546-4000 (800) 545-5979 (212) 645-1405 |
| eribulin (E7389) | Eisai <i>Woodcliff Lake, NJ</i> | (see also lung, prostate, sarcoma) | Phase II (888) 422-4743 |
| Foloty [®] pralatrexate (Orphan Drug) | Allos Therapeutics <i>Westminster, CO</i> | (see also breast, lung, lymphoma) | Phase II (303) 426-6262 |
| OGX-427 | Oncogenex Pharmaceuticals <i>Bothell, WA</i> | (see also breast, lung, ovarian, prostate) | Phase I (425) 686-1500 |
| Tarceva [®] erlotinib | Genentech <i>South San Francisco, CA</i> OSI Pharmaceuticals <i>Melville, NY</i> | (see also brain, breast, colorectal, head/neck, leukemia, liver, lung, other) | Phase II (650) 224-1000 (800) 572-1932 |
| tesetaxel | Genta <i>Berkeley Heights, NJ</i> | advanced bladder cancer (see also breast, prostate, skin, stomach) | Phase II (908) 286-9800 |
| VB4-845 | Viventia Biotechnologies <i>Mississauga, Canada</i> | (see also head/neck) | Phase II (905) 362-2973 |

* For more information about a specific medicine in this report, please call the telephone number listed.

BRAIN CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|--|--|---|
| 8H9 mAb | United Therapeutics <i>Silver Spring, MD</i> | (see also sarcoma, other) | Phase I (301) 608-9292 |
| ABT-888 (veliparib) | Abbott Laboratories <i>Abbott Park, IL</i> | (see also breast, colorectal, ovarian, prostate, skin, other) | Phase I (847) 937-6100 |
| AC480 | Ambit Biosciences <i>San Diego, CA</i> | glioma (see also solid tumors) | Phase I (858) 334-2100 |
| AEE788 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | glioblastoma multiforme | Phase I/II (888) 669-6682 |
| antineoplaston- AS2-1 IV (Orphan Drug) | Burzynski Research Institute <i>Houston, TX</i> | glioma | Phase II (713) 335-5697 |
| APN301 (hu14.18-IL2) | Apeiron Biologics <i>Vienna, Austria</i> | neuroblastoma (see also skin) | Phase II completed www.apeiron-biologics.com |
| AR-67 | Arno Therapeutics <i>Parsippany, NJ</i> | glioblastoma (see also other) | Phase I (862) 703-7170 |
| ARC-100 | Archer Biosciences <i>New York, NY</i> | glioblastoma, medulloblastoma, neuroblastoma (see also pancreatic, prostate, skin) | Phase II (616) 747-9090 |
| AT-101 | Ascenta Therapeutics <i>Malvern, PA</i> | glioblastoma (see also leukemia, lung, lymphoma, prostate, stomach) | Phase II (610) 408-0313 |
| AV-299 (ficlatuzumab) | AVEO Pharmaceuticals <i>Cambridge, MA</i> | recurrent glioblastoma (see also lymphoma, multiple myeloma, solid tumors) | Phase I (617) 299-5000 |
| Avastin [®] bevacizumab | Genentech <i>South San Francisco, CA</i> | first-line glioblastoma multiforme (see also breast, colorectal, lung, ovarian, other) | Phase III (650) 225-1000 |
| Azedra [™] iodine-labeled metaiodobenzyl- guanidine | Molecular Insight Pharmaceuticals <i>Cambridge, MA</i> | neuroblastoma in children (Fast Track) (see also other) | Phase II completed (617) 492-5554 |
| Azixa [™] verubulin | Myrexix <i>Salt Lake City, UT</i> | glioblastoma, metastatic brain cancer (Fast Track) (see also skin) | Phase II (801) 214-7800 |
| berubicin (Orphan Drug) | Reata Pharmaceuticals <i>Dallas, TX</i> | brain metastases, recurrent primary brain cancer | Phase II (972) 865-2200 |
| | | glioma | Phase I (972) 865-2200 |
| BIBW 2992 (afatinib) | Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i> | glioblastoma (see also breast, head/neck, lung) | Phase I/II (800) 243-0127 |
| BMS-844203 (VEGF R-2 adnectin) | Bristol-Myers Squibb <i>Princeton, NJ</i> | recurrent glioblastoma (see also colorectal, lung) | Phase II (212) 546-4000 |
| | | newly-diagnosed glioblastoma | Phase I (212) 546-4000 |

BRAIN CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|---|--|------------------------------------|
| ch14.18 mAb | United Therapeutics <i>Silver Spring, MD</i> | neuroblastoma in children | Phase III (301) 608-9292 |
| cilengitide (Orphan Drug) | EMD Serono <i>Rockland, MA</i> | newly diagnosed glioblastoma (see also lymphoma, prostate) | Phase III (800) 283-8088 |
| | | recurrent glioblastoma | Phase II (800) 283-8088 |
| cintredekin besudotox (Orphan Drug) | NeoPharm <i>Lake Bluff, IL</i> | glioma (Fast Track) | Phase I (847) 887-0800 |
| Cotara [®] mAb TNT-1 (Orphan Drug) | Peregrine Pharmaceuticals <i>Tustin, CA</i> | recurrent glioblastoma (Fast Track) | Phase II (714) 508-6000 |
| CPP-1X (eflornithine) | Cancer Prevention Pharmaceuticals <i>Tucson, AZ</i> | neuroblastoma | Phase I (520) 908-7774 |
| DCVax [®] - Brain [®] brain cancer vaccine (Orphan Drug) | Northwest Biotherapeutics <i>Bothell, WA</i> | glioblastoma | Phase II (425) 608-3000 |
| dendritic cell cancer vaccine | TriMed Biotech <i>Vienna, Austria</i> | glioblastoma | Phase II www.trimed-biotech.com |
| GliAtak [™] gene therapy (Orphan Drug) | Advantagene <i>Auburndale, MA</i> | | Phase I/II (617) 916-5445 |
| GRN 1005 | Geron <i>Menlo Park, CA</i> | glioma, metastatic brain cancer | Phase I/II (650) 473-7700 |
| Hiltonol [®] poly-ICIC (Orphan Drug) | Oncovir <i>Washington, DC</i> | anaplastic astrocytoma, glioblastoma in adolescents and children | Phase II www.oncovir.com |
| Hycamtin [®] topotecan | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | metastatic brain cancer | Phase III (888) 825-5249 |
| ICT-107 (cancer vaccine) (Orphan Drug) | ImmunoCellular Therapeutics <i>Woodland Hills, CA</i> | glioblastoma | Phase II (818) 992-2907 |
| lenvatinib (E7080) | Eisai <i>Woodcliff Lake, NJ</i> | glioma (see also kidney, liver, ovarian, skin, other) | Phase II (888) 422-4743 |
| Levulan [®] Kerastick [®] aminolevulinic acid | DUSA Pharmaceuticals <i>Wilmington, MA</i> | (see also skin) | Phase II (978) 657-7500 |
| Lucanix [®] belagenpumatucel-L | NovaRx <i>San Diego, CA</i> | glioma (see also lung) | Phase I (858) 552-8600 |
| motexafin gadolinium | PharmacyClics <i>Sunnyvale, CA</i> | glioblastoma (combination therapy) | Phase II (408) 774-0330 |
| nimotuzumab (Orphan Drug) | YM Biosciences USA <i>Lehigh Valley, PA</i> | brain metastases from non-small-cell lung cancer (NSCLC), recurrent glioma (see also breast, prostate) | Phase II (610) 560-0600 |

BRAIN CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|--|---|--|
| patupilone (EPO906) | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | (see also liver) | Phase II (888) 669-6682 |
| PD-0332991 | Pfizer <i>New York, NY</i> | recurrent Rb-positive glioblastoma (see also breast, lymphoma, multiple myeloma, sarcoma) | Phase II (860) 732-5156 |
| perifosine (KRX-0401) | AEterna Zentaris <i>Montreal, Canada</i> Keryx Biopharmaceuticals <i>New York, NY</i> | glioma (see also colorectal, kidney, leukemia, lymphoma, multiple myeloma, ovarian, sarcoma, stomach) | Phase II (212) 531-5965 |
| prophage (vitespen) (Orphan Drug) | Agenus <i>Lexington, MA</i> | glioma (see also kidney, skin) | Phase II (781) 674-4400 |
| Reolysin [®] reovirus | Oncolytics Biotech <i>Calgary, Canada</i> | glioma (see also colorectal, head/neck, lung, pancreatic, sarcoma, skin) | Phase I/II (403) 670-7377 |
| rilatumumab | Amgen <i>Thousand Oaks, CA</i> | recurrent glioma (see also colorectal, lung, prostate, stomach) | Phase II (800) 772-6436 |
| rindopepimut (Orphan Drug) | Celldex Therapeutics <i>Needham, MA</i> | newly diagnosed glioblastoma (Fast Track) (see also solid tumors) | Phase II (860) 732-5156 |
| sagopilone | Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> | (see also breast, ovarian, prostate) | Phase II (888) 842-2937 |
| SB-313-xTZ | Sangamo Biosciences <i>Richmond, CA</i> | glioblastoma | Phase I (510) 970-6000 |
| SBG and cancer vaccine | Biotec Pharmacon <i>Tromsø, Norway</i> | neuroblastoma (pediatric) | Phase I/II www.biotec.no |
| SL-701 vaccine | Stemline Therapeutics <i>New York, NY</i> | | Phase I/II completed (212) 831-1111 |
| Sprycel [®] dasatinib | Bristol-Myers Squibb <i>Princeton, NJ</i> | glioblastoma (see also breast, colorectal, leukemia, lung, lymphoma, multiple myeloma, prostate, skin) | Phase I/II (212) 546-4000 |
| tandutinib (MLN518) | Millennium Pharmaceuticals <i>Cambridge, MA</i> | glioblastoma, glioma | Phase II (800) 390-5663 |
| Tarceva [®] erlotinib (Orphan Drug) | Genentech <i>South San Francisco, CA</i> OSI Pharmaceuticals <i>Melville, NY</i> | ependymoma, glioblastoma, late-stage brain metastases (see also bladder, breast, colorectal, head/neck, leukemia, liver, lung, other) | Phase II (650) 225-1000 (800) 572-1932 |
| terameprocol (intravenous) | Erimos Pharmaceuticals <i>Houston, TX</i> | glioma (see also cervical, head/neck, solid tumors, other) | Phase I/II (713) 541-2000 |
| Toca-511 (cytosine deaminase gene therapy) | Tocagen <i>San Diego, CA</i> | glioblastoma | Phase I/II (858) 412-8400 |

BRAIN CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|--|---|-----------------------------|
| Trisenox [®] arsenic trioxide | Cephalon <i>Frazer, PA</i> | glioma (see also leukemia, multiple myeloma) | Phase I (610) 344-0200 |
| VB-111 | VBL Therapeutics <i>Or Yehuda, Israel</i> | glioblastoma (see also other) | Phase I/II www.vblrx.com |
| Xeloda [®] capecitabine | Roche <i>Nutley, NJ</i> | newly-diagnosed glioma | Phase I (973) 235-5000 |

BREAST CANCER

| Product Name | Sponsor | Indication | Development Status |
|---|---|--|------------------------------|
| 18F-fluorothymidine | Merck <i>Whitehouse Station, NJ</i> | diagnosis of breast cancer | Phase II (800) 672-6372 |
| abiraterone acetate (CB7630) | Cougar Biotechnology <i>Raritan, NJ</i> | (see also prostate) | Phase I/II (800) 817-5286 |
| ABT-869 (linifarib) | Abbott Laboratories <i>Abbott Park, IL</i> | (see also colorectal, kidney, liver, lung) | Phase II (847) 937-6100 |
| ABT-888 (veliparib) | Abbott Laboratories <i>Abbott Park, IL</i> | (see also brain, colorectal, ovarian, prostate, skin, other) | Phase II (847) 937-6100 |
| acolibifene | EndoCeutics <i>Quebec City, Canada</i> | prevention of breast cancer | Phase II (418) 653-0033 |
| aderbasib (INCB7839) | Incyte <i>Wilmington, DE</i> | | Phase II (302) 498-6700 |
| AE-37 | Antigen Express <i>Worcester, MA</i> | (see also ovarian) | Phase II (508) 852-8783 |
| afimoxifene | ASCEND Therapeutics <i>Herndon, VA</i> | breast cancer prevention | Phase II (703) 471-4744 |
| Afinitor [®] everolimus | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | (see also kidney, liver, lymphoma, stomach, other) | Phase III (888) 669-6682 |
| AMG 386 | Amgen <i>Thousand Oaks, CA</i> | (see also colorectal, kidney, liver, ovarian, stomach, other) | Phase II (800) 772-6436 |
| AMG 479 (ganitumab) | Amgen <i>Thousand Oaks, CA</i> | (see also colorectal, lung, pancreatic, sarcoma, other) | Phase II (800) 772-6436 |
| anti-CD3 anti-HER/neu activated T-cells | TransTarget <i>Hillsborough, CA</i> | metastatic breast cancer | Phase II |
| ARRY-380 | Array BioPharma <i>Boulder, CO</i> | | Phase I (303) 381-6600 |
| AUY922 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | (see also colorectal, lung, multiple myeloma, stomach) | Phase II (888) 669-6682 |
| AV-951 (tivozanib) | AVEO Pharmaceuticals <i>Cambridge, MA</i> | (see also kidney, lung, stomach) | Phase I/II (617) 299-5000 |

BREAST CANCER

| Product Name | Sponsor | Indication | Development Status |
|---|---|---|------------------------------|
| Avastin® bevacizumab | Genentech South San Francisco, CA | first-line metastatic breast cancer (with Xeloda ®) (see also brain, colorectal, lung, other) | Phase III (650) 225-1000 |
| | | HER2-positive breast cancer (adjuvant therapy), triple-negative breast cancer (adjuvant therapy), HER2-negative breast cancer (adjuvant therapy) | Phase III (650) 225-1000 |
| | | first-line HER2-positive metastatic breast cancer (with Herceptin ®) | Phase III (650) 225-1000 |
| AZD8931 (erbB kinase inhibitor) | AstraZeneca Wilmington, DE | breast cancer (see also solid tumors) | Phase II (800) 236-9933 |
| BIBW 2992 (afatinib) | Boehringer Ingelheim Pharmaceuticals Ridgefield, CT | metastatic breast cancer (see also brain, head/neck, lung) | Phase III (800) 243-0127 |
| BKM120 | Novartis Pharmaceuticals East Hanover, NJ | (see also solid tumors) | Phase I/II (888) 669-6682 |
| BMS-690514 (HER/VEGFR2 inhibitor) | Bristol-Myers Squibb Princeton, NJ | metastatic breast cancer (see also lung) | Phase II (212) 546-4000 |
| BMS-754807 (IGF-1R antagonist) | Bristol-Myers Squibb Princeton, NJ | (see also solid tumors) | Phase II (212) 546-4000 |
| breast cancer vaccine | Quantum Immunologics Tampa, FL | | Phase I/II (866) 213-4594 |
| BTSCAN | Molecular Targeting Technologies West Chester, PA | diagnosis of breast cancer | Phase I (610) 738-7938 |
| BZL-101 | Bionovo Emeryville, CA | | Phase I (510) 601-2000 |
| CDX-011 | Celldex Therapeutics Needham, MA | (Fast Track) (see also skin) | Phase II (781) 433-0771 |
| CNF-2024 | Biogen Idec Weston, MA | (see also stomach) | Phase II (781) 464-2000 |
| dalotuzumab | Merck Whitehouse Station, NJ | (see also colorectal, lung, pancreatic, other) | Phase I/II (800) 672-6372 |
| dinaciclib | Merck Whitehouse Station, NJ | (see also leukemia, lung, lymphoma) | Phase II (800) 672-6372 |
| DPX-0907 | Immunovaccine Halifax, Canada | (see also ovarian, prostate) | Phase I (902) 492-1819 |

BREAST CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|--|---|--|
| Erbitux [®] cetuximab | Bristol-Myers Squibb <i>Princeton, NJ</i> Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i> | (see also bladder, head/neck, lung) | Phase II (212) 546-4000 (800) 545-5979 (212) 645-1405 |
| EVO 022 | Evolve Oncology <i>New York, NY</i> | | in clinical trials (646) 723-8941 |
| EVO 033 | Evolve Oncology <i>New York, NY</i> | | in clinical trials (646) 723-8941 |
| Exelbine [™] vinorelbine emulsion | ADVENTRX Pharmaceuticals <i>San Diego, CA</i> | (see also lung, lymphoma) | application submitted (858) 552-0866 |
| EZN-2208 | Enzon Pharmaceuticals <i>Bridgewater, NJ</i> | metastatic breast cancer (see also colorectal, solid tumors) | Phase II (908) 541-8600 |
| Folotyn [®] pralatrexate | Allos Therapeutics <i>Westminster, CO</i> | (see also bladder, lung, lymphoma) | Phase II (303) 426-6262 |
| ganetespiib | Synta Pharmaceuticals <i>Lexington, MA</i> | (see also colorectal, lung, stomach, other) | Phase II (781) 274-8200 |
| GDC-0941 (PI3 kinase inhibitor) | Genentech <i>South San Francisco, CA</i> | metastatic breast cancer (see also lung, lymphoma, solid tumors) | Phase I (650) 224-1000 |
| GDC-0980 (PI3 kinase/mTOR dual inhibitor) | Genentech <i>South San Francisco, CA</i> | late-stage breast cancer (see also lymphoma, solid tumors) | Phase I (650) 224-1000 |
| GRN-163L (imetelstat) | Geron <i>Menlo Park, CA</i> | (see also leukemia, lung, multiple myeloma) | Phase II (650) 473-7700 |
| GVAX [®] Breast | BioSante Pharmaceuticals <i>Lincolnshire, IL</i> | (see also colorectal, leukemia, multiple myeloma, pancreatic) | Phase I (847) 478-0500 |
| Herceptin [®] SC rHuPH20/ trastuzumab | Halozyme <i>San Diego, CA</i> Roche <i>Nutley, NJ</i> | HER2-positive breast cancer | Phase III (858) 794-8889 (973) 235-5000 |
| IMT-1012 (immunotherapeutic vaccine) | Immunotope <i>Doylestown, PA</i> | (see also ovarian) | Phase I (215) 253-4180 |
| iniparib (BSI-201) | BiPar Sciences <i>South San Francisco, CA</i> sanofi-aventis <i>Bridgewater, NJ</i> | metastatic triple negative breast cancer (see also lung, ovarian) | Phase III (800) 633-1810 |
| | | neoadjuvant breast cancer | Phase II (800) 633-1810 |
| Ixempra [®] ixabepilone | Bristol-Myers Squibb <i>Princeton, NJ</i> | early-stage breast cancer (see also lung, stomach, other) | Phase II/III (212) 546-4000 |
| KW-2450 | Kyowa Hakko Kirin Pharma <i>Princeton, NJ</i> | | Phase I/II (609) 919-1100 |

BREAST CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|--|---|--|
| LEP-ETU | NeoPharm <i>Lake Bluff, IL</i> | | Phase II (847) 887-0800 |
| LOR-2040 | Lorus Therapeutics <i>Toronto, Canada</i> | metastatic breast cancer (see also colorectal, kidney, leukemia) | Phase II (416) 798-1200 |
| Lymphoseek™ | Neoprobe <i>Dublin, OH</i> | diagnosis of breast cancer (see also head/neck, skin) | Phase III (800) 793-0079 |
| MK-0752 | Merck <i>Whitehouse Station, NJ</i> | (see also solid tumors) | Phase I (800) 672-6372 |
| MK-2206 | Merck <i>Whitehouse Station, NJ</i> | (see also colorectal, other) | Phase I (800) 672-6372 |
| MM-111 | Merrimack Pharmaceuticals <i>Cambridge, MA</i> | (see also solid tumors) | Phase I/II (617) 441-1000 |
| motesanib (AMG 708) | Amgen <i>Thousand Oaks, CA</i> Millennium Pharmaceuticals <i>Cambridge, MA</i> | (see also lung) | Phase II (800) 772-6436 (800) 390-5663 |
| Myocet™ doxorubicin liposomal | Spherion Therapeutics <i>Princeton, NJ</i> | (Fast Track) | Phase III (609) 986-2021 |
| neratinib (HKI272) | Pfizer <i>New York, NY</i> | early-stage breast cancer, late-stage breast cancer | Phase III (860) 732-5156 |
| NeuVax™ E75 cancer vaccine | Apthera <i>Scottsdale, AZ</i> | (see also prostate) | Phase II www.apthera.com |
| Nexavar® sorafenib | Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> Onyx Pharmaceuticals <i>Emeryville, CA</i> | (see also colorectal, kidney, liver, lung, ovarian, other) | Phase II (888) 842-2937 (510) 597-6500 |
| nimotuzumab | YM Biosciences USA <i>Lehigh Valley, PA</i> | (see also brain, prostate) | Phase I completed (610) 560-0600 |
| NK-012 | Nippon Kayaku <i>Tokyo, Japan</i> | (see also lung) | Phase II |
| NKTR-102 | Nektar Therapeutics <i>San Francisco, CA</i> | (see also colorectal, ovarian) | Phase II (415) 482-5300 |
| NOV-002 | Novelos Therapeutics <i>Newton, MA</i> | early-stage breast cancer (see also ovarian) | Phase II (617) 244-1616 |
| OBP-301 | Oncolys Biopharma <i>Tokyo, Japan</i> | (see also head/neck, lung) | Phase I www.oncolys.com |
| OGX-427 | Oncogenex Pharmaceuticals <i>Bothell, WA</i> | (see also bladder, lung, ovarian, prostate) | Phase I (425) 686-1500 |
| OPT-822/OPT-821 | Optimer Pharmaceuticals <i>San Diego, CA</i> | | Phase I (858) 909-0736 |

BREAST CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|---|--|---|
| PD-0332991 | Pfizer <i>New York, NY</i> | (see also brain, lymphoma, multiple myeloma, sarcoma) | Phase I/II (860) 732-5156 |
| pertuzumab (RG 1273) | Roche <i>Nutley, NJ</i> | first-line metastatic HER2-positive breast cancer | Phase III (973) 235-5000 |
| | | early HER2-positive breast cancer, metastatic breast cancer | Phase II (973) 235-5000 |
| PF-01367338 | Pfizer <i>New York, NY</i> | (see also ovarian, skin) | Phase II (860) 732-5156 |
| Pixuvri™ pixantrone | Cell Therapeutics <i>Seattle, WA</i> | metastatic breast cancer (see also lymphoma) | Phase II (800) 215-2355 |
| PTC299 | PTC Therapeutics <i>South Plainfield, NJ</i> | (see also skin, solid tumors, other) | Phase I/II (908) 222-7000 |
| PX-1032 (HER2 breast cancer vaccine) | BN ImmunoTherapeutics <i>Mountain View, CA</i> | | Phase I (650) 681-4660 |
| Quinamed® amonafide | ChemGenex Pharmaceuticals <i>Menlo Park, CA</i> | (see also ovarian, prostate) | Phase II (650) 474-9800 |
| ramucirumab (IMC-1121B) | Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i> | (see also colorectal, liver, lung, stomach) | Phase III (800) 545-5979 (212) 645-1405 |
| Reximmune-C™ personalized cancer vaccine | Epeius Biotechnologies <i>San Marino, CA</i> | | Phase I/II (626) 441-6695 |
| Rexin-G™ tumor-targeted gene therapy | Epeius Biotechnologies <i>San Marino, CA</i> | recurrent, refractory metastatic breast cancer (see also pancreatic, sarcoma) | Phase I/II (626) 441-6695 |
| ridaforolimus | Merck <i>Whitehouse Station, NJ</i> | (see also lung, sarcoma) | Phase II (800) 672-6372 |
| sagopilone | Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> | (see also brain, ovarian, prostate) | Phase II completed (888) 842-2937 |
| SAR256212 (MM-121) | Merrimack Pharmaceuticals <i>Cambridge, MA</i> sanofi-aventis <i>Bridgewater, NJ</i> | (see also ovarian, solid tumors) | Phase II (617) 441-1000 (800) 633-1810 |
| SF1 (sonodynamic therapy) | SonneMed <i>Boston, MA</i> | advanced breast cancer | Phase I/II www.sonnemed.com |
| SNDX-275 (entinostat) | Syndax Pharmaceuticals <i>Waltham, MA</i> | (see also colorectal, leukemia, lymphoma, lung) | Phase II (781) 419-1400 |
| Sprycel® dasatinib | Bristol-Myers Squibb <i>Princeton, NJ</i> | (see also brain, colorectal, leukemia, lung, lymphoma, multiple myeloma, prostate, skin) | Phase II (212) 546-4000 |

BREAST CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|--|--|---|
| Tarceva [®] erlotinib | Genentech South San Francisco, CA OSI Pharmaceuticals Melville, NY | (see also bladder, brain, colorectal, head/neck, leukemia, liver, lung, other) | Phase II (650) 224-1000 (800) 572-1932 |
| TAS-108 | Taiho Pharma USA Princeton, NJ | | Phase II (609) 750-5300 |
| tesetaxel | Genta Berkeley Heights, NJ | advanced breast cancer (see also bladder, prostate, skin, stomach) | Phase II (908) 286-9800 |
| ThermoDox [®] LTSDEL | Celsion Columbia, MD | recurrent breast cancer (see also liver) | Phase I/II (410) 290-5390 |
| trabectedin | Johnson & Johnson Pharmaceutical Research & Development Raritan, NJ | metastatic breast cancer (see also ovarian, prostate, sarcoma) | Phase III (800) 817-5286 |
| trastuzumab-DM1 | Roche Nutley, NJ | advanced metastatic HER2-positive breast cancer, metastatic HER2- positive breast cancer ----- early HER2-positive breast cancer | Phase III (973) 235-5000 Phase II (973) 235-5000 |
| Tykerb [®] lapatinib | GlaxoSmithKline Rsch. Triangle Park, NC | breast cancer (adjuvant therapy) (see also head/neck, stomach) | Phase III (888) 825-5249 |
| Votrient [®] pazopanib and Tykerb [®] lapatinib | GlaxoSmithKline Rsch. Triangle Park, NC | inflammatory breast cancer (see also kidney, ovarian, sarcoma) | Phase III (888) 825-5249 |
| WX-671 | Wilex Munich, Germany | metastatic breast cancer | Phase II www.wilex.com |
| YM-155 | Astellas Pharma US Deerfield, IL | (see also lymphoma) | Phase II (800) 727-7003 |
| ZIO-301 (indibulin) | ZIOPHARM Oncology New York, NY | late-stage breast cancer | Phase I/II (646) 214-0700 |
| Zolinza [®] vorinostat | Merck Whitehouse Station, NJ | (see also multiple myeloma, other) | Phase II (800) 672-6372 |

CERVICAL CANCER

| Product Name | Sponsor | Indication | Development Status |
|--------------------------------|-----------------------------------|------------------------------------|--------------------------------------|
| ADXS-11001 | Advaxis North Brunswick, NJ | cervical intraepithelial neoplasia | Phase II (732) 545-1590 |
| interferon alpha-2b topical | Helix BioPharma Aurora, Canada | cervical dysplasia | Phase II completed (905) 841-2300 |
| PM-00104 | PharmaMar USA Cambridge, MA | (see also other) | Phase II (617) 868-3797 |

CERVICAL CANCER

| Product Name | Sponsor | Indication | Development Status |
|--------------------------------|--|---|-----------------------------|
| PV701 | Wellstat Biologics <i>Gaithersburg, MD</i> | (see also colorectal) | Phase II (240) 631-2500 |
| terameprocol (intravaginal) | Erimos Pharmaceuticals <i>Houston, TX</i> | cervical intraepithelial neoplasia (see also brain, head/neck, solid tumors, other) | Phase II (713) 541-2000 |
| TG4001 | Transgene <i>Kensington, MD</i> | cervical intraepithelial neoplasia | Phase II (301) 816-5404 |
| V503 | Merck <i>Whitehouse Station, NJ</i> | cervical cancer prevention (see also other) | Phase III (800) 672-6372 |
| V505 | Merck <i>Whitehouse Station, NJ</i> | cervical cancer prevention | Phase II (800) 672-6372 |
| VGX-3100 | Inovio Pharmaceuticals <i>Blue Bell, PA</i> | cervical intraepithelial neoplasia | Phase II (267) 440-4200 |

COLORECTAL CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|---|--|---|
| ABT-869 (linifanib) | Abbott Laboratories <i>Abbott Park, IL</i> | (see also breast, kidney, liver, lung) | Phase II (847) 937-6100 |
| ABT-888 (veliparib) | Abbott Laboratories <i>Abbott Park, IL</i> | (see also brain, breast, ovarian, prostate, skin, other) | Phase II (847) 937-6100 |
| aflibercept (VEGF-trap) | sanofi-aventis <i>Bridgewater, NJ</i> Regeneron Pharmaceuticals <i>Tarrytown, NY</i> | second-line metastatic colorectal cancer (see also lung, prostate) | Phase III (800) 633-1610 (914) 345-7400 |
| | | ----- first-line colorectal cancer | Phase II (800) 633-1610 (914) 345-7400 |
| AMG 386 | Amgen <i>Thousand Oaks, CA</i> | metastatic colorectal cancer (see also breast, kidney, liver, ovarian, stomach, other) | Phase II (800) 772-6436 |
| AMG 479 (ganitumab) | Amgen <i>Thousand Oaks, CA</i> | (see also breast, lung, pancreatic, sarcoma, other) | Phase II (800) 772-6436 |
| ARQ-197 | ArQule <i>Woburn, MA</i> Daiichi Sankyo <i>Parsippany, NJ</i> | (see also kidney, liver, lung, pancreatic, sarcoma, other) | Phase II (781) 994-0300 (973) 944-2600 |
| AUY922 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | (see also breast, lung, multiple myeloma, stomach) | Phase I (888) 669-6682 |
| Avastin [®] bevacizumab | Genentech <i>South San Francisco, CA</i> | metastatic colorectal cancer (see also brain, lung, ovarian, other) | Phase III (650) 225-1000 |
| AVX701 | AlphaVax <i>Rsch. Triangle Park, NC</i> | colorectal cancer prevention in patients with CEA-expressing malignancies | Phase I/II (919) 595-0400 |

COLORECTAL CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|--|---|---|
| BAY 73-4506 (regorafenib) | Bayer HealthCare Pharmaceuticals Wayne, NJ | metastatic colorectal cancer (see also kidney, lung, stomach) | Phase III (888) 842-2937 |
| BMS-844203 (VEGF R-2 adnectin) | Bristol-Myers Squibb Princeton, NJ | (see also brain, lung) | Phase II (212) 546-4000 |
| BMS-908662 (RAF kinase inhibitor) | Bristol-Myers Squibb Princeton, NJ Exelixis South San Francisco, CA | (see also skin) | Phase I/II (212) 546-4000 |
| conatumumab | Amgen Thousand Oaks, CA | (see also lung, pancreatic, sarcoma) | Phase II (800) 772-6436 |
| CPX-1 | Celator Pharmaceuticals Princeton, NJ | | Phase II completed (609) 243-0123 |
| CS-7017 (efatutazone) | Daiichi Sankyo Parsippany, NJ | (see also lung, other) | Phase II (973) 944-2600 |
| CT-011 | CureTech Yavne, Israel | (see also leukemia, lymphoma) | Phase II www.curetechbio.com |
| dalotuzumab | Merck Whitehouse Station, NJ | (see also breast, lung, pancreatic, other) | Phase II (800) 672-6372 |
| Davanat [®] galactomannan C | Pro-Pharmaceuticals Newton, MA | (see also liver) | Phase II (617) 559-0033 |
| dulanermin (rhApo2L/TRAIL) | Amgen Thousand Oaks, CA Genentech South San Francisco, CA | (see also lymphoma) | Phase I (800) 772-6436 (650) 225-1000 |
| E7820 | Eisai Woodcliff Lake, NJ | | Phase I/II (888) 422-4743 |
| EMD 525797 (DI17E6) | EMD Serono Rockland, MA | | Phase II (800) 283-8088 |
| encapsulated cell therapy (macrobeads) | Rogosin Institute New York, NY | refractory metastatic colorectal cancer (see also pancreatic, prostate) | Phase II (212) 746-1225 |
| ensituximab | Neogenix Oncology Great Neck, NY | metastatic colorectal cancer (see also pancreatic) | Phase I (516) 482-1200 |
| EZN-2208 | Enzon Pharmaceuticals Bridgewater, NJ | metastatic colorectal cancer (see also breast, solid tumors) | Phase II (908) 541-8600 |
| Fusilev [™] levoleucovorin (ready-to-use formulation) | Spectrum Pharmaceuticals Irvine, CA | | application submitted (949) 788-6700 |
| ganetespiab | Synta Pharmaceuticals Lexington, MA | refractory metastatic colorectal cancer (see also breast, lung, stomach, other) | Phase II (781) 274-8200 |
| GI-4000 | GlobelImmune Louisville, CO | (see also lung, pancreatic) | Phase I (303) 625-2700 |

COLORECTAL CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|--|--|---|
| GVAX® Colorectal | BioSante Pharmaceuticals <i>Lincolnshire, IL</i> | (see also breast, leukemia, multiple myeloma, pancreatic) | Phase I (847) 478-0500 |
| IMO-2055 (EMD-1201081) | EMD Serono <i>Rockland, MA</i> Idera Pharmaceuticals <i>Cambridge, MA</i> | (see also head/neck, lung) | Phase I (800) 283-8088 (617) 679-5500 |
| Imprime PGG® | Biothera <i>Eagen, MN</i> | (see also leukemia, lung, skin) | Phase III (651) 675-0300 |
| JX-594 | Jennerex Biotherapeutics <i>San Francisco, CA</i> | (see also liver) | Phase II (415) 281-8886 |
| KRN-330 | Kyowa Hakko Kirin Pharma <i>Princeton, NJ</i> | | Phase I/II (609) 919-1100 |
| Litx™ talaporfin | Light Sciences Oncology <i>Bellevue, WA</i> | metastatic colorectal cancer | Phase III (425) 957-8900 |
| LOR-2040 | Lorus Therapeutics <i>Toronto, Canada</i> | metastatic colorectal cancer (see also breast, kidney, leukemia) | Phase II (416) 798-1200 |
| MK-2206 | Merck <i>Whitehouse Station, NJ</i> | (see also breast, other) | Phase II (800) 672-6372 |
| Nexavar® sorafenib | Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> Onyx Pharmaceuticals <i>Emeryville, CA</i> | (see also breast, kidney, liver, lung, ovarian, other) | Phase II (888) 842-2837 (510) 597-6500 |
| NKTR-102 | Nektar Therapeutics <i>San Francisco, CA</i> | (see also breast, ovarian) | Phase II/III (415) 482-5300 |
| OncoVAX® cancer vaccine | Vaccinogen <i>Frederick, MD</i> | stage II colorectal cancer (Fast Track) | Phase III (301) 668-8400 |
| perifosine (KRX-1401) | Aeterna Zentaris <i>Montreal, Canada</i> Keryx Biopharmaceuticals <i>New York, NY</i> | refractory, metastatic colorectal cancer (Fast Track) (see also brain, kidney, leukemia, lymphoma, multiple myeloma, ovarian, sarcoma, stomach) | Phase III (212) 531-5965 |
| picoplatin intravenous | Poniard Pharmaceuticals <i>San Francisco, CA</i> | (see also lung, ovarian, prostate) | Phase II (650) 583-3774 |
| polyclonal antibody stimulator | Cancer Advances <i>Durham, NC</i> | (see also pancreatic, stomach) | Phase II (919) 361-2162 |
| PV701 | Wellstat Biologics <i>Gaithersburg, MD</i> | (see also cervical) | Phase II (240) 631-2500 |
| ramucirumab (IMC-1121B) | Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i> | (see also breast, liver, lung, stomach) | Phase III (800) 545-5979 (212) 645-1405 |
| Reolysin® reovirus | Oncolytics Biotech <i>Calgary, Canada</i> | (see also brain, head/neck, lung, pancreatic, sarcoma, skin) | Phase I (403) 670-7377 |
| RIGScan® CR49 radiodiagnostic agent | Neoprobe <i>Dublin, OH</i> | diagnosis of metastatic colorectal cancer | application submitted (800) 793-0079 |

COLORECTAL CANCER

| Product Name | Sponsor | Indication | Development Status |
|---|---|--|--|
| rilotumumab | Amgen <i>Thousand Oaks, CA</i> | metastatic colorectal cancer (see also brain, lung, prostate, stomach) | Phase II (800) 772-6436 |
| SNDX-275 (entinostat) | Syndax Pharmaceuticals <i>Waltham, MA</i> | (see also breast, leukemia, lymphoma, lung) | Phase II (781) 419-1400 |
| Sprycel [®] dasatinib | Bristol-Myers Squibb <i>Princeton, NJ</i> | (see also brain, breast, leukemia, lung, lymphoma, multiple myeloma, prostate, skin) | Phase I (212) 546-4000 |
| Tarceva [®] erlotinib | Genentech <i>South San Francisco, CA</i> OSI Pharmaceuticals <i>Melville, NY</i> | (see also bladder, brain, breast, head/neck, leukemia, liver, lung, other) | Phase II (650) 224-1000 (800) 572-1932 |
| TAS-102 | Taiho Pharma USA <i>Princeton, NJ</i> | | Phase II (609) 750-5300 |
| telatinib | ACT Biotech <i>San Francisco, CA</i> | (see also stomach) | Phase I (415) 230-3900 |
| TF2 | Immunomedics <i>Morris Plains, NJ</i> | diagnosis of colorectal cancer | Phase I (973) 605-8200 |
| tigatuzumab | Daiichi Sankyo <i>Parsippany, NJ</i> | (see also liver, lymphoma, ovarian, pancreatic) | Phase I (973) 359-2600 |
| TNFerade [™] golnerminogene pradenovec | GenVec <i>Gaithersburg, MD</i> | (see also head/neck, skin, stomach) | Phase II (877) 943-6832 |
| Vectibix [®] panitumumab | Amgen <i>Thousand Oaks, CA</i> | first-line colorectal cancer, second-line colorectal cancer (see also head/neck) | Phase III (800) 772-6436 |

HEAD/NECK CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|--|----------------------------------|--|
| Alimta [®] pemetrexed | Eli Lilly <i>Indianapolis, IN</i> | | Phase III (800) 545-5979 |
| BIBW 2992 (afatinib) | Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i> | (see also brain, breast, lung) | Phase II (800) 243-0127 |
| Erbix [®] cetuximab | Bristol-Myers Squibb <i>Princeton, NJ</i> Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i> | (see also bladder, breast, lung) | Phase II (212) 546-4000 (800) 545-5979 (212) 645-1405 |
| foretinib | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | (see also kidney) | Phase II (888) 825-5249 |
| HF10 | Takara Bio <i>Shiga, Japan</i> | | Phase I www.takara-bio.com |

HEAD/NECK CANCER

| Product Name | Sponsor | Indication | Development Status |
|---|---|---|--|
| IMO-2055 (EMD-1201081) | EMD Serono Rockland, MA Idera Pharmaceuticals Cambridge, MA | (see also colorectal, lung) | Phase II (800) 283-8088 (617) 679-5500 |
| IRX-2 | IRX Therapeutics New York, NY | (Fast Track) | Phase II (212) 582-1199 |
| LymphoSeek™ | Neoprobe Dublin, OH | diagnosis of head/neck cancer (see also breast, skin) | Phase III (800) 793-0079 |
| Multikine® leukocyte interleukin | CEL-SCI Vienna, VA | | Phase III (703) 506-9460 |
| OBP-301 | Oncolys Biopharma Tokyo, Japan | (see also breast, lung) | Phase I www.oncolys.com |
| OncoVEX ^{GM-CSF} | BioVex Woburn, MA | (see also skin) | Phase III (781) 376-4900 |
| ProLindac™ polymer-DACH platinum conjugate | Access Pharmaceuticals Dallas, TX | | Phase II (214) 905-5100 |
| Reolysin® reovirus | Oncolytics Biotech Calgary, Canada | (see also brain, colorectal, lung, pancreatic, sarcoma, skin) | Phase III (403) 670-7377 |
| Tarceva® erlotinib | Genentech South San Francisco, CA OSI Pharmaceuticals Melville, NY | (see also bladder, brain, breast, colorectal, leukemia, liver, lung, other) | Phase II (650) 224-1000 (800) 572-1932 |
| TAS-106 | Taiho Pharma USA Princeton, NJ | | Phase II (609) 750-5300 |
| terameprocol (intravaginal) | Erimos Pharmaceuticals Houston, TX | (see also brain, cervical, solid tumors, other) | Phase I (713) 541-2000 |
| TNFerade™ | GenVec Gaithersburg, MD | (see also colorectal, pancreatic, skin, stomach) | Phase I/II (240) 632-0740 |
| Tykerb® lapatinib | GlaxoSmithKline Rsch. Triangle Park, NC | (see also brain, stomach) | Phase III (888) 825-5249 |
| VB4-845 (Orphan Drug) | Viventia Biotechnologies Mississauga, Canada | (Fast Track) (see also bladder) | Phase II (905) 362-2973 |
| Vectibix® panitumumab | Amgen Thousand Oaks, CA | locally advanced head/neck cancer (see also colorectal) | Phase II (800) 772-6436 |
| zalutumumab | Genmab Princeton, NJ | (Fast Track) | Phase II (609) 430-2481 |

KIDNEY CANCER

| Product Name | Sponsor | Indication | Development Status |
|------------------------|--|---|--|
| ABT-869 (linifarib) | Abbott Laboratories Abbott Park, IL | (see also breast, colorectal, liver, lung) | Phase II (847) 937-6100 (650) 225-1000 |

KIDNEY CANCER

| Product Name | Sponsor | Indication | Development Status |
|----------------------------------|--|--|---|
| Afinitor® everolimus | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | tuberous sclerosis complex angiomyolipomas (see also breast, liver, lymphoma, stomach, other) | Phase II (888) 669-6682 |
| AGS-003 | Argos Therapeutics <i>Durham, NC</i> | | Phase II (919) 287-6300 |
| AGS-16M8F | Agensys <i>Santa Monica, CA</i> Astellas Pharma US <i>Deerfield, IL</i> | | Phase I (800) 695-4321 |
| AMG 386 | Amgen <i>Thousand Oaks, CA</i> | (see also breast, colorectal, liver, ovarian, stomach, other) | Phase II (800) 772-6436 |
| ARQ-197 | ArQule <i>Woburn, MA</i> Daiichi Sankyo <i>Parsippany, NJ</i> | (see also colorectal, liver, lung, pancreatic, sarcoma, other) | Phase II (781) 994-0300 (973) 944-2600 |
| AV-951 (tivozanib) | AVEO Pharmaceuticals <i>Cambridge, MA</i> | (see also breast, lung, stomach) | Phase III (617) 299-5000 |
| axitinib | Pfizer <i>New York, NY</i> | (see also lung, other) | Phase III (860) 732-5156 |
| BAY 73-4506 (regorafenib) | Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> | (see also colorectal, lung, stomach) | Phase II (888) 842-2937 |
| BNC 105 | Bionomics <i>Thebarton, Australia</i> | | Phase II www.bionomics.com.au |
| CA9-SCAN | Wilex <i>Munich, Germany</i> | diagnosis of kidney cancer | Phase III completed www.wilex.com |
| CYT-107 | Cytheris <i>Rockville, MD</i> | (see also leukemia, skin, solid tumors) | Phase I (301) 231-0450 |
| EC-17 | Endocyte <i>West Lafayette, IN</i> | | Phase II (765) 463-7175 |
| foretinib | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | papillary renal cell carcinoma (see also head/neck) | Phase II (888) 825-5249 |
| GC-1008 (fresolimumab) | Genzyme <i>Cambridge, MA</i> | (see also skin) | Phase I (617) 252-7000 |
| lenvatinib (E7080) | Eisai <i>Woodcliff Lake, NJ</i> | renal cell carcinoma (see also brain, liver, ovarian, skin, other) | Phase I/II (888) 422-4743 |
| LOR-2040 (Orphan Drug) | Lorus Therapeutics <i>Toronto, Canada</i> | metastatic kidney cancer (see also breast, colorectal, leukemia) | Phase II (416) 798-1200 |
| MDX-1203 (anti-CD70 ADC) | Bristol-Myers Squibb <i>Princeton, NJ</i> | (see also lymphoma) | Phase I (212) 546-4000 |
| naptumomab estafenatox | Active Biotech <i>Lund, Sweden</i> | (see also lung, pancreatic) | Phase I completed www.activebiotech.com |

KIDNEY CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|--|---|---|
| Nexavar® sorafenib | Bayer HealthCare Pharmaceuticals Wayne, NJ Onyx Pharmaceuticals Emeryville, CA | adjuvant therapy (see also breast, colorectal, liver, lung, ovarian, other) | Phase III (888) 842-2837 (510) 597-6500 |
| OSI-027 | OSI Pharmaceuticals Melville, NY | (see also lymphoma) | Phase II (800) 572-1932 |
| perifosine (KRX-0401) | AEterna Zentaris Montreal, Canada Keryx Biopharmaceuticals New York, NY | (see also brain, colorectal, leukemia, lymphoma, multiple myeloma, ovarian, sarcoma, stomach) | Phase II (212) 531-5965 |
| prophage (vitespen) (Orphan Drug) | Agenus Lexington, MA | (Fast Track) (see also brain, skin) | Phase II (781) 674-4400 |
| Rencarex® girentuximab (Orphan Drug) | Wilex Munich, Germany | non-metastatic, clear cell renal cell carcinoma | Phase III www.wilex.com |
| SGN-75 | Seattle Genetics Bothell, WA | renal cell carcinoma (see also lymphoma) | Phase I (425) 527-4000 |
| Sutent® sunitinib | Pfizer New York, NY | adjuvant therapy (see also pancreatic) | Phase III (860) 732-5156 |
| talactoferrin (Orphan Drug) | Agennix Houston, TX | (Fast Track) (see also lung) | Phase II (713) 552-1091 |
| Torisel® temsirolimus (Orphan Drug) | Pfizer New York, NY | combination therapy | Phase III (860) 732-5156 |
| tremelimumab (CP-675206) | Pfizer New York, NY | (see also pancreatic, skin, stomach, other) | Phase II (860) 732-5156 |
| vegin (VEGF antisense) | VasGene Therapeutics Los Angeles, CA | (see also lung, skin) | Phase I (323) 221-7818 |
| Votrient® pazopanib | GlaxoSmithKline Rsch. Triangle Park, NC | (see also breast, ovarian, sarcoma) | Phase III (888) 825-5249 |

LEUKEMIA

| Product Name | Sponsor | Indication | Development Status |
|-------------------------|---|---|------------------------------|
| ABIO05/01 (TALL-104) | Abiogen Pharma Pisa, Italy | chronic myeloid leukemia (CML) | Phase II |
| AC430 | Ambit Biosciences San Diego, CA | | Phase I (858) 334-2100 |
| AEG-35156 | Aegera Therapeutics Montreal, Canada | acute myeloid leukemia (AML) (see also lymphoma) | Phase II (514) 288-5532 |
| | | chronic lymphocytic leukemia (CLL) | Phase I/II (514) 288-5532 |

LEUKEMIA

| Product Name | Sponsor | Indication | Development Status |
|---|--|---|---|
| Aezea® cenersen (Orphan Drug) | Eleos <i>Omaha, NE</i> | AML | Phase II completed (402) 393-3034 |
| afutuzumab (GA101/RG7159) | Biogen Idec <i>Cambridge, MA</i> Roche <i>Nutley, NJ</i> | CLL (see also lymphoma) | Phase III (617) 679-2000 (973) 235-5000 |
| AFX-9154 | Afecta Pharmaceuticals <i>Irvine, CA</i> | | in clinical trials (949) 253-4688 |
| ALD-151 | Aldagen <i>Durham, NC</i> | | Phase I (919) 484-2571 |
| ALXN-6000 (samalizumab) | Alexion Pharmaceuticals <i>Cheshire, CT</i> | CLL (see also multiple myeloma) | Phase I/II (203) 272-2596 |
| aminopterin | Syntrix Biosystems <i>Auburn, WA</i> | acute lymphoblastic leukemia (ALL) | Phase II completed (253) 833-8009 |
| anti-CD22 ADC | Genentech <i>South San Francisco, CA</i> | recurrent CLL (see also lymphoma) | Phase I (650) 225-1000 |
| anti-CD22/CD19 mAb-toxin conjugate | Abiogen Pharma <i>Pisa, Italy</i> University of Texas Southwestern Medical Center <i>Dallas, TX</i> | ALL | Phase I www.abiogen.com |
| AR-42 | Arno Therapeutics <i>Parsippany, NJ</i> | CLL (see also lymphoma, multiple myeloma) | Phase I/II (862) 703-7170 |
| ARRY-520 | Array BioPharma <i>Boulder, CO</i> | AML (see also multiple myeloma, solid tumors) | Phase I/II (303) 381-6600 |
| ARRY-614 | Array BioPharma <i>Boulder, CO</i> | myelodysplastic syndromes | Phase I (303) 381-6600 |
| Arzerra® ofatumumab (Orphan Drug) | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | first-line CLL (see also lymphoma) | Phase III (888) 825-5249 |
| AS-1411 | Antisoma <i>Cambridge, MA</i> | AML | Phase II (617) 252-6100 |
| AT-101 | Ascenta Therapeutics <i>Malvern, PA</i> | CLL (see also brain, lung, lymphoma, prostate, stomach) | Phase II completed (610) 408-0313 |
| AT9283 | Astex Therapeutics <i>Cambridge, United Kingdom</i> | AML (see also solid tumors) | Phase I/II www.astex.therapeutics. com |
| bafetinib (Orphan Drug) | CytRx <i>Los Angeles, CA</i> | CLL (see also prostate) | Phase II (310) 826-5648 |
| | | ALL, CML | Phase I (310) 826-5648 |

LEUKEMIA

| Product Name | Sponsor | Indication | Development Status |
|--|--|---|---|
| BI 811283 | Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i> | AML (see also solid tumors) | Phase II (800) 243-0127 |
| blinatumomab | Micromet <i>Bethesda, MD</i> | ALL (see also lymphoma) | Phase II (240) 752-1420 |
| BMS-936564 (anti-CXCR4) | Bristol-Myers Squibb <i>Princeton, NJ</i> | AML | Phase I (212) 546-4000 |
| bosutinib | Pfizer <i>New York, NY</i> | CML | Phase III (860) 732-5156 |
| CAL-101 | Calistoga Pharmaceuticals <i>Seattle, WA</i> | CLL (see also lymphoma, multiple myeloma) | Phase II (206) 728-4700 |
| | | AML | Phase I (206) 728-4700 |
| Campath® alemtuzumab (intravenous) (Orphan Drug) | Genzyme <i>Cambridge, MA</i> | CLL combination therapy (see also cancer/chemotherapy) | Phase III (617) 252-7500 |
| Campath® alemtuzumab (subcutaneous) | Genzyme <i>Cambridge, MA</i> | CLL | Phase II (617) 252-7500 |
| cell permeation therapeutic vaccine | MaxCyte <i>Gaithersburg, MD</i> | CLL | Phase I/II (301) 944-1700 |
| Ceplene™ histamine dehydrochloride injection (Orphan Drug) | EpiCept <i>Tarrytown, NY</i> | AML | application submitted (914) 606-3500 |
| Clolar® clofarabine | Genzyme <i>Cambridge, MA</i> | AML in elderly (monotherapy) | application submitted (617) 252-7500 |
| | | AML in elderly (combination therapy) | Phase III (617) 252-7500 |
| | | AML in children, myelodysplastic syndromes | Phase II (617) 252-7500 |
| CNDO-109 | Coronado Biosciences <i>New York, NY</i> | AML | Phase I/II (212) 332-1665 |
| CPX-351 | Celator Pharmaceuticals <i>Princeton, NJ</i> | AML | Phase II (609) 243-0123 |
| CST-101 | ConKwest <i>Del Mar, CA</i> | AML (see also lung, lymphoma, skin) | Phase I (858) 380-1999 |
| CT-011 | CureTech <i>Yavne, Israel</i> | AML (see also colorectal, lymphoma) | Phase II www.curetechbio.com |
| CYT-107 | Cytheris <i>Rockville, MD</i> | myeloid leukemia (see also kidney, skin, solid tumors) | Phase I (301) 231-0450 |

LEUKEMIA

| Product Name | Sponsor | Indication | Development Status |
|---|---|--|---|
| dacetuzumab (anti-CD40) (Orphan Drug) | Seattle Genetics <i>Bothell, WA</i> | CLL (see also lymphoma, multiple myeloma) | Phase I/II (425) 527-4000 |
| danusertib | Nerviano Medical Sciences <i>Nerviano, Italy</i> | CML | Phase II www.nervianoms.com |
| DCC-2036 | Deciphera Pharmaceuticals <i>Lawrence, KS</i> | ALL, CML | Phase I/II (785) 838-3767 |
| dinaciclib | Merck <i>Whitehouse Station, NJ</i> | (see also breast, lung, lymphoma) | Phase II (800) 672-6372 |
| Elacyt™ elacytarabine (Orphan Drug) | Clavis Pharma <i>Oslo, Norway</i> | AML (Fast Track) | Phase III www.clavispharma.com |
| elesclomol | Synta Pharmaceuticals <i>Lexington, MA</i> | AML | Phase I (781) 274-8200 |
| epratuzumab (Orphan Drug) | Immunomedics <i>Morris Plains, NJ</i> | ALL in children (see also lymphoma) | Phase II (973) 605-8200 |
| Erwinaze® crisantaspase (Orphan Drug) | EUSA Pharma <i>Langhorne, PA</i> | ALL (Fast Track) | application submitted (800) 833-3533 |
| EZN-3042 | Enzon Pharmaceuticals <i>Bridgewater, NJ</i> | ALL in children (see also lymphoma, solid tumors) | Phase I (908) 541-8600 |
| Fodosine™ forodesine | BioCryst Pharmaceuticals <i>Birmingham, AL</i> | CLL (see also lymphoma) | Phase II (205) 444-4600 |
| Genasense® oblimersen (Orphan Drug) | Genta <i>Berkeley Heights, NJ</i> | CLL (Fast Track) (see also lymphoma, skin) | application submitted (908) 286-9800 |
| GNKG-68 | SBI Biotech <i>Tokyo, Japan</i> | CLL | Phase I www.sbibiotech.jp |
| GRN-163L (imetelstat) | Geron <i>Menlo Park, CA</i> | CLL (see also breast, lung, multiple myeloma) | Phase I/II (650) 473-7700 |
| GRNVAC1 | Geron <i>Menlo Park, CA</i> | AML (see also prostate) | Phase II (650) 473-7700 |
| GVAX® Leukemia (Orphan Drug) | BioSante Pharmaceuticals <i>Lincolnshire, IL</i> | AML, CML (see also breast, colorectal, multiple myeloma, pancreatic) | Phase II (847) 478-0500 |
| HuM195-Ac-225 | Actinium Pharmaceuticals <i>Newark, NJ</i> | AML | Phase I (973) 344-6500 |
| HuM195-Bi-213 | Actinium Pharmaceuticals <i>Newark, NJ</i> | AML | Phase I/II (973) 344-6500 |
| HuM195/rGel (lintuzumab-gelonin conjugate) | Targa Therapeutics <i>San Diego, CA</i> | AML, CML, myelodysplastic syndromes | Phase I (858) 483-6600 |
| Imprime PGG® | Biothera <i>Eagen, MN</i> | CLL (see also colorectal, lung, skin) | Phase I/II (651) 675-0300 |

LEUKEMIA

| Product Name | Sponsor | Indication | Development Status |
|---|--|---|--|
| ISF35 | Memgen <i>Dallas, TX</i> | CLL (see also lymphoma) | Phase II (214) 731-3141 |
| JNJ-26481585 | Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i> | refractory metastatic leukemia, refractory metastatic myelodysplastic syndromes | Phase I (800) 817-5286 |
| JVRS-100 immunotherapeutic | Juvaris BioTherapeutics <i>Burlingame, CA</i> | | Phase I (650) 259-1800 |
| L-annamycin (liposomal annamycin) (Orphan Drug) | Callisto Pharmaceuticals <i>New York, NY</i> | ALL, AML | Phase I/II (212) 297-0010 |
| LC-1 | Leuchemix <i>Redwood City, CA</i> | AML | Phase I (650) 851-9925 |
| lestaurtinib | Cephalon <i>Frazer, PA</i> | AML | Phase II (610) 344-0200 |
| LG740 | Lentigen <i>Gaithersburg, MD</i> University of Pennsylvania <i>Philadelphia, PA</i> | ALL, B-cell prolymphocytic leukemia, CLL (see also lymphoma) | Phase I (301) 527-4200 |
| LOR-2040 (Orphan Drug) | Lorus Therapeutics <i>Toronto, Canada</i> | AML (see also breast, colorectal, kidney) | Phase II (416) 798-1200 |
| | | CML, myelodysplastic syndromes | Phase I (416) 798-1200 |
| Marqibo® vincristine liposomal (Orphan Drug) | Talon Therapeutics <i>South San Francisco, CA</i> | ALL (Fast Track) (see also skin) | Phase II (650) 588-6404 |
| masitinib | AB Science USA <i>Short Hills, NJ</i> | mastocytosis (see also pancreatic, stomach) | Phase III (973) 218-2437 |
| MGCD-0103 | MethylGene <i>Montreal, Canada</i> | CLL (see also lymphoma, solid tumors) | Phase II completed (514) 337-3333 |
| midostaurin (PKC412) (Orphan Drug) | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | AML | Phase III (888) 669-6682 |
| | | aggressive systemic mastocytosis | Phase II (888) 669-6682 |
| milatuzumab (IMMU-115) (Orphan Drug) | Immunomedics <i>Morris Plains, NJ</i> | CLL (see lymphoma, multiple myeloma) | Phase I/II (973) 605-8200 |
| Mozobil™ plerixafor | Genzyme <i>Cambridge, MA</i> | AML, CLL | Phase I/II (617) 252-7500 |
| navitoclax (ABT-263/RG7433) | Abbott Laboratories <i>Abbott Park, IL</i> Genentech <i>South San Francisco, CA</i> | CLL (see also lung, lymphoma) | Phase II (847) 937-6100 (650) 225-1000 |

LEUKEMIA

| Product Name | Sponsor | Indication | Development Status |
|--|--|--|--|
| Nplate™ romiplostim | Amgen <i>Thousand Oaks, CA</i> | myelodysplastic syndromes (see also cancer/chemotherapy) | Phase II (800) 772-6436 |
| obatoclox (Orphan Drug) | Gemin X Biotechnologies <i>Montreal, Canada</i> | CLL (see also lung, lymphoma, multiple myeloma) | Phase I/II completed (514) 281-8989 |
| Omapro™ omacetaxine mepesuccinate (Orphan Drug) | ChemGenex Pharmaceuticals <i>Menlo Park, CA</i> | second-line CML (Fast Track) ----- AML, CML, myelodysplastic syndromes | application submitted (650) 474-9800 ----- Phase II (650) 474-9800 |
| ON-01910 (Orphan Drug) | Onconova Therapeutics <i>Princeton, NJ</i> | myelodysplastic syndromes (see also lymphoma, ovarian, solid tumors) ----- AML, CLL | Phase III (609) 844-7735 ----- Phase II (609) 844-7735 |
| ON-013105 | Onconova Therapeutics <i>Princeton, NJ</i> | ALL (see also lymphoma) | Phase I (609) 844-7735 |
| OXi4503 | OXiGENE <i>South San Francisco, CA</i> | AML (see also solid tumors) | Phase I (650) 635-7000 |
| PCI-32765 (BTK inhibitor) | Pharmacyclics <i>Sunnyvale, CA</i> | CLL (see also lymphoma) | Phase I (408) 774-0330 |
| perifosine (KRX-1401) | Aeterna Zentaris <i>Montreal, Canada</i> Keryx Biopharmaceuticals <i>New York, NY</i> | refractory metastatic CLL (see also brain, colorectal, kidney, lymphoma, multiple myeloma, ovarian, sarcoma, stomach) | Phase II (212) 531-5965 |
| polyphenon E (Orphan Drug) | Polyphenon Pharma <i>New York, NY</i> | CLL (see also prostate) | Phase I/II (212) 661-0578 |
| ponatinib (AP24534) | ARIAD Pharmaceuticals <i>Cambridge, MA</i> | ALL, CML | Phase II (617) 494-0400 |
| PR1 cancer vaccine | Vaccine Company <i>South San Francisco, CA</i> | AML ----- CML, myelodysplastic syndromes | Phase III (650) 244-4100 ----- Phase II (650) 244-4100 |
| PR104 | Proacta Therapeutics <i>San Diego, CA</i> | AML | Phase I/II (858) 642-0386 |
| quizartinib | Ambit Biosciences <i>San Diego, CA</i> Astellas Pharma US <i>Deerfield, IL</i> | AML (see also solid tumors) | Phase II (858) 334-2100 (800) 727-7003 |
| sapacitabine | Cyclacel Pharmaceuticals <i>Short Hills, NJ</i> | AML in elderly patients (see also lung) | Phase III (973) 847-5955 |
| SAR103168 (multikinase inhibitor) | sanofi-aventis <i>Bridgewater, NJ</i> | AML | Phase I (800) 633-1810 |
| SB939 | S*Bio <i>Redwood City, CA</i> | AML (see also solid tumors) | Phase II (650) 730-2860 |

LEUKEMIA

| Product Name | Sponsor | Indication | Development Status |
|--|---|---|--|
| SB1518 | S*Bio <i>Redwood City, CA</i> | myeloid leukemia (see also lymphoma) | Phase I/II (650) 730-2860 |
| SCH-900776 | Merck <i>Whitehouse Station, NJ</i> | (see also lymphoma) | Phase I (800) 672-6372 |
| SF1126 (Orphan Drug) | Semafore Pharmaceuticals <i>Indianapolis, IN</i> | CLL (see also multiple myeloma, solid tumors) | Phase I (317) 876-3075 |
| SGI-110 | SuperGen <i>Dublin, CA</i> | AML | Phase I/II (925) 560-0100 |
| SL-401 | Stemline Therapeutics <i>New York, NY</i> | AML | Phase I/II (212) 831-1111 |
| SNDX-275 (entinostat) | Syndax Pharmaceuticals <i>Waltham, MA</i> | (see also breast, leukemia, lung, lymphoma) | Phase II (781) 419-1400 |
| Sprycel® dasatinib | Bristol-Myers Squibb <i>Princeton, NJ</i> | myelodysplastic syndromes (see also brain, breast, colorectal, lung, lymphoma, multiple myeloma, prostate, skin) | Phase II (212) 546-4000 |
| tamibarotene (Orphan Drug) | CytRx <i>Los Angeles, CA</i> | acute promyelocytic leukemia (APL) (Fast Track) (see also lung) | Phase II (310) 826-5648 |
| Tarceva® erlotinib | Genentech <i>South San Francisco, CA</i> OSI Pharmaceuticals <i>Melville, NY</i> | myelodysplastic syndromes (see also bladder, brain, breast, colorectal, head/neck, liver, lung, other) | Phase II (650) 224-1000 (800) 572-1932 |
| Tasigna® nilotinib (Orphan Drug) | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | CML in adolescents and children (see also skin, stomach) | Phase II (888) 669-6682 |
| Telintra® ezatiostat | Telik <i>Palo Alto, CA</i> | myelodysplastic syndromes | Phase II (650) 845-7700 |
| Temodar® temozolomide | Merck <i>Whitehouse Station, NJ</i> | AML (see also lung, skin) | Phase II (800) 672-6372 |
| TH-302 | Threshold Pharmaceuticals <i>Redwood City, CA</i> | advanced leukemia (see also pancreatic, sarcoma, solid tumors) | Phase I (650) 474-8200 |
| thiarabine | Access Pharmaceuticals <i>Dallas, TX</i> | (see also lymphoma) | Phase I/II (214) 905-5100 |
| tosedostat (Orphan Drug) | Chroma Therapeutics <i>Oxford, United Kingdom</i> | AML | Phase II www.chroma therapeutics.com |
| treosulfan | medac <i>Wedel, Germany</i> | ALL, AML, myelodysplastic syndromes | Phase II www.medac.de |
| Trisenox® arsenic trioxide | Cephalon <i>Frazer, PA</i> | AML in elderly patients (see also brain, multiple myeloma) | Phase III (610) 344-0200 |
| TRU-016 (anti-CD37) | Emergent Biosolutions <i>Rockville, MD</i> | CLL (see also lymphoma) | Phase I/II (301) 795-1800 |

LEUKEMIA

| Product Name | Sponsor | Indication | Development Status |
|---|--|--|--|
| veltuzumab (IMMU-106) | Immunomedics <i>Morris Plains, NJ</i> | CLL (see also lymphoma) | Phase I/II completed (973) 605-8200 |
| Vidaza® azacitidine (Orphan Drug) | Celgene <i>Summit, NJ</i> | AML | Phase III (908) 673-9000 |
| vosaroxin (SNS-595) (Orphan Drug) | Sunesis Pharmaceuticals <i>South San Francisco, CA</i> | AML (Fast Track) (see also ovarian) | Phase III (650) 266-3500 |
| | | AML in the elderly | Phase II (650) 266-3500 |
| WT1 recombinant vaccine (antigen specific cancer immunotherapy) | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | AML | Phase II (888) 825-5249 |
| XmAb®5574 (MOR-208) | Xencor <i>Monrovia, CA</i> MorphoSys <i>Munich, Germany</i> | CLL | Phase I (626) 305-5900 |
| zosuquidar (Orphan Drug) | Kanisa Pharmaceuticals <i>San Diego, CA</i> | newly-diagnosed AML in elderly patients | Phase I/II (858) 436-1800 |

LIVER CANCER

| Product Name | Sponsor | Indication | Development Status |
|------------------------------------|--|---|--|
| ABT-869 (linifarib) | Abbott Laboratories <i>Abbott Park, IL</i> | (see also breast, colorectal, kidney, lung) | Phase III (847) 937-6100 |
| ADI-PEG 20 (Orphan Drug) | Polaris Pharmaceuticals <i>San Diego, CA</i> | (see also lung, skin) | Phase II (858) 452-6688 |
| Afinitor® everolimus | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | advanced hepatocellular carcinoma (see also breast, liver, lymphoma, stomach, other) | Phase III (888) 669-6682 |
| ALN-VSP | Alnylam Pharmaceuticals <i>Cambridge, MA</i> | | Phase I (617) 551-8200 |
| AMG 386 | Amgen <i>Thousand Oaks, CA</i> | (see also breast, colorectal, kidney, ovarian, stomach, other) | Phase II (800) 772-6436 |
| ARQ-197 | ArQule <i>Woburn, MA</i> Daiichi Sankyo <i>Parsippany, NJ</i> | hepatocellular carcinoma (see also colorectal, kidney, lung, pancreatic, sarcoma, solid tumors, other) | Phase II (781) 994-0300 (973) 944-2600 |
| bavituximab | Peregrine Pharmaceuticals <i>Tustin, CA</i> | (see also breast, pancreatic) | Phase I/II (714) 508-6000 |
| BAY 86-9766 | Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> | | Phase II (888) 842-2937 |

LIVER CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|--|--|---|
| BIIB 022 | Biogen Idec <i>Cambridge, MA</i> | (see also lung) | Phase I (617) 679-2000 |
| brivanib (VEGFR/FGFR kinase inhibitor) | Bristol-Myers Squibb <i>Princeton, NJ</i> | hepatocellular carcinoma (see also stomach) | Phase III (212) 546-4000 |
| CRS-100 | Aduro BioTech <i>Berkeley, CA</i> | | Phase I (510) 848-4400 |
| darinaparsin (ZIO-101) | ZIOPHARM Oncology <i>New York, NY</i> | (see also lymphoma, multiple myeloma, solid tumors) | Phase II completed (646) 214-0700 |
| Davanat™ galactomannan C | Pro-Pharmaceuticals <i>Newton, MA</i> | biliary cancer (see also colorectal) | Phase II (617) 559-0033 |
| E7050 | Eisai <i>Woodcliff Lake, NJ</i> | hepatocellular carcinoma (see also stomach, other) | Phase I/II (888) 422-4743 |
| GC-33/RG7686 | Chugai Pharma USA <i>Berkeley Heights, NJ</i> Roche <i>Nutley, NJ</i> | | Phase I (908) 516-1350 (973) 235-5000 |
| irinotecan eluting beads | Biocompatibles International <i>Surrey, United Kingdom</i> | liver metastases from colorectal cancer | Phase II www.biocompatibles.com |
| JX-594 | Jennerex Biotherapeutics <i>San Francisco, CA</i> | (see also colorectal) | Phase II (415) 281-8886 |
| lenvatinib (E7080) | Eisai <i>Woodcliff Lake, NJ</i> | hepatocellular carcinoma (see also brain, kidney, ovarian, skin, other) | Phase I/II (888) 422-4743 |
| mapatumumab | Human Genome Sciences <i>Rockville, MD</i> | (see also lung, multiple myeloma) | Phase I/II (301) 309-8504 |
| MB-07133 (Orphan Drug) | Ligand Pharmaceuticals <i>La Jolla, CA</i> | inoperable, unresectable liver cancer | Phase I/II completed (858) 550-7500 |
| melphalan drug delivery system | Delcath Systems <i>New York, NY</i> | secondary liver cancer arising from metastatic ocular or cutaneous melanoma | application submitted (212) 489-2100 |
| muparfostat (PI-88) | Progen Pharmaceuticals <i>Redwood City, CA</i> | (Fast Track) (see also skin) | Phase III (650) 610-7080 |
| Nexavar® sorafenib | Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> Onyx Pharmaceuticals <i>Emeryville, CA</i> | adjuvant therapy (see also breast, colorectal, kidney, lung, ovarian, other) | Phase III (888) 842-2837 (510) 597-6500 |
| NV1020 | Catherex <i>Arlington, VA</i> | | Phase I/II completed (703) 786-3790 |
| patupilone (EPO906) | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | (see also brain) | Phase II (888) 669-6682 |
| PrevOnco™ lansoprazole (Orphan Drug) | Apricus Biosciences <i>San Diego, CA</i> | | Phase II (858) 222-8041 |

LIVER CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|---|--|---|
| PV-10 | Provectis Pharmaceuticals <i>Knoxville, TN</i> | liver metastases (see also skin) | Phase I (866) 594-5999 |
| ramucirumab (IMC-1121B) | Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i> | (see also breast, colorectal, lung, stomach) | Phase III (800) 545-5979 (212) 645-1405 |
| Tarceva® erlotinib | Genentech <i>South San Francisco, CA</i> OSI Pharmaceuticals <i>Melville, NY</i> | inoperable, unresectable liver cancer (see also bladder, brain, breast, colorectal, head/neck, leukemia, lung, other) | Phase III (650) 224-1000 (800) 572-1932 |
| ThermoDox® LTSDEL (Orphan Drug) | Celsion <i>Columbia, MD</i> | inoperable, unresectable liver cancer (Fast Track) (see also breast) | Phase III (410) 290-5390 |
| tigatuzumab | Daiichi Sankyo <i>Parsippany, NJ</i> | (see also colorectal, lymphoma, ovarian, pancreatic) | Phase II (973) 359-2600 |

LUNG CANCER

| Product Name | Sponsor | Indication | Development Status |
|---|---|--|---|
| Abraxane® albumin-bound paclitaxel | Celgene <i>Summit, NJ</i> | advanced non-small-cell lung cancer (NSCLC) (see also bladder, ovarian, pancreatic, skin) | Phase III (908) 673-9000 |
| ABT-869 (linifarib) | Abbott Laboratories <i>Abbott Park, IL</i> | NSCLC (see also breast, kidney, liver) | Phase II (847) 937-6100 |
| ADI-PEG 20 (Orphan Drug) | Polaris Pharmaceuticals <i>San Diego, CA</i> | small-cell lung cancer (SCLC) (see also liver, skin) | Phase II (858) 452-6688 |
| | | mesothelioma | Phase I (858) 452-6688 |
| aflibercept (VEGF-trap) | sanofi-aventis <i>Bridgewater, NJ</i> Regeneron Pharmaceuticals <i>Tarrytown, NY</i> | second-line NSCLC (see also colorectal, prostate) | Phase III (800) 633-1610 (914) 345-7400 |
| AMG 479 (gunitumab) | Amgen <i>Thousand Oaks, CA</i> | SCLC (see also breast, colorectal, pancreatic, sarcoma, other) | Phase I/II (800) 772-6436 |
| amrubicin (Orphan Drug) | Celgene <i>Summit, NJ</i> | second-line SCLC (Fast Track) | Phase III (908) 673-9000 |
| | | first-line SCLC | Phase II (908) 673-9000 |
| apricoxib | Tragara Pharmaceuticals <i>San Diego, CA</i> | NSCLC (see also pancreatic) | Phase II (858) 350-6900 |

LUNG CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|--|---|--|
| ARQ-197 | ArQule Woburn, MA Daiichi Sankyo Parsippany, NJ | NSCLC (see also colorectal, kidney, liver, pancreatic, sarcoma, solid tumors, other) | Phase III (781) 994-0300 (973) 944-2600 |
| AT-101 | Ascenta Therapeutics Malvern, PA | NSCLC, SCLC (see also leukemia, lymphoma, prostate, stomach) | Phase II (610) 408-0301 |
| AUY922 | Novartis Pharmaceuticals East Hanover, NJ | NSCLC (see also breast, colorectal, multiple myeloma, stomach) | Phase II (888) 669-6682 |
| AV-951 (tivozanib) | AVEO Pharmaceuticals Cambridge, MA | NSCLC (see also breast, kidney, stomach) | Phase I/II (617) 299-5000 |
| Avastin [®] bevacizumab | Genentech South San Francisco, CA | NSCLC (adjuvant therapy) (see also brain, breast, colorectal, ovarian, other) | Phase III (650) 225-1000 |
| axitinib | Pfizer New York, NY | NSCLC (see also kidney, other) | Phase II (860) 732-5156 |
| bavituximab | Peregrine Pharmaceuticals Tustin, CA | NSCLC (see also liver, pancreatic) | Phase II (714) 508-6000 |
| BAY 73-4506 (regorafenib) | Bayer HealthCare Pharmaceuticals Wayne, NJ | NSCLC (see also colorectal, kidney, stomach) | Phase I (888) 842-2937 |
| belinostat | Spectrum Pharmaceuticals Irvine, CA TopoTarget USA Rockaway, NJ | NSCLC (see also lymphoma, other) | Phase I/II (949) 788-6700 (973) 895-6900 |
| BI 2536 | Boehringer Ingelheim Pharmaceuticals Ridgefield, CT | SCLC (see also lymphoma) | Phase II completed (800) 243-0127 |
| BIBF 1120 (intedanib) | Boehringer Ingelheim Pharmaceuticals Ridgefield, CT | NSCLC | Phase III (800) 243-0127 |
| BIBW 2992 (afatinib) | Boehringer Ingelheim Pharmaceuticals Ridgefield, CT | NSCLC (Fast Track) (see also brain, breast, head/neck) | Phase III (800) 243-0127 |
| BIIB 022 | Biogen Idec Cambridge, MA | NSCLC (see also liver) | Phase I (617) 679-2000 |
| BMS-690514 (HER/VEGFR2 inhibitor) | Bristol-Myers Squibb Princeton, NJ | NSCLC (see also breast) | Phase II (212) 546-4000 |
| BMS-844203 (VEGF R-2 adnectin) | Bristol-Myers Squibb Princeton, NJ | NSCLC (see also brain, colorectal) | Phase II (212) 546-4000 |
| cabozantinib (XL-184) | Exelixis South San Francisco, CA | NSCLC (see also other) | Phase I/II (650) 837-7000 |
| CBP501 | CanBas Shizuoka, Japan | mesothelioma, NSCLC | Phase II www.canbas.co.jp |

LUNG CANCER

| Product Name | Sponsor | Indication | Development Status |
|---|--|---|---|
| conatumumab | Amgen <i>Thousand Oaks, CA</i> | NSCLC (see also colorectal, pancreatic, sarcoma) | Phase I/II (800) 772-6436 |
| crizotinib | Pfizer <i>New York, NY</i> | NSCLC (Fast Track) | Phase III (860) 732-5156 |
| CS-7017 (efatutazone) | Daiichi Sankyo <i>Parsippany, NJ</i> | NSCLC (see also colorectal, other) | Phase II (973) 944-2600 |
| CST-101 | ConKwest <i>Del Mar, CA</i> | NSCLC, SCLC (see also leukemia, lymphoma, skin) | Phase I (858) 380-1999 |
| dalotuzumab | Merck <i>Whitehouse Station, NJ</i> | NSCLC (see also breast, colorectal, pancreatic, other) | Phase I/II (800) 672-6372 |
| dinaciclib | Merck <i>Whitehouse Station, NJ</i> | NSCLC (see also breast, leukemia, lymphoma) | Phase II (800) 672-6372 |
| EC-145 | Endocyte <i>West Lafayette, IN</i> | late-stage NSCLC (see also ovarian, other) | Phase II (765) 463-7175 |
| Erbix[®] cetuximab | Bristol-Myers Squibb <i>Princeton, NJ</i> Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i> | NSCLC (see also bladder, breast, head/neck) | Phase III (212) 546-4000 (800) 545-5979 (212) 645-1405 |
| eribulin (E7389) | Eisai <i>Woodcliff Lake, NJ</i> | NSCLC (see also bladder, prostate, sarcoma) | Phase I/II (888) 422-4743 |
| Exelb[™] vinorelbine emulsion | ADVENTRX Pharmaceuticals <i>San Diego, CA</i> | NSCLC (see also breast, lymphoma) | application submitted (858) 552-0866 |
| farletuzumab (MORAb-003) | Eisai <i>Woodcliff Lake, NJ</i> | NSCLC (see also ovarian) | Phase II (888) 422-4743 |
| Foloty[®] pralatrexate | Allos Therapeutics <i>Westminster, CO</i> | NSCLC (see also bladder, breast, lymphoma) | Phase II (303) 426-6262 |
| ganetespib | Synta Pharmaceuticals <i>Lexington, MA</i> | NSCLC (see also breast, colorectal, stomach, other) | Phase II (781) 274-8200 |
| GDC-0941 (PI3 kinase inhibitor) | Genentech <i>South San Francisco, CA</i> | metastatic NSCLC (see also breast, lymphoma, solid tumors) | Phase I (650) 224-1000 |
| GI-4000 | GlobelImmune <i>Louisville, CO</i> | NSCLC (see also colorectal, pancreatic) | Phase I (303) 625-2700 |
| GRN-163L (imetelstat) | Geron <i>Menlo Park, CA</i> | NSCLC (see also breast, leukemia, multiple myeloma) | Phase II (650) 473-7700 |
| GSK2302032A (PRAME immunotherapeutic recombinant vaccine) | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | resectable NSCLC (see also skin) | Phase I (888) 825-5249 |

LUNG CANCER

| Product Name | Sponsor | Indication | Development Status |
|---|--|--|---|
| HS-L1 | Heat Biologics <i>Miami Beach, FL</i> | NSCLC | Phase I (305) 432-4684 |
| HyperAcute® Lung lung cancer vaccine | NewLink Genetics <i>Ames, IA</i> | NSCLC | Phase I/II (515) 296-5555 |
| IMGN-901 (Orphan Drug) | ImmunoGen <i>Cambridge, MA</i> | SCLC (see also multiple myeloma) | Phase I/II (617) 995-2500 |
| IMO-2055 (EMD-1201081) | EMD Serono <i>Rockland, MA</i> Idera Pharmaceuticals <i>Cambridge, MA</i> | NSCLC (see also colorectal, kidney) | Phase I (800) 283-8088 (617) 679-5500 |
| Imprime PGG® | Biothera <i>Eagen, MN</i> | NSCLC (see also colorectal, leukemia, skin) | Phase II (651) 675-0300 |
| iniparib (BSI-201) | BiPar Sciences <i>South San Francisco, CA</i> sanofi-aventis <i>Bridgewater, NJ</i> | squamous lung cancer (see also breast, ovarian) | Phase III (650) 615-7000 (800) 633-1810 |
| | | ----- non-squamous NSCLC | Phase II (650) 615-7000 (800) 633-1810 |
| ipilimumab | Bristol-Myers Squibb <i>Princeton, NJ</i> | NSCLC (see also prostate, skin) | Phase II (212) 546-4000 |
| Ixempra® ixabepilone | Bristol-Myers Squibb <i>Princeton, NJ</i> | NSCLC (see also breast, stomach, other) | Phase II (212) 546-4000 |
| JNJ-26854165 | Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i> | NSCLC (see also prostate, solid tumors) | Phase I (800) 817-5286 |
| Lucanix® belagenpumatucel-L | NovaRx <i>San Diego, CA</i> | NSCLC (Fast Track) (see also brain) | Phase III (858) 552-8600 |
| MAGE-A3 recombinant vaccine (antigen-specific cancer immunotherapeutic) | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | NSCLC (see also skin) | Phase III (888) 825-5249 |
| mapatumumab | Human Genome Sciences <i>Rockville, MD</i> | NSCLC (see also liver, multiple myeloma) | Phase II (301) 309-8504 |
| MetmAb (RG 3638) | Genentech <i>South San Francisco, CA</i> | NSCLC | Phase II (650) 225-1000 |
| MGCD-265 | MethylGene <i>Montreal, Canada</i> | NSCLC (see also solid tumors) | Phase II (514) 337-3333 |
| MORAb-009 | Eisai <i>Woodcliff Lake, NJ</i> | mesothelioma | Phase II (888) 422-4743 |
| motesanib (AMG 706) | Amgen <i>Thousand Oaks, CA</i> Millennium Pharmaceuticals <i>Cambridge, MA</i> | NSCLC (see also breast) | Phase III (800) 772-6436 (800) 390-5663 |

LUNG CANCER

| Product Name | Sponsor | Indication | Development Status |
|---|--|---|---|
| naptumomab estafenatox | Active Biotech <i>Lund, Sweden</i> | NSCLC (Fast Track) (see also kidney, pancreatic) | Phase I completed www.activebiotech.com |
| navitoclax (ABT-263/RG7433) | Abbott Laboratories <i>Abbott Park, IL</i> Genentech <i>South San Francisco, CA</i> | SCLC (see also leukemia, lymphoma) | Phase II (847) 937-6100 (650) 225-1000 |
| necitumumab (IMC-11F8) | Bristol-Myers Squibb <i>Princeton, NJ</i> Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i> | NSCLC | Phase III (212) 546-4000 (800) 545-5979 (212) 645-1405 |
| Nexavar® sorafenib | Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> Onyx Pharmaceuticals <i>Emeryville, CA</i> | NSCLC (see also breast, colorectal, kidney, liver, ovarian, other) | Phase III (888) 842-2837 (510) 597-6500 |
| NK-012 | Nippon Kayaku <i>Tokyo, Japan</i> | SCLC (see also breast) | Phase II |
| NTX-10 | Neotropix <i>Malvern, PA</i> | SCLC (see also other) | Phase II (617) 460-1200 |
| obatoclax | Gemin X Biotechnologies <i>Montreal, Canada</i> | SCLC (see also leukemia, lymphoma, multiple myeloma) | Phase I/II (514) 281-8989 |
| OBP-301 | Oncolys Biopharma <i>Tokyo, Japan</i> | mesothelioma (see also breast, head/neck) | Phase I www.oncolys.com |
| OGX-427 | Oncogenex Pharmaceuticals <i>Bothell, WA</i> | NSCLC (see also bladder, breast, ovarian, prostate) | Phase I (425) 686-1500 |
| Onconase® ranpirnase | Tamir Biotechnology <i>Monmouth Junction, NJ</i> | NSCLC | Phase II (732) 823-1003 |
| Opaxio™ paclitaxel poliglumex | Cell Therapeutics <i>Seattle, WA</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i> | NSCLC (see also ovarian, other) | Phase III (800) 215-2355 (888) 669-6682 |
| OSI-906 (linsitinib) | OSI Pharmaceuticals <i>Melville, NY</i> | NSCLC (see also ovarian, other) | Phase II (631) 962-2000 |
| P2045 | Bryan Oncor <i>Somerville, MA</i> | NSCLC, SCLC | Phase I (617) 273-2466 |
| palifosfamide (ZIO-201) | ZIOPHARM Oncology <i>New York, NY</i> | SCLC (see also sarcoma) | Phase I (212) 214-0700 |
| PF-00299804 | Pfizer <i>New York, NY</i> | NSCLC | Phase III (860) 732-5156 |
| picoplatin intravenous (Orphan Drug) | Poniard Pharmaceuticals <i>San Francisco, CA</i> | SCLC (Fast Track) (see also colorectal, ovarian, prostate) | Phase II (650) 583-3774 |

LUNG CANCER

| Product Name | Sponsor | Indication | Development Status |
|---|--|---|---|
| plinabulin (NPI-2358) | Nereus Pharmaceuticals <i>San Diego, CA</i> | NSCLC | Phase II (858) 587-4090 |
| PM-02734 (elisidepsin) | Pharmamar USA <i>New York, NY</i> | NSCLC | Phase II www.pharmamar.com |
| ramucirumab (IMC-1121B) | Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i> | NSCLC (see also breast, colorectal, liver, stomach) | Phase III (800) 545-5979 (212) 645-1405 |
| Rencentin™ cediranib | AstraZeneca <i>Wilmington, DE</i> | NSCLC | Phase II (800) 236-9933 |
| Reolysin® reovirus | Oncolytics Biotech <i>Calgary, Canada</i> | NSCLC (see also brain, colorectal, head/neck, pancreatic, sarcoma, skin) | Phase II (403) 670-7377 |
| retaspimycin (IPI-504) | Infinity Pharmaceuticals <i>Cambridge, MA</i> | NSCLC (see also solid tumors) | Phase II (617) 453-1000 |
| ridaforolimus | Merck <i>Whitehouse Station, NJ</i> | NSCLC (see also breast, sarcoma) | Phase II (800) 672-6372 |
| rilotumumab | Amgen <i>Thousand Oaks, CA</i> | SCLC (see also brain, colorectal, prostate, stomach) | Phase II (800) 772-6436 |
| salirasib | Concordia Pharmaceuticals <i>Ft. Lauderdale, FL</i> | NSCLC (see also pancreatic) | Phase II www.concordiapharma.com |
| sapacitabine | Cyclacel Pharmaceuticals <i>Short Hills, NJ</i> | NSCLC (see also leukemia) | Phase II (973) 847-5955 |
| SNDX-275 (entinostat) | Syndax Pharmaceuticals <i>Waltham, MA</i> | NSCLC (see also breast, colorectal, leukemia, lymphoma) | Phase I/II (781) 419-1400 |
| Sprycel® dasatinib | Bristol-Myers Squibb <i>Princeton, NJ</i> | NSCLC (see also brain, breast, colorectal, leukemia, lymphoma, multiple myeloma, prostate, skin) | Phase II (212) 546-4000 |
| | | mesothelioma | Phase I (212) 546-4000 |
| Stimuvax® emepepimut-S (BLP25 liposomal cancer vaccine) | EMD Serono <i>Rockland, MA</i> Oncothyreon <i>Bellevue, WA</i> | NSCLC (Fast Track) | Phase III (800) 283-8088 (425) 450-0370 |
| talactoferrin (Orphan Drug) | Agennix <i>Houston, TX</i> | NSCLC (Fast Track) (see also kidney) | Phase III (713) 552-1091 |
| tamibarotene | CytRx <i>Los Angeles, CA</i> | NSCLC (see also leukemia) | Phase II (310) 826-5648 |
| Tarceva® erlotinib | Roche <i>Nutley, NJ</i> OSI Pharmaceuticals <i>Melville, NY</i> | NSCLC (see also bladder, brain, breast, colorectal, head/neck, leukemia, liver, other) | Phase III (973) 235-5000 (800) 572-1932 |

LUNG CANCER

| Product Name | Sponsor | Indication | Development Status |
|------------------------------------|---|---|---|
| Tavocept™ dimesna | BioNumerik Pharmaceuticals <i>San Antonio, TX</i> | (see also cancer/chemotherapy) | Phase III (210) 614-1701 |
| Telcyta® canfosfimide | Telik <i>Palo Alto, CA</i> | NSCLC (see also lymphoma, ovarian) | Phase III completed (650) 845-7700 |
| Temodar® temozolomide | Merck <i>Whitehouse Station, NJ</i> | SCLC (see also leukemia, skin) | Phase II (800) 672-6372 |
| topotecan liposomal | Talon Therapeutics <i>South San Francisco, CA</i> | SCLC (see also ovarian) | Phase I (650) 588-6404 |
| TV-1011/OGX-011 (custiren) | Teva Pharmaceutical <i>Tikva, Israel</i> Oncogenex Pharmaceuticals <i>Bothell, WA</i> | NSCLC (see also prostate) | Phase I/II (425) 686-1500 www.tevapharm.com |
| vegin (VEGF antisense) | VasGene Therapeutics <i>Los Angeles, CA</i> | mesothelioma (see also kidney, skin) | Phase I (323) 221-7818 |
| volociximab | Biogen Idec <i>Cambridge, MA</i> Facet Biotech <i>Redwood City, CA</i> | NSCLC (see also ovarian) | Phase II (617) 679-2000 (650) 454-1000 |
| XL647 | Symphony Evolution <i>Rockville, MD</i> | NSCLC | Phase II www.symphony evolution.com |
| Zybrestat™ fosbretabulin | OXIGENE <i>South San Francisco, CA</i> | first-line NSCLC (see also ovarian, other) | Phase II (650) 635-7000 |

LYMPHOMA

| Product Name | Sponsor | Indication | Development Status |
|--------------------------------|---|--|---|
| AEG-35156 | Aegera Therapeutics <i>Montreal, Canada</i> | B-cell lymphoma (see also leukemia) | Phase I/II (514) 288-5532 |
| AEZS-112 | AEterna-Zentaris <i>Warren, NJ</i> | (see also solid tumors) | Phase I (908) 626-5428 |
| Afinitor® everolimus | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | diffuse large B-cell lymphoma (see also breast, kidney, liver, stomach, other) | Phase III (888) 669-6682 |
| | | ----- mantle-cell lymphoma | Phase II (888) 669-6682 |
| AFM13 | Affimed Therapeutics <i>Heidelberg, Germany</i> | Hodgkin's lymphoma | Phase I www.affimed.com |
| afutuzumab (GA101/RG7159) | Biogen Idec <i>Cambridge, MA</i> Roche <i>Nutley, NJ</i> | indolent non-Hodgkin's lymphoma (see also leukemia) | Phase III (617) 679-2000 (973) 235-5000 |
| | | ----- aggressive non-Hodgkin's lymphoma | Phase II (617) 679-2000 (973) 235-5000 |

LYMPHOMA

| Product Name | Sponsor | Indication | Development Status |
|--|--|--|--|
| AME133 (anti-CD20mAb) | MENTRIK Biotech <i>Dallas, TX</i> | non-Hodgkin's lymphoma | Phase II completed (214) 594-0002 |
| amuvatinib | SuperGen <i>Dublin, CA</i> | (see also solid tumors) | Phase I (925) 560-0100 |
| anti-CD22 ADC | Genentech <i>South San Francisco, CA</i> | recurrent non-Hodgkin's lymphoma (see also leukemia) | Phase I (650) 225-1000 |
| anti-CD22 mAb-toxin conjugate | Abiogen Pharma <i>Pisa, Italy</i> University of Texas Southwestern Medical Center <i>Dallas, TX</i> | B-cell lymphoma | Phase I www.abiogen.com |
| Aplidin [®] plitidepsin | PharmaMar USA <i>Cambridge, MA</i> | (see also multiple myeloma, solid tumors) | Phase I (617) 868-3797 |
| AR-12 | Arno Therapeutics <i>Parsippany, NJ</i> | (see also solid tumors) | Phase I (862) 703-7170 |
| AR-42 | Arno Therapeutics <i>Parsippany, NJ</i> | (see also leukemia, multiple myeloma) | Phase I/II (862) 703-7170 |
| Arzerra [®] ofatumumab | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | follicular lymphoma, diffuse large B-cell lymphoma (see also leukemia) | Phase III (888) 825-5249 |
| ASP-3026 | Astellas Pharma US <i>Deerfield, IL</i> | late-stage non-Hodgkin's lymphoma | Phase I (800) 477-6472 |
| AT-101 | Ascenta Therapeutics <i>Malvern, PA</i> | non-Hodgkin's lymphoma (see also brain, leukemia, lung, prostate, stomach) | Phase II completed (610) 408-0301 |
| AT-406 | Ascenta Therapeutics <i>Malvern, PA</i> | lymphoma (see also solid tumors) | Phase I (610) 408-0313 |
| AV-299 (ficlatuzumab) | AVEO Pharmaceuticals <i>Cambridge, MA</i> | (see also brain, multiple myeloma, solid tumors) | Phase I (617) 299-5000 |
| belinostat | Spectrum Pharmaceuticals <i>Irvine, CA</i> TopoTarget USA <i>Rockaway, NJ</i> | peripheral T-cell lymphoma (see also lung, other) | Phase II (949) 788-6700 (973) 895-6900 |
| Bexxar [®] tositumomab | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | mantle-cell lymphoma | Phase II (888) 825-5249 |
| BI 2536 | Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i> | non-Hodgkin's lymphoma (see also lung) | Phase I (800) 243-0127 |
| BiovaxID [®] B-cell lymphoma vaccine | Biovest International <i>Tampa, FL</i> | follicular lymphoma (Fast Track) | Phase III (813) 864-2554 |
| | | mantle-cell lymphoma | Phase II (813) 864-2554 |
| blinatumomab | Micromet <i>Bethesda, MD</i> | non-Hodgkin's lymphoma (see also leukemia) | Phase I (240) 752-1420 |

LYMPHOMA

| Product Name | Sponsor | Indication | Development Status |
|---|--|--|--|
| CAL-101 | Calistoga Pharmaceuticals <i>Seattle, WA</i> | non-Hodgkin's lymphoma (see also leukemia, multiple myeloma) | Phase I (206) 728-4700 |
| cancer vaccine | Bayer Innovation <i>Dusseldorf, Germany</i> Stellar Biotechnologies <i>Port Hueneme, CA</i> | follicular lymphoma (prevention of relapse) | Phase I (805) 488-2147 |
| CC-223 | Celgene <i>Summit, NJ</i> | non-Hodgkin's lymphoma (see also leukemia, solid tumors) | Phase I/II (908) 673-9000 |
| cilengitide | EMD Serono <i>Rockland, MA</i> | late-stage lymphoma (see also brain, prostate) | Phase I completed (800) 283-8088 |
| CST-101 | ConKwest <i>Del Mar, CA</i> | (see also leukemia, lung, skin) | Phase I (858) 380-1999 |
| CT-011 | CureTech <i>Yavne, Israel</i> | diffuse large B-cell lymphoma, follicular lymphoma (see also colorectal, leukemia) | Phase II www.curetechbio.com |
| dacetuzumab (anti-CD40) | Seattle Genetics <i>Bothell, WA</i> | non-Hodgkin's lymphoma (see also leukemia, multiple myeloma) | Phase I (425) 527-4000 |
| darinaparsin (ZIO-101) | ZIOPHARM Oncology <i>New York, NY</i> | (see also liver, multiple myeloma, solid tumors) | Phase II (646) 214-0700 |
| DI-Leu16-IL2 (antibody-cytokine fusion protein) | Provenance Biopharmaceuticals <i>Waltham, MA</i> | non-Hodgkin's lymphoma | Phase I (781) 497-9888 |
| dinaciclib | Merck <i>Whitehouse Station, NJ</i> | mantle-cell lymphoma (see also breast, leukemia, lung) | Phase II (800) 672-6371 |
| dulanermin (rhApo2L/TRAIL) | Amgen <i>Thousand Oaks, CA</i> Genentech <i>South San Francisco, CA</i> | non-Hodgkin's lymphoma (see also colorectal) | Phase I/II (800) 772-6436 (650) 225-1000 |
| enzastaurin | Eli Lilly <i>Indianapolis, IN</i> | diffuse large B-cell lymphoma | Phase III (800) 545-5979 |
| epratuzumab (Orphan Drug) | Immunomedics <i>Morris Plains, NJ</i> | diffuse large B-cell lymphoma, follicular lymphoma (see also leukemia) | Phase II (973) 605-8200 |
| epratuzumab Y-90 | Immunomedics <i>Morris Plains, NJ</i> | recurrent non-Hodgkin's lymphoma | Phase I/II (973) 605-8200 |
| Exelbine™ vinorelbine emulsion | ADVENTRX Pharmaceuticals <i>San Diego, CA</i> | non-Hodgkin's lymphoma (see also breast, lung) | application submitted (858) 552-0866 |
| EZN-2968 | Enzon Pharmaceuticals <i>Bridgewater, NJ</i> | (see also solid tumors) | Phase I (908) 541-8600 |
| EZN-3042 | Enzon Pharmaceuticals <i>Bridgewater, NJ</i> | (see also leukemia, solid tumors) | Phase I (908) 541-8600 |
| Fodosine™ forodesine | BioCryst Pharmaceuticals <i>Birmingham, AL</i> | cutaneous T-cell lymphoma (see also leukemia) | Phase II (205) 444-4600 |

LYMPHOMA

| Product Name | Sponsor | Indication | Development Status |
|--|--|---|--|
| Folotyn® pralatrexate (Orphan Drug) | Allos Therapeutics Westminster, CO | B-cell lymphoma (see also bladder, breast, lung) | Phase II (303) 426-6262 |
| | | Hodgkin's disease, non-Hodgkin's lymphoma | Phase I/II (303) 426-6262 |
| | | cutaneous T-cell lymphoma | Phase I (303) 426-6262 |
| GDC-0917 (IAP antagonist) | Genentech South San Francisco, CA | (see also solid tumors) | Phase I (650) 224-1000 |
| GDC-0941 (PI3 kinase inhibitor) | Genentech South San Francisco, CA | non-Hodgkin's lymphoma (see also breast, lung, solid tumors) | Phase I (650) 224-1000 |
| GDC-0980 (PI3 kinase/mTOR dual inhibitor) | Genentech South San Francisco, CA | non-Hodgkin's lymphoma (see also breast, solid tumors) | Phase I (650) 224-1000 |
| Genasense® oblimersen | Genta Berkeley Heights, NJ | non-Hodgkin's lymphoma (see also leukemia, skin) | Phase II (908) 286-9800 |
| GSK2141795 (AKT protein kinase inhibitor) | GlaxoSmithKline Rsch. Triangle Park, NC | (see also solid tumors) | Phase I (888) 825-5249 |
| HGS-1029 | Human Genome Sciences Rockville, MD | (see also solid tumors) | Phase I (301) 309-8504 |
| INK128 (TORC1/2 inhibitor) | Intellikine La Jolla, CA | Waldenström's macroglobulinemia (see also multiple myeloma, solid tumors) | Phase I (858) 768-6500 |
| inotuzumab ozogamicin (CMC-544) | UCB Smyrna, GA Pfizer New York, NY | aggressive non-Hodgkin's lymphoma | Phase III (770) 970-7500 (860) 732-5156 |
| | | indolent non-Hodgkin's lymphoma | Phase II (770) 970-7500 (860) 732-5156 |
| ISF35 | Memgen Dallas, TX | diffuse large-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma | Phase II (214) 731-3141 |
| Istodax® romidepsin (Orphan Drug) | Celgene Summit, NJ | peripheral T-cell lymphoma (Fast Track) | application submitted (908) 673-9000 |
| LEE011 | Novartis Pharmaceuticals East Hanover, NJ | (see also solid tumors) | Phase I (888) 669-6682 |
| LG740 | Lentigen Gaithersburg, MD University of Pennsylvania Philadelphia, PA | diffuse large B-cell lymphoma, follicular lymphoma, mantle-cell lymphoma (see also leukemia) | Phase I (301) 527-4200 |
| lucatumumab (HCD122) | Novartis Pharmaceuticals East Hanover, NJ XOMA Berkeley, CA | | Phase I/II (888) 669-6682 (510) 204-7200 |

LYMPHOMA

| Product Name | Sponsor | Indication | Development Status |
|--|--|--|--|
| MabThera® SC/ rHuPH20/ rituximab | Halozyme San Diego, CA Roche Nutley, NJ | follicular lymphoma | Phase III (858) 794-8889 (973) 235-5000 |
| MDX-1203 (anti-CD70 ADC) | Bristol-Myers Squibb Princeton, NJ | non-Hodgkin's lymphoma (see also kidney) | Phase I (212) 546-4000 |
| mechlorethamine gel (Orphan Drug) | Yaupon Therapeutics Radnor, PA | cutaneous T-cell lymphoma (Fast Track) | Phase III (610) 975-9290 |
| MGCD-0103 | MethylGene Montreal, Canada | diffuse large B-cell lymphoma, follicular lymphoma (see also leukemia, solid tumors) | Phase II (514) 337-3333 |
| milatuzumab (IMMU-115) | Immunomedics Morris Plains, NJ | non-Hodgkin's lymphoma (see also leukemia, multiple myeloma) | Phase I/II (973) 605-8200 |
| mogamulizumab | Kyowa Hakko Kirin Pharma Princeton, NJ | T-cell lymphoma | Phase II (609) 919-1100 |
| navitoclax (ABT-263/RG7433) | Abbott Laboratories Abbott Park, IL Genentech South San Francisco, CA | relapsed or refractory lymphoid malignancies (see also leukemia, lung) | Phase I/II (847) 937-6100 (650) 225-1000 |
| NPI-0052 (marizomib) | Nereus Pharmaceuticals San Diego, CA | (see also multiple myeloma, solid tumors) | Phase I (858) 587-4090 |
| obatoclax | Gemin X Biotechnologies Montreal, Canada | follicular lymphoma (see also leukemia, lung, multiple myeloma) | Phase II (514) 281-8989 |
| | | ----- mantle-cell lymphoma | Phase I/II (514) 281-8989 |
| ON-01910 | Onconova Therapeutics Princeton, NJ | (see also leukemia, ovarian, solid tumors) | Phase II (609) 844-7735 |
| ON-013105 | Onconova Therapeutics Princeton, NJ | (see also leukemia) | Phase I (609) 844-7735 |
| OSI-027 | OSI Pharmaceuticals Melville, NY | (see also kidney) | Phase I (800) 572-1932 |
| P276 | Piramal Life Sciences Mumbai, India | mantle-cell lymphoma | Phase II |
| panobinostat (LBH589) | Novartis Pharmaceuticals East Hanover, NJ | Hodgkin's lymphoma (see also multiple myeloma, other) | application submitted (888) 669-6682 |
| PCI-24781 (HDAC inhibitor) | Pharmacyclics Sunnyvale, CA | (see also sarcoma) | Phase II (408) 774-0330 |
| PCI-32765 (BTK inhibitor) | Pharmacyclics Sunnyvale, CA | mantle-cell lymphoma (see also leukemia) | Phase II (408) 774-0330 |

LYMPHOMA

| Product Name | Sponsor | Indication | Development Status |
|---|--|--|---|
| PD-0332991 | Pfizer <i>New York, NY</i> | mantle-cell lymphoma (see also brain, breast, multiple myeloma, sarcoma) | Phase I (860) 732-5156 |
| perifosine (KRX-0401) | AEterna Zentaris <i>Montreal, Canada</i> Keryx Biopharmaceuticals <i>New York, NY</i> | recurrent lymphoma, Waldenström's macroglobulinemia (see also brain, colorectal, kidney, leukemia, multiple myeloma, ovarian, sarcoma, stomach) | Phase II (212) 531-5965 |
| Pixuvri™ pixantrone | Cell Therapeutics <i>Seattle, WA</i> | non-Hodgkin's lymphoma (Fast Track) (see also breast) | application submitted (800) 215-2355 |
| | | diffuse large B-cell lymphoma | Phase II (800) 215-2355 |
| PLX3397 | Plexxikon <i>Berkeley, CA</i> | recurrent or refractory Hodgkin's disease (see also solid tumors) | Phase II (510) 647-4000 |
| PX-478 | Oncothyreon <i>Seattle, WA</i> | (see also solid tumors) | Phase I completed (206) 801-2100 |
| Rituxan® rituxumab | Biogen Idec <i>Cambridge, MA</i> Roche <i>Nutley, NJ</i> | non-Hodgkin's lymphoma (subcutaneous) | Phase III (617) 679-2000 (973) 235-5000 |
| | | non-Hodgkin's lymphoma (fast fusion) | Phase III (617) 679-2000 (973) 235-5000 |
| SAR3419 | sanofi-aventis <i>Bridgewater, NJ</i> | non-Hodgkin's lymphoma | Phase I (800) 633-1610 |
| SB1518 | S*Bio <i>Redwood City, CA</i> | late-stage lymphoma (see also leukemia) | Phase II (650) 730-2860 |
| SCH-900776 | Merck <i>Whitehouse Station, NJ</i> | (see also leukemia) | Phase I (800) 672-6372 |
| SGN-35 (brentuximab vedotin) (Orphan Drug) | Millennium Pharmaceuticals <i>Cambridge, MA</i> Seattle Genetics <i>Bothell, WA</i> | Hodgkin's disease (combination therapy), recurrent non-Hodgkin's lymphoma | application submitted (800) 390-5663 (425) 527-4000 |
| | | non-Hodgkin's lymphoma (monotherapy) (Fast Track) | Phase II (800) 390-5663 (425) 527-4000 |
| SGN-75 | Seattle Genetics <i>Bothell, WA</i> | non-Hodgkin's lymphoma (see also kidney) | Phase I (425) 527-4000 |
| SNDX-275 (entinostat) | Syndax Pharmaceuticals <i>Waltham, MA</i> | Hodgkin's disease (see also breast, colorectal, leukemia, lung) | Phase II (781) 419-1400 |
| Sprycel® dasatinib | Bristol-Myers Squibb <i>Princeton, NJ</i> | non-Hodgkin's lymphoma (see also brain, breast, colorectal, leukemia, lung, multiple myeloma, prostate, skin) | Phase I/II (212) 546-4000 |

LYMPHOMA

| Product Name | Sponsor | Indication | Development Status |
|---|---|--|---|
| stem cell therapy | Benitec <i>Melbourne, Australia</i> City of Hope Medical Center <i>Duarte, CA</i> | AIDS-related lymphoma | Phase I www.benitec.com |
| Telcyta [®] canfosfamide | Telik <i>Palo Alto, CA</i> | diffuse large B-cell lymphoma, mantle-cell lymphoma non-Hodgkin's lymphoma (see also lung, ovarian) | Phase II (650) 845-7700 |
| thiarabine | Access Pharmaceuticals <i>Dallas, TX</i> | (see also leukemia) | Phase I/II (214) 905-5100 |
| tigatuzumab | Daiichi Sankyo <i>Parsippany, NJ</i> | (see also colorectal, liver, ovarian, pancreatic) | Phase I completed (973) 359-2600 |
| TKM-PLK1 | Tekmira Pharmaceuticals <i>Vancouver, Canada</i> | (see also solid tumors) | Phase I (604) 419-3200 |
| Treanda [®] bendamustine | Cephalon <i>Frazer, PA</i> | first-line non-Hodgkin's lymphoma ----- mantle-cell lymphoma | Phase III (610) 344-0200 Phase II (610) 344-0200 |
| TRU-016 (anti-CD37) | Emergent Biosolutions <i>Rockville, MD</i> | recurrent non-Hodgkin's lymphoma (see also leukemia) | Phase I (301) 795-1800 |
| UNBS-5162 | Drais Pharmaceuticals <i>Bridgewater, NJ</i> | (see also solid tumors) | Phase I (908) 895-1200 |
| Velcade [®] bortezomib | Millennium Pharmaceuticals <i>Cambridge, MA</i> | relapsed or refractory follicular lymphoma, first-line mantle-cell lymphoma (see also multiple myeloma) ----- diffuse large B-cell lymphoma | Phase III (800) 390-5663 Phase II (800) 390-5663 |
| veltuzumab (IMMU-106) | Immunomedics <i>Morris Plains, NJ</i> | non-Hodgkin's lymphoma (see also leukemia) | Phase I/II (973) 605-8200 |
| vinorelbine liposomal | Talon Therapeutics <i>South San Francisco, CA</i> | non-Hodgkin's lymphoma (see also solid tumors) | Phase I (650) 588-6404 |
| XmAb 2513 | Xencor <i>Monrovia, CA</i> | Hodgkin's disease, T-cell lymphoma | Phase I (626) 305-5900 |
| YM-155 | Astellas Pharma US <i>Deerfield, IL</i> | non-Hodgkin's lymphoma (see also breast) | Phase II (800) 727-7003 |
| zanolimumab | TenX Biopharma <i>Philadelphia, PA</i> | cutaneous T-cell lymphoma (Fast Track) ----- peripheral T-cell lymphoma | Phase III (215) 774-1176 Phase II completed (215) 774-1176 |

MULTIPLE MYELOMA

| Product Name | Sponsor | Indication | Development Status |
|--|--|---|--|
| ACE-041 | Acceleron Pharma <i>Cambridge, MA</i> | (see also solid tumors) | Phase I (617) 649-9200 |
| Actimid™ pomalidomide | Celgene <i>Summit, NJ</i> | recurrent multiple myeloma | Phase II (908) 673-9000 |
| ALXN-6000 (samalizumab) | Alexion Pharmaceuticals <i>Cheshire, CT</i> | (see also leukemia) | Phase I/II (203) 272-2596 |
| anti-FGFR3 mAb (RG7444) | Genentech <i>South San Francisco, CA</i> | refractory, metastatic multiple myeloma | Phase I (650) 224-1000 |
| Aplidin® plitidepsin (Orphan Drug) | PharmaMar USA <i>Cambridge, MA</i> | (see also lymphoma, solid tumors) | Phase III (617) 868-3797 |
| AR-42 | Arno Therapeutics <i>Parsippany, NJ</i> | (see also leukemia, lymphoma) | Phase I/II (862) 703-7170 |
| ARRY-520 | Array BioPharma <i>Boulder, CO</i> | (see also leukemia, solid tumors) | Phase II (303) 381-6600 |
| AT7519 | Astex Therapeutics <i>Cambridge, United Kingdom</i> | (see also solid tumors) | Phase I/II www.astex-therapeutics.com |
| ATN-224 | Tactic Pharma <i>Evanston, IL</i> | (see also prostate, skin) | Phase I/II (847) 733-0940 |
| AUY922 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | (see also breast, colorectal, lung, stomach) | Phase I/II (888) 669-6682 |
| AV-299 (ficlatuzumab) | AVEO Pharmaceuticals <i>Cambridge, MA</i> | (see also brain, lymphoma, solid tumors) | Phase I (617) 299-5000 |
| BHQ880 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | (see also solid tumors) | Phase II (888) 669-6682 |
| BI-505 | BioInvent International <i>Lund, Sweden</i> | late-stage multiple myeloma | Phase I www.bioinvent.com |
| BIW-8962 | BioWa <i>Princeton, NJ</i> | | Phase I/II (609) 580-7500 |
| BT-062 (Orphan Drug) | Biotest <i>Dreieich, Germany</i> | | Phase I/II www.biotest.com |
| CAL-101 | Calistoga Pharmaceuticals <i>Seattle, WA</i> | (see also leukemia, lymphoma) | Phase I (206) 728-4700 |
| carfilzomib (Orphan Drug) | Onyx Pharmaceuticals <i>Emeryville, CA</i> | (Fast Track) (see also solid tumors) | application submitted (510) 597-6500 |
| CB3304 | Cougar Biotechnology <i>Los Angeles, CA</i> | | Phase I/II (310) 943-8040 |
| CC-223 | Celgene <i>Summit, NJ</i> | (see also lymphoma, solid tumors) | Phase I/II (908) 673-9000 |
| CEP-18770 (proteasome inhibitor) | Cephalon <i>Frazer, PA</i> | | Phase II (610) 344-0200 |
| CNTO 328 (siltuximab) | Centocor Ortho Biotech <i>Horsham, PA</i> | (see also prostate, other) | Phase II (800) 457-6399 |

MULTIPLE MYELOMA

| Product Name | Sponsor | Indication | Development Status |
|--|---|---|--|
| CX-4945 | Cylene Pharmaceuticals <i>San Diego, CA</i> | (see also solid tumors, other) | Phase I (858) 875-5100 |
| dacetuzumab (anti-CD40) (Orphan Drug) | Seattle Genetics <i>Bothell, WA</i> | (see also leukemia, lymphoma) | Phase I (425) 527-4000 |
| darinaparsin (ZIO-101) | Ziopharm Oncology <i>New York, NY</i> | (see also liver, lymphoma, solid tumors) | Phase II completed (646) 214-0700 |
| elotuzumab (BMS-901608) | Bristol-Myers Squibb <i>Princeton, NJ</i> Facet Biotech <i>Redwood City, CA</i> | | Phase I/II (212) 546-4000 (650) 454-1000 |
| ENMD-2076 | EntreMed <i>Rockville, MD</i> | relapsed or refractory multiple myeloma (see also ovarian, other) | Phase I (240) 864-2600 |
| GRN-163L (imetelstat) | Geron <i>Menlo Park, CA</i> | (see also breast, leukemia, lung) | Phase II (650) 473-7700 |
| GVAX® Multiple Myeloma | BioSante Pharmaceuticals <i>Lincolnshire, IL</i> | (see also breast, colorectal, leukemia, pancreatic) | Phase II (847) 478-0500 |
| IMGN-901 | ImmunoGen <i>Cambridge, MA</i> | (see also lung) | Phase I (617) 995-2500 |
| INK128 (TORC1/2 inhibitor) | Intellikine <i>La Jolla, CA</i> | (see also lymphoma, solid tumors) | Phase I (858) 768-6500 |
| IPH-2101 | Innate Pharma <i>Marseille, France</i> | | Phase II www.innate-pharma.com |
| KW-2478 | Kyowa Hakko Kirin Pharma <i>Princeton, NJ</i> | | Phase I/II (609) 919-1100 |
| LY2127399 (BAFF antibody) | Applied Molecular Evolution <i>San Diego, CA</i> Eli Lilly <i>Indianapolis, IN</i> | | Phase I (800) 545-5979 |
| mapatumumab | Human Genome Sciences <i>Rockville, MD</i> | (see also liver, lung) | Phase II (301) 309-8504 |
| melphalan intravenous (Orphan Drug) | CyDex Pharmaceuticals <i>Lenexa, KS</i> | | Phase II (888) 436-6910 |
| milatuzumab (IMMU-115) (Orphan Drug) | Immunomedics <i>Morris Plains, NJ</i> | (see also leukemia, lymphoma) | Phase I/II (973) 605-8200 |
| NPI-0052 (marizomib) | Nereus Pharmaceuticals <i>San Diego, CA</i> | (see also lymphoma, solid tumors) | Phase I (858) 587-4090 |
| obatoclax | Gemin X Biotechnologies <i>Montreal, Canada</i> | (see also leukemia, lung, lymphoma) | Phase I (514) 281-8989 |
| panobinostat (LBH589) | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | (see also lymphoma, other) | Phase III (888) 669-6682 |
| PD-0332991 | Pfizer <i>New York, NY</i> | (see also brain, breast, lymphoma, sarcoma) | Phase I/II (860) 732-5156 |

MULTIPLE MYELOMA

| Product Name | Sponsor | Indication | Development Status |
|---|--|---|--|
| perifosine (KRX-0401) (Orphan Drug) | AEterna Zentaris <i>Montreal, Canada</i> Keryx Biopharmaceuticals <i>New York, NY</i> | recurrent multiple myeloma (Fast Track) (see also brain, colorectal, kidney, leukemia, lymphoma, ovarian, sarcoma, stomach) | Phase III (212) 531-5965 |
| Quadramet [®] samarium sm-153 lexidronam injection | EUSA Pharma <i>Langhorne, PA</i> | (see also prostate, sarcoma, other) | Phase I/II completed (800) 833-3533 |
| SF1126 | Semafore Pharmaceuticals <i>Indianapolis, IN</i> | (see also multiple myeloma, solid tumors) | Phase I (317) 876-3075 |
| Sprycel [®] dasatinib | Bristol-Myers Squibb <i>Princeton, NJ</i> | (see also brain, breast, colorectal, leukemia, lung, lymphoma, prostate, skin) | Phase I (212) 546-4000 |
| Treanda [®] bendamustine | Cephalon <i>Frazer, PA</i> | (see also lymphoma) | Phase II (610) 344-0200 |
| Trisenox [®] arsenic trioxide | Cephalon <i>Frazer, PA</i> | combination therapy (see also brain, leukemia) | Phase II (610) 344-0200 |
| VEL-0230 | Velcura Therapeutics <i>Ann Arbor, MI</i> | | Phase I completed (734) 973-1000 |
| Velcade [®] bortezomib (subcutaneous) | Millennium Pharmaceuticals <i>Cambridge, MA</i> | (see also lymphoma) | Phase III (800) 390-5663 |
| Zolinza [®] vorinostat (Orphan Drug) | Merck <i>Whitehouse Station, NJ</i> | (see also breast, other) | Phase III (800) 672-6372 |

OVARIAN CANCER

| Product Name | Sponsor | Indication | Development Status |
|---|---|---|----------------------------------|
| Å6 | Angstrom Pharmaceuticals <i>Solana Beach, CA</i> | (see also other) | Phase II (858) 314-2356 |
| abagovomab (anti-idiotypic ovarian cancer vaccine) (Orphan Drug) | Menarini <i>Florence, Italy</i> | | Phase II/III www.menarini.com |
| Abraxane [®] albumin-bound paclitaxel | Celgene <i>Summit, NJ</i> | (see also bladder, lung, pancreatic, skin) | Phase II (908) 673-9000 |
| ABT-888 (veliparib) | Abbott Laboratories <i>Abbott Park, IL</i> | (see also brain, breast, colorectal, prostate, skin, other) | Phase II (847) 937-6100 |
| AE-37 | Antigen Express <i>Worcester, MA</i> | (see also breast) | Phase I (508) 852-8783 |
| AMG 386 | Amgen <i>Thousand Oaks, CA</i> | (see also breast, colorectal, kidney, liver, stomach, other) | Phase III (800) 772-6436 |

OVARIAN CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|--|---|--|
| Avastin® bevacizumab | Genentech <i>South San Francisco, CA</i> | first-line metastatic ovarian cancer, recurrent platinum-sensitive ovarian cancer (see also brain, breast, colorectal, lung, other) | Phase III (650) 225-1000 |
| BC-819 | BioCancell Therapeutics <i>Jerusalem, Israel</i> | (see also bladder, pancreatic) | Phase I/II www.biocancell.com |
| catumaxomab | Fresenius Biotech North America <i>Waltham, MA</i> | (see also other) | Phase II www.fresenius-biotech.com |
| CVax™ MUC-2 cancer vaccine | Prima BioMed <i>Armadale, Australia</i> | | Phase II www.prima biomed.com.au |
| DCVax®-L ovarian cancer vaccine | Northwest Biotherapeutics <i>Bothell, WA</i> | (see also other) | Phase I/II (425) 608-3000 |
| DPX-0907 | Immunovaccine <i>Halifax, Canada</i> | (see also breast, prostate) | Phase I (902) 492-1819 |
| EC-145 | Endocyte <i>West Lafayette, IN</i> | (see also lung, other) | Phase II (765) 463-7175 |
| EGEN 001 (Orphan Drug) | EGEN <i>Huntsville, AL</i> | recurrent ovarian cancer (see also other) | Phase II (256) 512-0077 |
| | | refractory metastatic ovarian cancer | Phase I (256) 512-0077 |
| ENMD-2076 | EntreMed <i>Rockville, MD</i> | platinum-resistant ovarian cancer (see also multiple myeloma, other) | Phase II (240) 864-2600 |
| farletuzumab (MORAb-003) | Eisai <i>Woodcliff Lake, NJ</i> | (see also lung) | Phase III (888) 422-4743 |
| iboctadekin | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | | Phase I (888) 825-5249 |
| IMT-1012 (immunotherapeutic vaccine) | Immunotope <i>Doylestown, PA</i> | (see also breast) | Phase I (215) 253-4180 |
| iniparib (BSI-201) | BiPar Sciences <i>South San Francisco, CA</i> sanofi-aventis <i>Bridgewater, NJ</i> | (see also breast, lung) | Phase II (800) 633-1810 |
| Karenitecin® cositecan | BioNumerik Pharmaceuticals <i>San Antonio, TX</i> | advanced epithelial ovarian cancer | Phase III (210) 614-1701 |
| KHK-2866 | Kyowa Hakkō Kirin Pharma <i>Princeton, NJ</i> | (see also solid tumors) | Phase I (609) 919-1100 |
| lenvatinib (E7080) | Eisai <i>Woodcliff Lake, NJ</i> | (see also brain, kidney, liver, skin, other) | Phase I/II (888) 422-4743 |

OVARIAN CANCER

| Product Name | Sponsor | Indication | Development Status |
|---|--|--|---|
| Nexavar® sorafenib | Bayer HealthCare Pharmaceuticals Wayne, NJ Onyx Pharmaceuticals Emeryville, CA | (see also breast, colorectal, kidney, liver, lung, other) | Phase II (888) 842-2837 (510) 597-6500 |
| NKTR-102 | Nektar Therapeutics San Francisco, CA | metastatic ovarian cancer (see also breast, colorectal) | Phase II (415) 482-5300 |
| NOV-002 | Novelos Therapeutics Newton, MA | (see also breast) | Phase II completed (617) 244-1616 |
| OGX-427 | Oncogenex Pharmaceuticals Bothell, WA | (see also bladder, breast, lung, prostate) | Phase I (425) 686-1500 |
| olaparib | AstraZeneca Wilmington, DE | serous ovarian cancer | Phase II (800) 236-9933 |
| ON-01910 | Onconova Therapeutics Princeton, NJ | (see also leukemia, lymphoma, solid tumors) | Phase II (609) 844-7735 |
| Opaxio™ paclitaxel poliglumex | Cell Therapeutics Seattle, WA Novartis Pharmaceuticals East Hanover, NJ | (see also lung, other) | Phase III (800) 215-2355 (888) 669-6682 |
| oregovomab | Quest Pharmatech Edmonton, Canada | | Phase I/II (780) 448-1400 |
| OSI-906 (linsitinib) | OSI Pharmaceuticals Melville, NY | (see also lung, other) | Phase II (631) 962-2000 |
| OVax® ovarian cancer vaccine (Orphan Drug) | AVAX Technologies Philadelphia, PA | | Phase I/II (215) 241-9760 |
| perifosine (KRX-0401) | AEterna Zentaris Montreal, Canada Keryx Biopharmaceuticals New York, NY | (see also brain, colorectal, kidney, leukemia, lymphoma, multiple myeloma, sarcoma, stomach) | Phase I (212) 531-5965 |
| PF-01367338 | Pfizer New York, NY | (see also breast, skin) | Phase II (860) 732-5156 |
| phenoxodiol | Marshall Edwards San Diego, CA | late-stage ovarian cancer (Fast Track) (see also prostate, other) | Phase III (858) 792-6300 |
| picoplatin intravenous | Poniard Pharmaceuticals San Francisco, CA | (see also colorectal, lung, prostate) | Phase II (650) 583-3774 |
| Quinamed® amonafide | ChemGenex Pharmaceuticals Menlo Park, CA | (see also breast, prostate) | Phase II (650) 474-9800 |
| sagopilone | Bayer HealthCare Pharmaceuticals Wayne, NJ | (see also brain, breast, prostate) | Phase II (888) 842-2937 |

OVARIAN CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|---|--|--|
| SAR256212 (MM-121) | Merrimack Pharmaceuticals <i>Cambridge, MA</i> sanofi-aventis <i>Bridgewater, NJ</i> | (see also breast, solid tumors) | Phase I (617) 441-1000 (800) 633-1810 |
| SG2000 | Spirogen <i>London, United Kingdom</i> | | Phase II www.spirogen.com |
| squalamine | OHR Pharmaceuticals <i>New York, NY</i> | resistant ovarian cancer | Phase II (212) 682-8452 |
| Telcyta® canfosfimide | Telik <i>Palo Alto, CA</i> | (see also lung, lymphoma) | Phase III completed (650) 845-7700 |
| tigatuzumab | Daiichi Sankyo <i>Parsippany, NJ</i> | (see also colorectal, liver, lymphoma, pancreatic) | Phase II (973) 359-2600 |
| topotecan liposomal | Talon Therapeutics <i>South San Francisco, CA</i> | (see also lung) | Phase I (650) 588-6404 |
| trabectedin (Orphan Drug) | Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i> | (see also breast, prostate, sarcoma) | application submitted (800) 817-5286 |
| volociximab | Biogen Idec <i>Cambridge, MA</i> Facet Biotech <i>Redwood City, CA</i> | (see also lung) | Phase II (617) 679-2000 (650) 454-1000 |
| vosaroxin (SNS-595) | Sunesis Pharmaceuticals <i>South San Francisco, CA</i> | platinum-resistant ovarian cancer (see also leukemia) | Phase II (650) 266-3500 |
| Votrient® pazopanib | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | (see also breast, kidney, sarcoma) | Phase III (888) 825-5249 |
| Zybrestat™ fosbretabulin (Orphan Drug) | OXIGENE <i>South San Francisco, CA</i> | (see also lung, other) | Phase II (650) 635-7000 |

PANCREATIC CANCER

| Product Name | Sponsor | Indication | Development Status |
|---|--|---|--|
| Abraxane® albumin-bound paclitaxel (Orphan Drug) | Celgene <i>Summit, NJ</i> | (see also bladder, lung, ovarian, skin) | Phase III (908) 673-9000 |
| AGS-1C4D4 | Agensys <i>Santa Monica, CA</i> Astellas Pharma US <i>Deerfield, IL</i> | | Phase II (310) 820-8029 (800) 477-6472 |
| AMG 479 (ganitumab) | Amgen <i>Thousand Oaks, CA</i> | (see also breast, colorectal, lung, sarcoma, other) | Phase III (800) 772-6436 |
| anti-MUC1 mAb | Quest PharmaTech <i>Edmonton, Canada</i> | | Phase I/II (780) 448-1400 |

PANCREATIC CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|--|--|---|
| apricoxib | Tragara Pharmaceuticals <i>San Diego, CA</i> | (see also lung) | Phase II (858) 350-6900 |
| ARC-100 | Archer Biosciences <i>New York, NY</i> | (see also brain, prostate, skin) | Phase II (646) 747-9090 |
| ARQ-197 | ArQule <i>Woburn, MA</i> Daiichi Sankyo <i>Parsippany, NJ</i> | (see also colorectal, kidney, liver, lung, sarcoma, solid tumors, other) | Phase I (781) 994-0300 (973) 944-2600 |
| ASG-5ME | Agensys <i>Santa Monica, CA</i> Astellas Pharma US <i>Deerfield, IL</i> | metastatic pancreatic cancer (see also prostate) | Phase I (301) 820-8029 (800) 477-6472 |
| bavituximab | Peregrine Pharmaceuticals <i>Tustin, CA</i> | (see also breast, liver) | Phase II (714) 508-6000 |
| BC-819 | BioCancell Therapeutics <i>Jerusalem, Israel</i> | inoperable/unresectable pancreatic cancer (see also bladder, ovarian) | Phase I/II www.biocancell.com |
| CO-101/CP-4126 (Orphan Drug) | Clovis Oncology <i>Boulder, CO</i> | | Phase II (303) 625-5000 |
| conatumumab | Amgen <i>Thousand Oaks, CA</i> | (see also colorectal, lung, sarcoma) | Phase I/II (800) 772-6436 |
| CPI-613 (Orphan Drug) | Cornerstone Pharmaceuticals <i>Cranbury, NJ</i> | (see also other) | Phase I/II (609) 409-7050 |
| dalotuzumab | Merck <i>Whitehouse Station, NJ</i> | (see also breast, colorectal, lung, other) | Phase I/II (888) 669-6682 |
| encapsulated cell therapy (macrobeads) | Rogosin Institute <i>New York, NY</i> | refractory metastatic pancreatic cancer (see also colorectal, prostate) | Phase II (212) 746-1225 |
| ensituximab | Neogenix Oncology <i>Great Neck, NY</i> | inoperable/unresectable, late-stage, metastatic pancreatic cancer (see also colorectal) | Phase I (516) 482-1200 |
| FG-3019 | Fibrogen <i>San Francisco, CA</i> | | Phase II (415) 978-1200 |
| GI-4000 | Globelimmune <i>Louisville, CO</i> | (see also colorectal, lung) | Phase II (303) 625-2700 |
| glufosfamide (Orphan Drug) | Eleison Pharmaceuticals <i>Princeton, NJ</i> | (Fast Track) | Phase III completed (215) 416-7620 |
| GSK1120212 (MEK inhibitor) | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | (see also skin, solid tumors) | Phase II (888) 825-5249 |
| GVAX® Pancreatic (Orphan Drug) | BioSante Pharmaceuticals <i>Lincolnshire, IL</i> | (see also breast, colorectal, leukemia, multiple myeloma) | Phase II (847) 478-0500 |
| HyperAcute® Pancreas algenpantucel-L (Orphan Drug) | NewLink Genetics <i>Ames, IA</i> | (Fast Track) | Phase III (515) 296-5555 |

PANCREATIC CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|--|---|--|
| IPI-926 | Infinity Pharmaceuticals <i>Cambridge, MA</i> | (see also sarcoma, solid tumors) | Phase I/II (617) 453-1000 |
| JX-929 | Jenerex Biotherapeutics <i>San Francisco, CA</i> | | Phase I (415) 281-8886 |
| LE-DT | NeoPharm <i>Lake Bluff, IL</i> | late-stage, metastatic pancreatic cancer (see also prostate) | Phase II (847) 887-0800 |
| masitinib | AB Science USA <i>Short Hills, NJ</i> | (see also leukemia, stomach) | Phase III (973) 218-2437 |
| MM-398 | Merrimack Pharmaceuticals <i>Cambridge, MA</i> | metastatic pancreatic cancer | Phase II (617) 441-1000 |
| naptumomab estafenatox | Active Biotech <i>Lund, Sweden</i> | (see also kidney, lung) | Phase I completed www.activebiotech.com |
| PancAtak™ gene therapy | Advantagene <i>Auburndale, MA</i> | | Phase I (617) 916-5445 |
| PCI-27483 (factor VIIa inhibitor) | Pharmacyclics <i>Sunnyvale, CA</i> | | Phase II (408) 774-0330 |
| polyclonal antibody stimulator (Orphan Drug) | Cancer Advances <i>Durham, NC</i> | (see also colorectal, stomach) | Phase III (919) 361-2162 |
| Reolysin® reovirus | Oncolytics Biotech <i>Calgary, Canada</i> | (see also brain, colorectal, head/neck, lung, sarcoma, skin) | Phase II (403) 670-7377 |
| Rexin-G™ tumor-targeted gene therapy (Orphan Drug) | Epeius Biotechnologies <i>San Marino, CA</i> | recurrent, refractory metastatic pancreatic cancer (Fast Track) (see also breast, sarcoma) | Phase I/II (626) 441-6695 |
| RX-0201 (Orphan Drug) | Rexahn Pharmaceuticals <i>Rockville, MD</i> | | Phase II (240) 268-5300 |
| salirasib (Orphan Drug) | Concordia Pharmaceuticals <i>Ft. Lauderdale, FL</i> | (see also lung) | Phase I/II www.concordiapharma.com |
| Sutent® sunitinib | Pfizer <i>New York, NY</i> | pancreatic islet cell tumors (see also kidney) | application submitted (860) 732-5156 |
| TH-302 | Threshold Pharmaceuticals <i>Redwood City, CA</i> | (see also leukemia, sarcoma, solid tumors) | Phase II (650) 474-8200 |
| tigatuzumab | Daiichi Sankyo <i>Parsippany, NJ</i> | (see also colorectal, liver, lymphoma, ovarian) | Phase II completed (973) 359-2600 |
| tremelimumab (CP-675206) | Pfizer <i>New York, NY</i> | (see also kidney, skin, stomach, other) | Phase II (860) 732-5156 |
| virulizin | Zor Pharmaceuticals <i>Wilmington, NC</i> | | Phase III (919) 946-4457 |
| Y-90 hPAM4 (IMMU-107) (Orphan Drug) | Immunomedics <i>Morris Plains, NJ</i> | | Phase I/II (973) 605-8200 |

PROSTATE CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|---|---|---|
| ABI-008 (nab [®] -docetaxel) | Celgene <i>Summit, NJ</i> | hormone-refractory prostate cancer | Phase II (908) 673-9000 |
| abiraterone acetate (CB7630) | Cougar Biotechnology <i>Raritan, NJ</i> | metastatic advanced prostate cancer (see also breast) | application submitted (800) 817-5286 |
| ABR-215050 (tasquinimod) | Active Biotech <i>Lund, Sweden</i> | | Phase III www.activebiotech.com |
| ABT-888 (veliparib) | Abbott Laboratories <i>Abbott Park, IL</i> | (see also brain, breast, colorectal ovarian, skin, other) | Phase I (847) 937-6100 |
| Acapodene[®] toremifene | GTx <i>Memphis, TN</i> | prostatic intraepithelial neoplasia (prevention) (see also cancer/chemotherapy) | Phase III (901) 523-9700 |
| AEZS-108 | AEterna-Zentaris <i>Warren, NJ</i> | (see also bladder) | Phase I/II (908) 626-5428 |
| aflibercept (VEGF-trap) | sanofi-aventis <i>Bridgewater, NJ</i> Regeneron Pharmaceuticals <i>Tarrytown, NY</i> | first-line metastatic prostate cancer (see also colorectal, lung) | Phase III (800) 633-1610 (714) 345-7400 |
| androgen receptor antagonist | Endo Pharmaceuticals <i>Chadds Ford, PA</i> Orion <i>Espoo, Finland</i> | | Phase I (800) 462-3636 |
| ARC-100 | Archer Biosciences <i>New York, NY</i> | (see also brain, pancreatic, skin) | Phase II (646) 747-9090 |
| ARN-509 | Aragon Pharmaceuticals <i>San Diego, CA</i> | | Phase I/II (858) 369-7600 |
| ASG-5ME | Agensys <i>Santa Monica, CA</i> Astellas Pharma US <i>Deerfield, IL</i> | castration-resistant prostate cancer (see also pancreatic) | Phase I (301) 820-8029 (800) 477-6472 |
| AT-101 | Ascenta Therapeutics <i>Malvern, PA</i> | (see also brain, leukemia, lung, lymphoma, stomach) | Phase II (618) 408-0301 |
| ATN-224 | Tactic Pharma <i>Evanston, IL</i> | (see also multiple myeloma, skin) | Phase II (847) 733-0940 |
| Avodart[®] dutasteride | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | prostate cancer prevention, prostatic intraepithelial neoplasia | application submitted (888) 825-5249 |
| AZD3514 (androgen receptor down regulator) | AstraZeneca <i>Wilmington, DE</i> | | Phase I (800) 236-9933 |
| bafetinib | CytRx <i>Los Angeles, CA</i> | hormone-refractory prostate cancer (see also leukemia) | Phase II (310) 826-5648 |
| BPX-101 (BP-GMAX-CD1) | Bellicum Pharmaceuticals <i>Houston, TX</i> | | Phase I/II (713) 341-6472 |
| carlumab | Centocor Ortho Biotech <i>Horsham, PA</i> | metastatic prostate cancer (see also solid tumors) | Phase II (800) 457-6399 |
| cilengitide | EMD Serono <i>Rockland, MA</i> | (see also brain, lymphoma) | Phase II (800) 283-8088 |

PROSTATE CANCER

| Product Name | Sponsor | Indication | Development Status |
|---|---|---|--|
| CNTO 95 | Centocor Ortho Biotech <i>Horsham, PA</i> | (see also skin, solid tumors) | Phase II completed (800) 457-6399 |
| CNTO 328 (siltuximab) | Centocor Ortho Biotech <i>Horsham, PA</i> | hormone-refractory prostate cancer (see also multiple myeloma, other) | Phase I (800) 457-6399 |
| CV9103 | Curevac <i>Tübingen, Germany</i> | | Phase I/II www.curevac.de |
| DCVax®-Prostate prostate cancer vaccine | Northwest Biotherapeutics <i>Bothell, WA</i> | | Phase III (425) 608-3000 |
| DPX-0907 | Immunovaccine <i>Halifax, Canada</i> | (see also breast, ovarian) | Phase I (902) 492-1819 |
| encapsulated cell therapy (macrobeads) | Rogosin Institute <i>New York, NY</i> | refractory metastatic pancreatic cancer (see also colorectal, pancreatic) | Phase II (212) 746-1225 |
| eribulin (E7389) | Eisai <i>Woodcliff Lake, NJ</i> | (see also bladder, lung, sarcoma) | Phase II (888) 422-4743 |
| Gleevec® imatinib | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | | Phase II/III (888) 669-6682 |
| GRNVAC1 | Geron <i>Menlo Park, CA</i> | (see also leukemia) | Phase I/II (650) 473-7700 |
| GTx-758 | GTx <i>Memphis, TN</i> | | Phase II completed (901) 523-9700 |
| HE-3235 | Harbor Biosciences <i>San Diego, CA</i> | hormone-resistant prostate cancer | Phase II completed (858) 587-9333 |
| HyperAcute® Prostate prostate cancer vaccine | NewLink Genetics <i>Ames, IA</i> | hormone-refractory prostate cancer | Phase I/II completed (515) 296-5555 |
| INSM-18 | Triact Therapeutics <i>Palo Alto, CA</i> | | Phase I/II |
| ipilimumab | Bristol-Myers Squibb <i>Princeton, NJ</i> | (see also lung, skin) | Phase III (212) 546-4000 |
| irofulven (E7850) | Eisai <i>Woodcliff Lake, NJ</i> | | Phase II (888) 422-4743 |
| irosustat | Ipsen <i>Paris, France</i> | | Phase I www.ipsen.com |
| JNJ-26854165 | Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i> | (see also lung, solid tumors) | Phase I (800) 817-5286 |
| KX2-391 | Kinex Pharmaceuticals <i>Buffalo, NY</i> | | Phase II (716) 881-8984 |
| LE-DT | NeoPharm <i>Lake Bluff, IL</i> | castration-resistant metastatic prostate cancer (see also pancreatic) | Phase II (847) 887-0800 |

PROSTATE CANCER

| Product Name | Sponsor | Indication | Development Status |
|---|--|--|---|
| Leupron Depot® leuporelin depot (6-month formulation) | Abbott Pharmaceuticals <i>Abbott Park, IL</i> | | application submitted (847) 937-6100 |
| MDV-3100 | Astellas Pharma US <i>Deerfield, IL</i> Medivation <i>San Francisco, CA</i> | hormone-refractory prostate cancer | Phase III (800) 727-7003 (415) 543-3470 |
| mepacrine (CBLC102) | Incuron <i>Buffalo, NY</i> | hormone-refractory prostate cancer | Phase II completed (716) 849-6810 |
| MER-104 | Merrion Pharmaceuticals <i>Wilmington, NC</i> | | Phase I (910) 799-1847 |
| MIP1095 | Molecular Insight Pharmaceuticals <i>Cambridge, MA</i> | diagnosis of prostate cancer | Phase I (617) 492-5554 |
| MVA-5T4 | Oxford BioMedica <i>Oxford, United Kingdom</i> | | Phase II www.oxfordbiomedica. co.uk |
| MVA-BN®-PRO | BN ImmunoTherapeutics <i>Mountain View, CA</i> | | Phase I/II (650) 681-4660 |
| NeuVax™ E75 cancer vaccine | Aphera <i>Scottsdale, AZ</i> | (see also breast) | Phase I/II www.apthera.com |
| nimotuzumab | YM Biosciences USA <i>Lehigh Valley, PA</i> | (see also brain, breast) | Phase II (610) 560-0600 |
| OGX-427 | Oncogenex Pharmaceuticals <i>Bothell, WA</i> | hormone-refractory prostate cancer (see also bladder, breast, lung, ovarian) | Phase II (425) 686-1500 |
| Onyvox-P anti-idiotypic cancer vaccine 105AD7 | VaxOnco <i>Seoul, South Korea</i> | | Phase II www.vaxonco.com |
| ozarelix | Spectrum Pharmaceuticals <i>Irvine, CA</i> | | Phase II (949) 788-6700 |
| phenoxodiol | Marshall Edwards <i>San Diego, CA</i> | (Fast Track) (see also ovarian, other) | Phase II completed (858) 792-6300 |
| picoplatin intravenous | Poniard Pharmaceuticals <i>San Francisco, CA</i> | (see also colorectal, lung, ovarian) | Phase II (650) 583-3774 |
| polyphenon E | Polyphenon Pharma <i>New York, NY</i> | prostatic intraepithelial neoplasia (see also leukemia) | Phase II (212) 661-0578 |
| Proscar® finasteride | Merck <i>Whitehouse Station, NJ</i> | prevention of prostate cancer | Phase III completed (800) 673-6372 |
| ProstAtak™ gene therapy | Advantagene <i>Auburndale, MA</i> | | Phase II completed (617) 916-5445 |
| Prostvac®-VF prostate cancer vaccine | BN ImmunoTherapeutics <i>Mountain View, CA</i> | metastatic prostate cancer (Fast Track) | Phase II (650) 681-4660 |

PROSTATE CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|---|--|--------------------------------|
| Provenge® sipuleucel-T | Dendreon Seattle, WA | androgen-dependent recurrent prostate cancer | Phase III (877) 256-4545 |
| | | early-stage prostate cancer (neoadjuvant therapy) | Phase II (877) 256-4545 |
| PRX302 | Protox Therapeutics Vancouver, Canada | | Phase II (604) 688-0199 |
| PSMA ADC | Progenics Pharmaceuticals Tarrytown, NY | | Phase I (914) 789-2800 |
| PSMA subunit vaccine | Progenics Tarrytown, NY | | Phase I (914) 789-2800 |
| PSMA VRP | Progenics Pharmaceuticals Tarrytown, NY | | Phase I (914) 789-2800 |
| Quadramet® samarium SM-153 lexidronam injection | EUSA Pharma Langhorne, PA | (see also multiple myeloma, sarcoma, other) | Phase II (800) 833-3533 |
| Quinamed® amonafide | ChemGenex Pharmaceuticals Menlo Park, CA | (see also breast, ovarian) | Phase II (650) 474-9800 |
| REIC gene therapy | Momotaro-Gene Okayama, Japan | | Phase I www.mt-gene.com |
| Revlimid® lenalidomide | Celgene Summit, NJ | | Phase III (908) 673-9000 |
| rilotumumab | Amgen Thousand Oaks, CA | (see also brain, colorectal, lung, stomach) | Phase II (800) 772-6436 |
| sagopilone | Bayer HealthCare Pharmaceuticals Wayne, NJ | (see also brain, breast, ovarian) | Phase II (888) 842-2937 |
| seocalcitol (CB1089) | Cougar Biotechnology Los Angeles, CA | | Phase I (310) 943-8040 |
| SL052 | Quest PharmaTech Edmonton, Canada | | Phase I/II (780) 448-1400 |
| Sprycel® dasatinib | Bristol-Myers Squibb Princeton, NJ | (see also brain, breast, colorectal, leukemia, lung, lymphoma, multiple myeloma, skin) | Phase II/III (212) 546-4000 |
| TAK-448 | Millennium Pharmaceuticals Cambridge, MA | | Phase I/II (800) 390-5663 |
| TAK-700 (orteronel) | Millennium Pharmaceuticals Cambridge, MA | metastatic hormone-refractory prostate cancer | Phase III (800) 390-5663 |
| tesetaxel | Genta Berkeley Heights, NJ | advanced prostate cancer (see also bladder, breast, skin, stomach) | Phase II (908) 286-9800 |
| tigapotide | Kotinos Pharmaceuticals New York, NY | | Phase II |

PROSTATE CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|---|---|--|
| TOK-01 | Tokai Pharmaceuticals <i>Cambridge, MA</i> | | Phase I/II (617) 225-4305 |
| trabectedin | Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i> | (see also breast, ovarian, sarcoma) | Phase II (800) 817-5286 |
| TRC105 | TRACON Pharmaceuticals <i>San Diego, CA</i> | metastatic prostate cancer (see also solid tumors) | Phase I/II (858) 550-0780 |
| Trofex™ radiolabelled diagnostic | Molecular Insight Pharmaceuticals <i>Cambridge, MA</i> | diagnosis of prostate cancer | Phase I (617) 492-5554 |
| TV-1001/OCX-011 (custiren) | OncoGenex Pharmaceuticals <i>Bothell, WA</i> Teva Pharmaceutical <i>Tikva, Israel</i> | metastatic prostate cancer (Fast Track) (see also lung) | Phase III (425) 686-1500 www.tevapharm.com |
| zibotentan | AstraZeneca <i>Wilmington, DE</i> | castration-resistant prostate cancer (Fast Track) | Phase III (800) 236-9933 |

SARCOMA

| Product Name | Sponsor | Indication | Development Status |
|-------------------------|--|--|--|
| 8H9 mAb | United Therapeutics <i>Silver Spring, MD</i> | soft tissue sarcoma (see also brain, other) | Phase I (301) 608-9292 |
| AMG 479 (ganitumab) | Amgen <i>Thousand Oaks, CA</i> | (see also breast, colorectal, lung, pancreatic, other) | Phase II (800) 772-6436 |
| ARQ-197 | ArQule <i>Woburn, MA</i> Daiichi Sankyo <i>Parsippany, NJ</i> | soft tissue sarcoma (see also colorectal, liver, lung, pancreatic, sarcoma, other) | Phase II (781) 994-0300 (973) 944-2600 |
| cancer vaccine | MabVax Therapeutics <i>San Diego, CA</i> | | Phase II (858) 259-9405 |
| conatumumab | Amgen <i>Thousand Oaks, CA</i> | (see also colorectal, lung, pancreatic) | Phase I/II (800) 772-6436 |
| eribulin (E7389) | Eisai <i>Woodcliff Lake, NJ</i> | (see also bladder, lung, prostate) | Phase II (888) 422-4743 |
| IPI-926 | Infinity Pharmaceuticals <i>Cambridge, MA</i> | inoperable/unresectable chondrosarcoma | Phase I (617) 453-1000 |
| mifamurtide | Millennium Pharmaceuticals <i>Cambridge, MA</i> | osteosarcoma | Phase III (800) 390-5663 |
| ombrabulin (AVE8062) | sanofi-aventis <i>Bridgewater, NJ</i> | | Phase III (800) 633-1610 |

SARCOMA

| Product Name | Sponsor | Indication | Development Status |
|---|--|--|------------------------------|
| palifosfamide (ZIO-201) (Orphan Drug) | ZIOPHARM Oncology <i>New York, NY</i> | soft-tissue sarcoma (first-line therapy) (see also lung) | Phase III (212) 214-0700 |
| | | soft-tissue sarcoma (second-line therapy) (see also lymphoma) | Phase I/II (212) 214-0700 |
| PCI-24781 (HDAC inhibitor) | Pharmacyclics <i>Sunnyvale, CA</i> | (see also lymphoma) | Phase I (408) 774-0330 |
| PD-0332991 | Pfizer <i>New York, NY</i> | late-stage liposarcoma (see also brain, breast, lymphoma) | Phase II (860) 732-5156 |
| perifosine (KRX-0401) | AEterna Zentaris <i>Montreal, Canada</i> Keryx Biopharmaceuticals <i>New York, NY</i> | (see also brain, colorectal, kidney, leukemia, lymphoma, multiple myeloma, ovarian, stomach) | Phase II (212) 531-5965 |
| Quadramet® samarium sm-153 lexidronam injection | EUSA Pharma <i>Langhorne, PA</i> | osteosarcoma (see also multiple myeloma, prostate, other) | Phase I/II (800) 833-3533 |
| Reolysin® reovirus | Oncolytics Biotech <i>Calgary, Canada</i> | (see also brain, colorectal, head/neck, lung, pancreatic, skin) | Phase II (403) 670-7377 |
| Rexin-G™ tumor-targeted gene therapy (Orphan Drug) | Epeius Biotechnologies <i>San Marino, CA</i> | osteosarcoma (see also breast, pancreatic) | Phase II (626) 441-6695 |
| | | soft tissue sarcoma | Phase I/II (626) 441-6695 |
| ridaforolimus (Orphan Drug) | Merck <i>Whitehouse Station, NJ</i> | oral formulation (Fast Track) (see also breast, lung) | Phase III (800) 672-6372 |
| | | intravenous formulation | Phase II (800) 672-6372 |
| robatumumab | Merck <i>Whitehouse Station, NJ</i> | osteosarcoma, sarcoma (see also solid tumors) | Phase II (800) 672-6372 |
| TH-302 | Threshold Pharmaceuticals <i>Redwood City, CA</i> | soft tissue sarcoma (see also leukemia, pancreatic, solid tumors) | Phase I/II (650) 474-8200 |
| trabectedin (Orphan Drug) | Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i> | soft tissue sarcoma (see also breast, ovarian, prostate, other) | Phase III (800) 817-5286 |
| | | soft tissue sarcoma in adolescents and children | Phase II (800) 817-5286 |
| Votrient® pazopanib | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | (see also breast, kidney, ovarian) | Phase III (888) 669-6682 |

SKIN CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|--|---|---|
| Abraxane® albumin-bound paclitaxel (Orphan Drug) | Celgene <i>Summit, NJ</i> | malignant melanoma (see also bladder, lung, ovarian, pancreatic) | Phase III (908) 673-9000 |
| ABT-888 (veliparib) | Abbott Laboratories <i>Abbott Park, IL</i> | malignant melanoma (see also brain, breast, colorectal, ovarian, prostate, other) | Phase II (847) 937-6100 |
| AD-1001 | Intrexon <i>Germantown, MD</i> ZIOPHARM Oncology <i>New York, NY</i> | late-stage malignant melanoma | Phase I (646) 214-0700 |
| ADI-PEG 20 (Orphan Drug) | Polaris Pharmaceuticals <i>San Diego, CA</i> | malignant melanoma (see also liver, lung) | Phase II (858) 452-6688 |
| Allovectin-7® velimogene aliplasmid (immunotherapeutic vaccine) (Orphan Drug) | Vical <i>San Diego, CA</i> | malignant melanoma (Fast Track) | Phase III (858) 646-1100 |
| ALS-357 (betulinic topical) | Advanced Life Sciences <i>Woodridge, IL</i> | malignant melanoma | Phase I (630) 739-6744 |
| ALT-801 | Altor BioScience <i>Miramar, FL</i> | malignant melanoma | Phase I/II (954) 443-8600 |
| APN301 (hu14.18-IL2) | Apeiron Biologics <i>Vienna, Austria</i> | malignant melanoma (see also brain) | Phase II www.apeiron- biologics.com |
| ARC-100 | Archer Biosciences <i>New York, NY</i> | malignant melanoma (see also brain, pancreatic, prostate) | Phase II (646) 747-9090 |
| ATN-224 | Tactic Pharma <i>Evanston, IL</i> | malignant melanoma (see also multiple myeloma, prostate) | Phase II (847) 733-0940 |
| Azixa™ (verubulin) | Myrexix <i>Salt Lake City, UT</i> | malignant melanoma (see also brain) | Phase II (801) 214-7800 |
| BMS-908662 (RAF kinase inhibitor) | Bristol-Myers Squibb <i>Princeton, NJ</i> Exelixis <i>South San Francisco, CA</i> | malignant melanoma (see also colorectal) | Phase I (212) 546-4000 |
| BMS-936558 (anti-PD1) | Bristol-Myers Squibb <i>Princeton, NJ</i> | inoperable/unresectable malignant melanoma (see also solid tumors) | Phase I (212) 546-4000 |
| CDX-011 | Celldex Therapeutics <i>Needham, MA</i> | malignant melanoma (see also breast) | Phase II (781) 433-0771 |
| CNTO 95 | Centocor Ortho Biotech <i>Horsham, PA</i> | malignant melanoma (see also prostate, solid tumors) | Phase I/II (800) 457-6399 |
| CST-101 | ConKwest <i>Del Mar, CA</i> | stage IV malignant melanoma (see also leukemia, lung, lymphoma) | Phase I (858) 380-1999 |

SKIN CANCER

| Product Name | Sponsor | Indication | Development Status |
|---|---|---|---|
| CYT-107 | Cytheris <i>Rockville, MD</i> | malignant melanoma (see also kidney, leukemia, solid tumors) | Phase I (301) 231-0450 |
| denenicokin (IL-21) (Orphan Drug) | Bristol-Myers Squibb <i>Princeton, NJ</i> | malignant melanoma | Phase II (212) 546-5000 |
| E7272 | Eisai <i>Woodcliff Lake, NJ</i> | melanoma | Phase II (888) 422-4743 |
| ecromeximab | Life Sciences Pharmaceuticals <i>Darien, CT</i> | malignant melanoma | Phase II (203) 656-2500 |
| GC-1008 (fresolimumab) | Genzyme <i>Cambridge, MA</i> | malignant melanoma (see also kidney) | Phase I (617) 252-7000 |
| Genasense® oblimersen (Orphan Drug) | Genta <i>Berkeley Heights, NJ</i> | malignant melanoma (Fast Track) (see also leukemia, lymphoma) | Phase III (908) 286-9800 |
| GMX-1777 (teglarinad) | Gemin X Biotechnologies <i>Montreal, Canada</i> | malignant melanoma | Phase I completed (514) 281-8989 |
| GSK1120212 (MEK inhibitor) | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | malignant melanoma (see also pancreatic, solid tumors) | Phase III (888) 825-5249 |
| | | combination therapy | Phase II (888) 825-5249 |
| GSK2118436 (BRaf protein kinase inhibitor) | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | metastatic malignant melanoma (see also lung) | Phase III (888) 825-5249 |
| GSK2302032A (PRAME immunotherapeutic recombinant vaccine) | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | metastatic melanoma | Phase I (888) 825-5249 |
| GSK2401502 | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> Lipotek <i>Acton, Australia</i> | malignant melanoma | Phase I (888) 825-5249 |
| HyperAcute® Melanoma melanoma vaccine | NewLink Genetics <i>Ames, IA</i> | malignant melanoma | Phase II (515) 296-5555 |
| IMC-20D7S | Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i> | malignant melanoma | Phase I (800) 545-5979 (212) 645-1405 |
| IMC-gp100 | Immunocore <i>Oxon, United Kingdom</i> | malignant melanoma | Phase 0 www.immunocore.com |
| Imprime PGG® | Biothera <i>Eagen, MN</i> | malignant melanoma (see also colorectal, leukemia, lung) | Phase I/II (651) 675-0300 |

SKIN CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|---|--|--------------------------------|
| ioflubenzamide I-131 | Molecular Insight Pharmaceuticals Cambridge, MA | malignant melanoma | Phase I (617) 492-5554 |
| ipilimumab (Orphan Drug) | Bristol-Myers Squibb Princeton, NJ | metastatic melanoma, combination therapy, first-line therapy (Fast Track) (see also lung, prostate) | Phase III (212) 546-4000 |
| lenvatinib (E7080) | Eisai Woodcliff Lake, NJ | melanoma (see also brain, kidney, liver, other) | Phase I/II (888) 422-4743 |
| Levulan® Kerastick® aminolevulinic acid | DUSA Pharmaceuticals Wilmington, MA | prevention of skin cancer in solid organ transplant patients | Phase II (978) 657-7500 |
| Lymphoseek™ | Neoprobe Dublin, OH | diagnosis of malignant melanoma (see also breast, head/neck) | Phase III (800) 793-0079 |
| MAGE-A3 recombinant vaccine (antigen- specific cancer immunotherapeutic) | GlaxoSmithKline Rsch. Triangle Park, NC | malignant melanoma (see also lung) | Phase III (888) 825-5249 |
| Marqibo® vincristine liposomal (Orphan Drug) | Talon Therapeutics South San Francisco, CA | malignant melanoma (see also leukemia) | Phase II (650) 588-6404 |
| melanoma vaccine | Ichor Medical Systems San Diego, CA Memorial Sloan-Kettering Cancer Center New York, NY | malignant melanoma | Phase I (858) 550-2022 |
| Metvixia® methyl aminolevulinate | PhotoCure Oslo, Norway | basal cell cancer | Phase III www.photocure.com |
| MKC1106-MT | MannKind Valencia, CA | malignant melanoma | Phase II (661) 775-5300 |
| MORAb-028 | Eisai Woodcliff Lake, NJ | malignant melanoma | Phase I (888) 422-4743 |
| muparfostat (PI-88) (Orphan Drug) | Progen Pharmaceuticals Redwood City, CA | malignant melanoma (see also liver) | Phase II (650) 610-7080 |
| OncoVEX ^{GM-CSF} | BioVex Woburn, MA | malignant melanoma (see also head/neck) | Phase III (781) 376-4900 |
| Ontak® denileukin diftitox | Eisai Woodcliff Lake, NJ | melanoma | Phase II (888) 422-4743 |
| PEP005 | LEO Pharma Parsippany, NJ | non-melanoma skin cancer | Phase II (877) 494-4536 |
| PF-1367338 | Pfizer New York, NY | malignant melanoma (see also breast, ovarian) | Phase II (860) 732-5156 |

SKIN CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|--|--|---|
| prophage (vitespen) (Orphan Drug) | Agenus <i>Lexington, MA</i> | malignant melanoma (Fast Track) (see also brain, kidney) | Phase III (781) 674-4400 |
| PTC299 | PTC Therapeutics <i>South Plainfield, NJ</i> | Kaposi's sarcoma (see also breast, solid tumors, other) | Phase I/II (908) 222-7000 |
| PTI-188 | Pain Therapeutics <i>San Mateo, CA</i> | malignant melanoma | Phase I completed (650) 624-8200 |
| PV-10 | Provectus Pharmaceuticals <i>Knoxville, TN</i> | malignant melanoma (see also liver) | Phase II (866) 594-5999 |
| RAF265 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | malignant melanoma | Phase I (888) 669-6682 |
| Reolysin [®] reovirus | Oncolytics Biotech <i>Calgary, Canada</i> | malignant melanoma (see also brain, colorectal, head/neck, lung, pancreatic, sarcoma) | Phase II (403) 670-7377 |
| RG3616 (systemic hedgehog antagonist) | Curis <i>Lexington, MA</i> Roche <i>Nutley, NJ</i> | basal cell carcinoma | Phase II (973) 235-5000 |
| RG7204 (BRAF kinase inhibitor) | Plexxikon <i>Berkeley, CA</i> Roche <i>Nutley, NJ</i> | first-line malignant melanoma | Phase III (510) 647-4000 (973) 235-5000 |
| | | ----- second- and third-line malignant melanoma | Phase II (510) 647-4000 (973) 235-5000 |
| RG7256 | Roche <i>Nutley, NJ</i> | BRAF-mutated malignant melanoma | Phase I (973) 235-5000 |
| Sprycel [®] dasatinib | Bristol-Myers Squibb <i>Princeton, NJ</i> | malignant melanoma (see also brain, breast, colorectal, leukemia, lung, lymphoma, multiple myeloma, prostate) | Phase I/II (212) 546-4000 |
| Tasigna [®] nilotinib | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | malignant melanoma (see also leukemia, stomach) | Phase III (888) 669-6682 |
| Temodar [®] temozolomide | Merck <i>Whitehouse Station, NJ</i> | malignant melanoma (see also leukemia, lung) | Phase I (800) 672-6372 |
| tesetaxel (Orphan Drug) | Genta <i>Berkeley Heights, NJ</i> | advanced melanoma (see also bladder, breast, prostate, stomach) | Phase II (908) 286-9800 |
| TNFerade [™] golnerminogene pradenovec | GenVec <i>Gaithersburg, MD</i> | malignant melanoma (see also colorectal, head/neck, stomach) | Phase II completed (240) 632-0740 |
| tremelimumab (CP-675206) | Pfizer <i>New York, NY</i> | malignant melanoma (see also kidney, pancreatic, stomach, other) | Phase II (860) 732-5156 |
| TRX518 | Tolerx <i>Cambridge, MA</i> | malignant melanoma | Phase I (617) 354-8100 |

SKIN CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|--|---|--------------------------------------|
| veglin (VEGF antisense) | VasGene Therapeutics <i>Los Angeles, CA</i> | Kaposi's sarcoma (see also kidney, lung) | Phase I (323) 221-7818 |
| Zadaxin® thymalfasin (Orphan Drug) | SciClone Pharmaceuticals <i>Foster City, CA</i> | malignant melanoma | Phase II completed (650) 358-3456 |

SOLID TUMORS

| Product Name | Sponsor | Indication | Development Status |
|-----------------------------|--|---|---|
| 1MT | NewLink Genetics <i>Ames, IA</i> | metastatic disease | Phase I (515) 296-5555 |
| ABI-009 (nab®-rapamycin) | Celgene <i>Summit, NJ</i> | | Phase I (908) 673-9000 |
| ABI-101 (nab®-17AAG) | Celgene <i>Summit, NJ</i> | | Phase I (908) 673-9000 |
| ABT-348 | Abbott Laboratories <i>Abbott Park, IL</i> | late-stage disease (see also other) | Phase I (847) 937-6100 |
| ABT-806 | Abbott Laboratories <i>Abbott Park, IL</i> | | Phase I (847) 937-6100 |
| AC480 | Ambit Biosciences <i>San Diego, CA</i> | (see also brain) | Phase II completed (858) 334-2100 |
| | | ----- solid tumors (combination therapy) | Phase I (858) 334-2100 |
| ACE-041 | Acceleron Pharma <i>Cambridge, MA</i> | (see also multiple myeloma) | Phase I (617) 649-9200 |
| AEW541 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | (see also other) | Phase I (888) 669-6682 |
| AEZS-112 | AEterna-Zentaris <i>Warren, NJ</i> | (see also lymphoma) | Phase I (908) 626-5428 |
| AFP-464 | Tigris Pharmaceuticals <i>Bonita Springs, FL</i> | | Phase I (239) 444-5400 |
| AI-850 | Acusphere <i>Watertown, MA</i> Cephalon <i>Frazer, PA</i> | | Phase I (617) 648-8800 (610) 344-0200 |
| ALB 109564(a) | AMRI <i>Albany, NY</i> | | Phase I (518) 512-2000 |
| AMG 208 | Amgen <i>Thousand Oaks, CA</i> | | Phase I (800) 772-6436 |
| AMG 780 | Amgen <i>Thousand Oaks, CA</i> | | Phase I (800) 772-6436 |
| AMG 820 | Amgen <i>Thousand Oaks, CA</i> | | Phase I (800) 772-6436 |

SOLID TUMORS

| Product Name | Sponsor | Indication | Development Status |
|--|--|--|---|
| AMG 888 (U3-1287) | Amgen <i>Thousand Oaks, CA</i> | | Phase I (800) 772-6436 |
| AMG 900 | Amgen <i>Thousand Oaks, CA</i> | | Phase I (800) 772-6436 |
| Amplimexon [®] imexon | AmpliMed <i>Tucson, AZ</i> | | Phase I/II completed (520) 529-1000 |
| amuvatinib | SuperGen <i>Dublin, CA</i> | (see also lymphoma) | Phase I (925) 560-0100 |
| anti-EGFL7 mAb (RG7414) | Genentech <i>South San Francisco, CA</i> | | Phase I (650) 224-1000 |
| anti-HER3/EGFR DAF (RG7597) | Genentech <i>South San Francisco, CA</i> | | Phase I (650) 224-1000 |
| Aplidin [®] plitidepsin | PharmaMar USA <i>Cambridge, MA</i> | (see also lymphoma, multiple myeloma) | Phase I (617) 868-3797 |
| AR-12 | Arno Therapeutics <i>Parsippany, NJ</i> | (see also lymphoma) | Phase I (862) 703-7170 |
| ARQ-621 | ArQule <i>Woburn, MA</i> | late-stage solid tumors | Phase I (781) 994-0300 |
| ARQ-736 | ArQule <i>Woburn, MA</i> | late-stage solid tumors | Phase I (781) 994-0300 |
| ARRY-520 | Array BioPharma <i>Boulder, CO</i> | (see also leukemia, multiple myeloma) | Phase I (303) 381-6600 |
| ARRY-543 (varlitinib) | Array BioPharma <i>Boulder, CO</i> | | Phase II (303) 381-6600 |
| AT-406 | Ascenta Therapeutics <i>Malvern, PA</i> | (see also lymphoma) | Phase I (610) 408-0313 |
| AT7519 | Astex Therapeutics <i>Cambridge, United Kingdom</i> | (see also multiple myeloma) | Phase I www.astex-therapeutics.com |
| AT9283 | Astex Therapeutics <i>Cambridge, United Kingdom</i> | (see also leukemia) | Phase I www.astex-therapeutics.com |
| ATI-1123 | Azaya Therapeutics <i>San Antonio, TX</i> | | Phase I (210) 341-6600 |
| AT13387 | Astex Therapeutics <i>Cambridge, United Kingdom</i> | | Phase I www.astex-therapeutics.com |
| ATN-161 | Tactic Pharma <i>Evanston, IL</i> | | Phase II (847) 733-0940 |
| AV-299 (ficlatuzumab) | AVEO Pharmaceuticals <i>Cambridge, MA</i> | (see also glioblastoma, lymphoma, multiple myeloma) | Phase I (617) 299-5000 |
| AZD1480 (JAK2 inhibitor) | AstraZeneca <i>Wilmington, DE</i> | (see also other) | Phase I (800) 236-9933 |
| AZD2014 (TOR kinase inhibitor) | AstraZeneca <i>Wilmington, DE</i> | | Phase I (800) 236-9933 |

SOLID TUMORS

| Product Name | Sponsor | Indication | Development Status |
|---|--|-----------------------------|------------------------------|
| AZD2461 (PARP inhibitor) | AstraZeneca <i>Wilmington, DE</i> | | Phase I (800) 236-9933 |
| AZD4547 (FGFR tyrosine kinase inhibitor) | AstraZeneca <i>Wilmington, DE</i> | | Phase I/II (800) 236-9933 |
| AZD5363 (AKT inhibitor) | AstraZeneca <i>Wilmington, DE</i> | | Phase I (800) 236-9933 |
| AZD7762 (CHK1 kinase inhibitor) | AstraZeneca <i>Wilmington, DE</i> | | Phase I (800) 236-9933 |
| AZD8055 (TOR kinase inhibitor) | AstraZeneca <i>Wilmington, DE</i> | | Phase I (800) 236-9933 |
| AZD8330 (ARRY-704) | Array Bio Pharma <i>Boulder, CO</i> AstraZeneca <i>Wilmington, DE</i> | | Phase I (800) 236-9933 |
| AZD8931 (erbB kinase inhibitor) | AstraZeneca <i>Wilmington, DE</i> | (see also breast) | Phase II (800) 236-9933 |
| BAY 79-4620 | Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> | | Phase I (888) 842-2937 |
| BAY 80-6946 | Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> | | Phase I (888) 842-2937 |
| BAY 10-00394 | Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> | | Phase I (888) 842-2937 |
| BBI608 | Boston Biomedical <i>Norwood, MA</i> | | Phase I (781) 278-0900 |
| BEZ235 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | late-stage solid tumors | Phase I/II (888) 669-6682 |
| BGJ398 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | | Phase I (888) 669-6682 |
| BGT226 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | | Phase I/II (888) 669-6682 |
| BHQ880 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | (see also multiple myeloma) | Phase I (888) 669-6682 |
| BI 811283 | Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i> | (see also leukemia) | Phase I (800) 243-0127 |
| BI 831266 | Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i> | | Phase I (800) 243-0127 |

SOLID TUMORS

| Product Name | Sponsor | Indication | Development Status |
|--|---|--|--|
| BIIB 015 | Biogen Idec <i>Cambridge, MA</i> | | Phase I (617) 679-2000 |
| BKM120 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | (see also breast) | Phase I (888) 669-6682 |
| BMN-673 | BioMarin Pharmaceuticals <i>Novato, CA</i> | | Phase I/II (415) 506-6700 |
| BMS-247615 (DNA topoisomerase I and II inhibitor) | Bristol-Myers Squibb <i>Princeton, NJ</i> | | Phase I (212) 546-4000 |
| BMS-754807 (IGF-1R antagonist) | Bristol-Myers Squibb <i>Princeton, NJ</i> | (see also breast) | Phase I/II (212) 546-4000 |
| BMS-777607 (receptor protein-tyrosine kinase antagonists) | Bristol-Myers Squibb <i>Princeton, NJ</i> | advanced solid tumors | Phase I/II completed (212) 546-4000 |
| BMS-833923 (SMO inhibitor) | Bristol-Myers Squibb <i>Princeton, NJ</i> | | Phase I (212) 546-4000 |
| BMS-936558 (anti-PD1) | Bristol-Myers Squibb <i>Princeton, NJ</i> | (see also skin) | Phase I (212) 546-4000 |
| BMS-936559 (anti-PDL-L1) | Bristol-Myers Squibb <i>Princeton, NJ</i> | | Phase I (212) 546-4000 |
| BQS481 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | | Phase I (888) 669-6682 |
| BYL719 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | late-stage solid tumors | Phase I (888) 669-6682 |
| c31510 for injection | Cytotech Labs <i>Natick, MA</i> | | Phase I |
| CALAA 01 | Calando Pharmaceuticals <i>Pasadena, CA</i> | | Phase I (626) 683-7200 |
| carfilzomib | Onyx Pharmaceuticals <i>Emeryville, CA</i> | (see also multiple myeloma) | Phase II (510) 597-6500 |
| carlumab | Centocor Ortho Biotech <i>Horsham, PA</i> | (see also prostate) | Phase I (800) 457-6399 |
| CC-223 | Celgene <i>Summit, NJ</i> | late-stage solid tumors (see also leukemia, lymphoma) | Phase I/II (908) 673-9000 |
| CDX-1401 | Celldex Therapeutics <i>Needham, MA</i> | | Phase I/II (781) 433-0771 |
| CEP-9722 (PARP inhibitor) | Cephalon <i>Frazer, PA</i> | | Phase I (610) 344-0200 |
| CEP-11981 (VEGF-R/TIE2 kinase inhibitor) | Cephalon <i>Frazer, PA</i> | | Phase I (610) 344-0200 |
| CG201 | CG Therapeutics <i>Seattle, WA</i> | | Phase II (206) 336-5604 |

SOLID TUMORS

| Product Name | Sponsor | Indication | Development Status |
|--|---|---|-------------------------------------|
| CLR1404 | Collectar <i>Madison, WI</i> | | Phase I (608) 441-8120 |
| CNTO 95 | Centocor Ortho Biotech <i>Horsham, PA</i> | (see also prostate, skin) | Phase I completed (800) 457-6399 |
| CRLX101 | Cerulean Pharma <i>Cambridge, MA</i> | late-stage solid tumors | Phase I/II (617) 551-9600 |
| crolibulin | EpiCept <i>Tarrytown, NY</i> | | Phase I/II (914) 606-3500 |
| CRS-207 | Aduro BioTech <i>Berkeley, CA</i> | | Phase I (510) 848-4400 |
| CUDC-101 | Curis <i>Cambridge, MA</i> | | Phase I (617) 503-6500 |
| CX-4945 | Cylene Pharmaceuticals <i>San Diego, CA</i> | (see also multiple myeloma, other) | Phase I (858) 875-5100 |
| CYC-116 | Cyclacel Pharmaceuticals <i>Berkeley Heights, NJ</i> | | Phase I (908) 517-7330 |
| CYT-107 | Cytheris <i>Rockville, MD</i> | vaccine enhancer (see also kidney, leukemia, skin) | Phase I (301) 231-0450 |
| CYT 6091 | CytImmune Sciences <i>Rockville, MD</i> | | Phase I (301) 825-3041 |
| darinaparsin oral (ZIO-101) | ZIOPHARM Oncology <i>New York, NY</i> | (see also liver, lymphoma, multiple myeloma) | Phase I (646) 214-0700 |
| denibulin (MN-029) | MediciNova <i>San Diego, CA</i> | | Phase I (858) 373-1500 |
| dovitinib (TKI258) | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | | Phase II (888) 669-6682 |
| EC-0489 | Endocyte <i>West Lafayette, IN</i> | | Phase I (765) 463-7175 |
| elsamitrucin | Spectrum Pharmaceuticals <i>Irvine, CA</i> | advanced solid tumors | Phase I (949) 788-6700 |
| EMD-1204831 (c-Met kinase inhibitor) | EMD Serono <i>Rockland, MA</i> | late-stage solid tumors | Phase I (800) 283-8088 |
| EMD-1214063 (c-Met kinase inhibitor) | EMD Serono <i>Rockland, MA</i> | | Phase I (800) 283-8088 |
| EP-100 | Esperance Pharmaceuticals <i>Baton Rouge, LA</i> | | Phase I (225) 615-8944 |
| ETBX-011 | Etubics <i>Seattle, WA</i> | late-stage solid tumors | Phase I (206) 838-5110 |
| EZN-2208 | Enzon Pharmaceuticals <i>Bridgewater, NJ</i> | refractory metastatic solid tumors (see also breast, colorectal) | Phase I (908) 541-8600 |

SOLID TUMORS

| Product Name | Sponsor | Indication | Development Status |
|--|---|---|------------------------------|
| EZN-2968 | Enzon Pharmaceuticals <i>Bridgewater, NJ</i> | (see also lymphoma) | Phase I (908) 541-8600 |
| EZN-3042 | Enzon Pharmaceuticals <i>Bridgewater, NJ</i> | (see also leukemia, lymphoma) | Phase I (908) 541-8600 |
| fluciclatide F-18 | GE Healthcare <i>Waukesha, WI</i> | diagnosis of solid tumors | Phase II |
| FP-1039 | Five Prime Therapeutics <i>San Francisco, CA</i> | (see also other) | Phase I (415) 365-5600 |
| G-202 | GenSpera <i>San Antonio, TX</i> | | Phase I (210) 479-8112 |
| GDC-0068 (Akt inhibitor) | Genentech <i>South San Francisco, CA</i> | | Phase I (650) 224-1000 |
| GDC-0623 (MEK inhibitor) | Genentech <i>South San Francisco, CA</i> | | Phase I (650) 224-1000 |
| GDC-0917 (IAP antagonist) | Genentech <i>South San Francisco, CA</i> | (see also lymphoma) | Phase I (650) 224-1000 |
| GDC-0941 (PI3 kinase inhibitor) | Genentech <i>South San Francisco, CA</i> | (see also breast, lung, lymphoma) | Phase I (650) 224-1000 |
| GDC-0973 (MEK inhibitor) | Exelixis <i>South San Francisco, CA</i> Genentech <i>South San Francisco, CA</i> | | Phase I (650) 837-7000 |
| GDC-0980 (PI3 kinase/mTOR dual inhibitor) | Genentech <i>South San Francisco, CA</i> | (see also breast, lymphoma) | Phase I (650) 224-1000 |
| Genasense [®] oblimersen | Genta <i>Berkeley Heights, NJ</i> | brief, high-dose IV-infusion (see also breast, leukemia, lung, lymphoma, skin) | Phase I/II (908) 286-9800 |
| | | intermittent therapy | Phase I (908) 286-9800 |
| Genz-644282 | Genzyme <i>Cambridge, MA</i> | | Phase I (617) 252-7500 |
| GGTI-2418 | Tigris Pharmaceuticals <i>Bonita Springs, FL</i> | | Phase I (239) 444-5400 |
| GL-ONC1 | Genelux <i>San Diego, CA</i> | | Phase I (858) 483-0024 |
| GO-203-2c | Genus Oncology <i>Vernon Hills, IL</i> | advanced solid tumors | Phase I (847) 549-6500 |
| GS 6624 | Gilead Sciences <i>Foster City, CA</i> | | Phase I (800) 445-3235 |
| GSK1070916A | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | | Phase I (888) 825-5249 |
| GSK1120212 (MEK inhibitor) | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | (see also pancreatic, skin) | Phase I (888) 825-5249 |

SOLID TUMORS

| Product Name | Sponsor | Indication | Development Status |
|--|--|--|--|
| GSK2141795 (AKT protein kinase inhibitor) | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | (see also lymphoma) | Phase I (888) 825-5249 |
| GSK2256098 (FAK inhibitor) | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | | Phase I (888) 825-5249 |
| HER2/neu receptor (active cellular immunotherapy) | Dendreon <i>Seattle, WA</i> | | Phase I (877) 256-4545 |
| HGS-1029 | Human Genome Sciences <i>Rockville, MD</i> | (see also lymphoma) | Phase I (301) 309-8504 |
| HSP990 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | | Phase I (888) 669-6682 |
| IMC-RON8 | Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i> | | Phase I (800) 545-5979 (212) 645-1405 |
| IMGN-388 | ImmunoGen <i>Waltham, MA</i> | | Phase I (781) 895-0600 |
| INCB-18424 (ruxolitinib) | Incyte <i>Wilmington, DE</i> | | Phase I (302) 498-6700 |
| INCB-24360 (IDO inhibitor) | Incyte <i>Wilmington, DE</i> | | Phase I/II (302) 498-6700 |
| INCB-28060 (c-MET inhibitor) | Incyte <i>Wilmington, DE</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i> | | Phase I/II (302) 498-6700 (888) 669-6682 |
| INK128 (TORC1/2 inhibitor) | Intellikine <i>La Jolla, CA</i> | (see also lymphoma, multiple myeloma) | Phase I (858) 768-6500 |
| INNO-206 | CytRx <i>Los Angeles, CA</i> | | Phase I completed (310) 826-5648 |
| IPI-493 | Infinity Pharmaceuticals <i>Cambridge, MA</i> | advanced solid tumors (see also other) | Phase I (617) 453-1000 |
| IPI-926 | Infinity Pharmaceuticals <i>Cambridge, MA</i> | (see also pancreatic, sarcoma) | Phase I (617) 453-1000 |
| Jl-101 | Jubilant Innovation <i>Bedminster, NJ</i> | | Phase I/II (215) 369-0965 |
| JNJ-26854165 | Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i> | late-stage solid tumors (see also lung, prostate) | Phase I (800) 817-5286 |
| JNJ-38877605 | Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i> | | Phase I/II (800) 817-5286 |
| KHK-2866 | Kyowa Hakko Kirin Pharma <i>Princeton, NJ</i> | (see also ovarian) | Phase I (609) 919-1100 |

SOLID TUMORS

| Product Name | Sponsor | Indication | Development Status |
|---------------------------------|--|--|--|
| LCL161 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | | Phase I (888) 669-6682 |
| LDE225 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | | Phase II (888) 669-6682 |
| LDK378 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | | Phase II (888) 669-6682 |
| LEE011 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | (see also lymphoma) | Phase I (888) 669-6682 |
| LEQ506 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | | Phase I (888) 669-6682 |
| L-MDAM | BioNumerik Pharmaceuticals <i>San Antonio, TX</i> | | Phase I (210) 614-1701 |
| LOR-253 | Lorus Therapeutics <i>Toronto, Canada</i> | | Phase I (416) 798-1200 |
| LP-261 | Ansaris <i>Blue Bell, PA</i> | | Phase I (215) 358-2000 |
| MEDI-565 (anti-CEA BiTE) | AstraZeneca <i>Wilmington, DE</i> MedImmune <i>Gaithersburg, MD</i> | | Phase I (800) 236-9933 (301) 398-0000 |
| MEDI-573 (anti-IGF mAb) | AstraZeneca <i>Wilmington, DE</i> MedImmune <i>Gaithersburg, MD</i> | | Phase I (800) 236-9933 (301) 398-0000 |
| MEDI-575 | AstraZeneca <i>Wilmington, DE</i> MedImmune <i>Gaithersburg, MD</i> | | Phase II (800) 236-9933 (301) 398-0000 |
| MEDI-3617 (anti-ANG-2 mAb) | AstraZeneca <i>Wilmington, DE</i> MedImmune <i>Gaithersburg, MD</i> | | Phase I (800) 236-9933 (301) 398-0000 |
| MEK162/ ARRY-162 | Array BioPharma <i>Boulder, CO</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i> | | Phase I (303) 381-6600 (888) 669-6682 |
| MGAH22 (anti-HER2) | MacroGenics <i>Rockville, MD</i> | | Phase I (301) 251-5172 |
| MGCD-265 | MethylGene <i>Montreal, Canada</i> | late-stage solid tumors (see also lung) | Phase I (514) 337-3333 |
| MGCD-0103 | MethylGene <i>Montreal, Canada</i> | (see also leukemia, lymphoma) | Phase I/II (514) 337-3333 |
| MINT-1526A (anti-angiogenic) | Genentech <i>South San Francisco, CA</i> | advanced solid tumors | Phase I (650) 224-1000 |

SOLID TUMORS

| Product Name | Sponsor | Indication | Development Status |
|--------------------------------------|---|--|---|
| MK-0752 | Merck <i>Whitehouse Station, NJ</i> | (see also breast) | Phase I (800) 672-6372 |
| MK-1496 | Merck <i>Whitehouse Station, NJ</i> | | Phase I completed (800) 672-6372 |
| MK-1775 | Merck <i>Whitehouse Station, NJ</i> | | Phase I (800) 672-6372 |
| MK-4827 | Merck <i>Whitehouse Station, NJ</i> | late-stage solid tumors | Phase I (800) 672-6372 |
| MK-5108 (VX-689) | Merck <i>Whitehouse Station, NJ</i> Vertex Pharmaceuticals <i>Cambridge, MA</i> | late-stage or refractory solid tumors | Phase I (800) 672-6372 |
| MKC1106-PP | MannKind <i>Valencia, CA</i> | | Phase I completed (661) 775-5300 |
| MLN4924 | Millennium Pharmaceuticals <i>Cambridge, MA</i> | (see also other) | Phase I (800) 390-5663 |
| MLN8237 | Millennium Pharmaceuticals <i>Cambridge, MA</i> | (see also other) | Phase I/II (800) 390-5663 |
| MLN9708 | Millennium Pharmaceuticals <i>Cambridge, MA</i> | (see also other) | Phase I/II (800) 390-5663 |
| MM-111 | Merrimack Pharmaceuticals <i>Cambridge, MA</i> | (see also breast) | Phase I/II (617) 441-1000 |
| MN-201 | Marillion Pharmaceuticals <i>Exton, PA</i> | advanced solid tumors | Phase I (484) 875-3018 |
| MORAb-004 | Eisai <i>Woodcliff Lake, NJ</i> | | Phase I (888) 422-4743 |
| MT-110 | Micromet <i>Bethesda, MD</i> | | Phase I (240) 752-1420 |
| NB-1011 | Kiadis Pharma <i>Amsterdam, The Netherlands</i> | | Phase I/II www.kiadis.com |
| NKTR-105 (pegylated docetaxel) | Nektar Therapeutics <i>San Francisco, CA</i> | | Phase I (415) 482-5300 |
| NMS-1116354 | Nerviano Medical Sciences <i>Milan, Italy</i> | metastatic solid tumors | Phase I www.nervianoms.com |
| NMS-1286937 | Nerviano Medical Sciences <i>Milan, Italy</i> | | Phase I www.nervianoms.com |
| NPI-0052 (marizomib) | Nereus Pharmaceuticals <i>San Diego, CA</i> | (see also lymphoma, multiple myeloma) | Phase I (858) 587-4090 |
| OMP-21M18 | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> OncoMed Pharmaceuticals <i>Redwood City, CA</i> | | Phase I (888) 825-5249 (650) 995-8200 |

SOLID TUMORS

| Product Name | Sponsor | Indication | Development Status |
|--|---|--|---|
| OMP-59R5 | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> OncoMed Pharmaceuticals <i>Redwood City, CA</i> | late-stage solid tumors | Phase I (888) 825-5249 (650) 995-8200 |
| omtriptolide | Pharmagenesis <i>Redwood City, CA</i> Pierre Fabre Pharmaceuticals <i>Parsippany, NJ</i> | | Phase I (650) 842-7060 (973) 898-1042 |
| ON-01910 | Onconova Therapeutics <i>Princeton, NJ</i> | (see also leukemia, lymphoma, ovarian) | Phase I (609) 844-7735 |
| ONX-0801 | Onyx Pharmaceuticals <i>Emeryville, CA</i> | | Phase I (510) 597-6500 |
| ONX-0912 | Onyx Pharmaceuticals <i>Emeryville, CA</i> | late-stage solid tumors | Phase I (510) 597-6500 |
| ortatexal | Spectrum Pharmaceuticals <i>Irvine, CA</i> | taxane-refractory solid tumors | Phase II (949) 788-6700 |
| OSI-930 | OSI Pharmaceuticals <i>Melville, NY</i> | late-stage solid tumors | Phase I (631) 962-2000 |
| OXi4503 | OXiGENE <i>South San Francisco, CA</i> | (see also leukemia) | Phase I/II (650) 635-7000 |
| PA799 | Chugai Pharma USA <i>Berkeley Heights, NJ</i> | | Phase I (908) 516-1350 |
| PDL-192 (enavatuzumab) | Facet Biotech <i>Redwood City, CA</i> | | Phase I (650) 454-1000 |
| PEGPH20 (pegylated recombinant human hyaluronidase) | Halozyme <i>San Diego, CA</i> | | Phase I (858) 794-8889 |
| PF-03446962 | Pfizer <i>New York, NY</i> | late-stage solid tumors | Phase I (860) 732-5156 |
| PF-03758309 | Pfizer <i>New York, NY</i> | | Phase I (860) 732-5156 |
| PF-04605412 | Pfizer <i>New York, NY</i> | | Phase I (860) 732-5156 |
| PF-04691502 | Pfizer <i>New York, NY</i> | | Phase I (860) 732-5156 |
| PF-04856884 (CVX060) | Pfizer <i>New York, NY</i> | | Phase I (860) 732-5156 |
| PF-05057459 (CVX 241) | Pfizer <i>New York, NY</i> | | Phase I (860) 732-5156 |
| PG11047 | Progen Pharmaceuticals <i>Redwood City, CA</i> | | Phase I (650) 610-7800 |
| picoplatin oral | Poniard Pharmaceuticals <i>San Francisco, CA</i> | | Phase I (650) 583-3774 |

SOLID TUMORS

| Product Name | Sponsor | Indication | Development Status |
|--|---|--|---|
| PLX3397 | Plexxikon <i>Berkeley, CA</i> | (see also lymphoma) | Phase I (510) 647-4000 |
| PM-01183 | PharmaMar USA <i>Cambridge, MA</i> | | Phase I completed (617) 868-3797 |
| PM-060184 | PharmaMar USA <i>Cambridge, MA</i> | | Phase I (617) 868-3797 |
| PNT2258 | ProNAi Therapeutics <i>Kalamazoo, MI</i> | | Phase I (269) 815-8098 |
| PRLX-93936 | Prolexys Pharmaceuticals <i>Salt Lake City, UT</i> | | Phase I (801) 303-1700 |
| PTC299 | PTC Therapeutics <i>South Plainfield, NJ</i> | (see also breast, skin, other) | Phase I (908) 222-7000 |
| purine nucleoside phosphorylase gene therapy | PNP Therapeutics <i>Birmingham, AL</i> | | Phase I www.pnptherapeutics.com |
| PX-478 | Oncothyreon <i>Seattle, WA</i> | (see also lymphoma) | Phase I completed (206) 801-2100 |
| PX-866 | Oncothyreon <i>Seattle, WA</i> | | Phase I/II (206) 801-2100 |
| quizartinib | Ambit Biosciences <i>San Diego, CA</i> Astellas Pharma US <i>Deerfield, IL</i> | late-stage solid tumors (see also leukemia) | Phase I (858) 334-2100 (800) 727-7003 |
| retaspimycin (IPI 504) | Infinity Pharmaceuticals <i>Cambridge, MA</i> | (see also lung) | Phase I (617) 453-1000 |
| RG7112 | Roche <i>Nutley, NJ</i> | (see also other) | Phase I (973) 235-5000 |
| RG7160 (HumAb EGFR) | Roche <i>Nutley, NJ</i> | | Phase I (973) 235-5000 |
| RG7167 | Roche <i>Nutley, NJ</i> | | Phase I (973) 235-5000 |
| RG7304 (Raf/MEK dual inhibitor) | Roche <i>Nutley, NJ</i> | | Phase I (973) 235-5000 |
| RG7334 (anti-PLGF mAb) | Roche <i>Nutley, NJ</i> | | Phase I (973) 235-5000 |
| RG7347 | Genentech <i>South San Francisco, CA</i> | | Phase I (650) 224-1000 |
| RG7422 (PI3 kinase inhibitor) | Genentech <i>South San Francisco, CA</i> | | Phase I (650) 224-1000 |
| RG7593 | Genentech <i>South San Francisco, CA</i> | | Phase I (650) 224-1000 |
| RG7594 | Genentech <i>South San Francisco, CA</i> | | Phase I (650) 224-1000 |
| rindopepimut | Celldex Therapeutics <i>Needham, MA</i> | (see also brain) | Phase I (860) 732-5156 |

SOLID TUMORS

| Product Name | Sponsor | Indication | Development Status |
|---|--|---|---|
| robatumumab | Merck <i>Whitehouse Station, NJ</i> | solid tumors (see also sarcoma) | Phase II (800) 672-6372 |
| | | solid tumors in children | Phase I (800) 672-6372 |
| SAR256212 (MM-121) | Merrimack Pharmaceuticals <i>Cambridge, MA</i> sanofi-aventis <i>Bridgewater, NJ</i> | (see also ovarian) | Phase I (617) 441-1000 (800) 633-1810 |
| SAR566658 (maytansin-loaded anti-DS6) | sanofi-aventis <i>Bridgewater, NJ</i> | | Phase I (800) 633-1810 |
| SB939 | S*Bio <i>Redwood City, CA</i> | late-stage solid tumors (see also leukemia) | Phase I (650) 730-2860 |
| selumetinib (AZD6244/ ARRY-886) | Array BioPharma <i>Boulder, CO</i> AstraZeneca <i>Wilmington, DE</i> | | Phase II (800) 236-9933 |
| selumetinib (AZD6244/ ARRY-886) MK-2206 combination | Array Bio Pharma <i>Boulder, CO</i> AstraZeneca <i>Wilmington, DE</i> Merck <i>Whitehouse Station, NJ</i> | | Phase I (800) 236-9933 (800) 672-6372 |
| SF1126 | Semafore Pharmaceuticals <i>Indianapolis, IN</i> | (see also leukemia, multiple myeloma) | Phase I (317) 876-3075 |
| simotaxel | Taxolog <i>Fairfield, NJ</i> | | Phase I (877) 829-6564 |
| SN2310 | OncoGenex Pharmaceuticals <i>Bothell, WA</i> | | Phase I completed (425) 686-1500 |
| sonpcizumab | Lpath <i>San Diego, CA</i> | | Phase II (858) 678-0800 |
| Sym004 | Symphogen <i>Lyngby, Denmark</i> | | Phase I www.symphogen.com |
| TAK-441 | Millennium Pharmaceuticals <i>Cambridge, MA</i> | late-stage solid tumors | Phase I (800) 390-5663 |
| TAK-701 | Millennium Pharmaceuticals <i>Cambridge, MA</i> | | Phase I (800) 390-5663 |
| TAK-733 | Millennium Pharmaceuticals <i>Cambridge, MA</i> | | Phase I (800) 390-5663 |
| TAK-901 | Millennium Pharmaceuticals <i>Cambridge, MA</i> | (see also other) | Phase I (800) 390-5663 |
| TAK-960 | Millennium Pharmaceuticals <i>Cambridge, MA</i> | | Phase I (800) 390-5663 |
| terameprocol (intravenous) | Erimos Pharmaceuticals <i>Houston, TX</i> | (see also brain, cervical, head/neck, other) | Phase I (713) 541-2000 |

SOLID TUMORS

| Product Name | Sponsor | Indication | Development Status |
|-----------------------|---|--|---|
| TH-302 | Threshold Pharmaceuticals <i>Redwood City, CA</i> | late-stage solid tumors (see also leukemia, sarcoma) | Phase I/II (650) 474-8200 |
| TKM-PLK1 | Tekmira Pharmaceuticals <i>Vancouver, Canada</i> | (see also lymphoma) | Phase I (604) 419-3200 |
| TLC388 | Taiwan Liposome <i>Taipei, Taiwan</i> | | Phase I |
| TRC093 | TRACON Pharmaceuticals <i>San Diego, CA</i> | | Phase I completed (858) 550-0780 |
| TRC102 | TRACON Pharmaceuticals <i>San Diego, CA</i> | | Phase I (858) 550-0780 |
| TRC105 | TRACON Pharmaceuticals <i>San Diego, CA</i> | locally advanced or metastatic solid tumors (see also prostate) | Phase I (858) 550-0780 |
| TRPM8 (D-3263) | Dendreon <i>Seattle, WA</i> | | Phase I (877) 256-4545 |
| TST10088 | Cangene <i>Winnipeg, Canada</i> | | Phase I (204) 275-4200 |
| U3-1565 | Amgen <i>Thousand Oaks, CA</i> U3 Pharma <i>Martinsried, Germany</i> | | Phase I (800) 772-6436 (973) 359-2600 |
| UNBS-5162 | Drais Pharmaceuticals <i>Bridgewater, NJ</i> | (see also lymphoma) | Phase I (908) 895-1200 |
| V935 | Merck <i>Whitehouse Station, NJ</i> | | Phase I (800) 672-6372 |
| vinorelbine liposomal | Talon Therapeutics <i>South San Francisco, CA</i> | (see also lymphoma) | Phase I (650) 588-6404 |
| VX15 | Vaccinex <i>Rochester, NY</i> | | Phase I (585) 271-2700 |
| WX-UK1 | Wilex <i>Munich, Germany</i> | | Phase I www.wilex.com |
| X-82 | Tyrogenex <i>West Palm Beach, FL</i> | | Phase I (561) 835-9356 |
| XMT-1001 | Mersana Therapeutics <i>Cambridge, MA</i> | refractory metastatic disease | Phase I (617) 498-0020 |
| XMT-1107 | Mersana Therapeutics <i>Cambridge, MA</i> | | Phase I (617) 498-0020 |

STOMACH CANCER

| Product Name | Sponsor | Indication | Development Status |
|--------------------------------|---|---|-----------------------------|
| Afinitor® everolimus | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | GIST (see also breast, kidney, liver, lymphoma, other) | Phase III (888) 669-6682 |

STOMACH CANCER

| Product Name | Sponsor | Indication | Development Status |
|---|--|--|---|
| AMG 386 | Amgen <i>Thousand Oaks, CA</i> | gastric and gastroesophageal junction adenocarcinoma (see also breast, colorectal, kidney, liver, ovarian, other) | Phase II (800) 772-6436 |
| | | distal esophageal adenocarcinoma | Phase II (800) 772-6436 |
| AT-101 | Ascenta Therapeutics <i>Malvern, PA</i> | esophageal cancer (see also brain, leukemia, lung, lymphoma, prostate) | Phase II (610) 408-0313 |
| AUY922 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | gastric cancer (see also breast, colorectal, lung, multiple myeloma) | Phase II (888) 669-6682 |
| AV-951 (tivozanib) | AVEO Pharmaceuticals <i>Cambridge, MA</i> | gastrointestinal cancer (see also breast, kidney, lung) | Phase I/II (617) 299-5000 |
| BAY 73-4506 (regorafenib) (Orphan Drug) | Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> | late-stage GIST (see also colorectal, kidney, lung) | Phase III (888) 842-2937 |
| brivanib (VEGFR/FGFR kinase inhibitor) | Bristol-Myers Squibb <i>Princeton, NJ</i> | gastrointestinal cancer (see also liver) | Phase I (212) 546-4000 |
| CNF-2024 | Biogen Idec <i>Weston MA</i> | GIST (see also breast) | Phase II (781) 464-2000 |
| E7050 | Eisai <i>Woodcliff Lake, NJ</i> | gastric cancer (see also liver, other) | Phase I/II (888) 422-4743 |
| ganetespi | Synta Pharmaceuticals <i>Lexington, MA</i> | esophageal cancer, GIST (see also breast, colorectal, lung, other) | Phase II (781) 274-8200 |
| Ixempra [®] ixabepilone | Bristol-Myers Squibb <i>Princeton, NJ</i> | gastric cancer, esophageal cancer (see also breast, lung, other) | Phase II (212) 546-4000 |
| masitinib | AB Science USA <i>Short Hills, NJ</i> | GIST (see also leukemia, pancreatic) | Phase III (973) 218-2437 |
| OncoGel [™] paclitaxel controlled-release (Orphan Drug) | Protherics <i>Brentwood, TN</i> | esophageal cancer | Phase II (615) 327-1027 |
| perifosine (KRX-1401) | Aeterna Zentaris <i>Montreal, Canada</i> Keryx Biopharmaceuticals <i>New York, NY</i> | late-stage GIST (see also brain, colorectal, kidney, leukemia, lymphoma, multiple myeloma, sarcoma, ovarian) | Phase II (212) 531-5965 |
| polyclonal antibody stimulator (Orphan Drug) | Cancer Advances <i>Durham, NC</i> | gastric cancer (see also colorectal, pancreatic) | Phase III (919) 361-2162 |
| ramucirumab (IMC-1121B) | Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i> | gastric cancer (see also breast, colorectal, liver, lung) | Phase III (800) 545-5979 (212) 645-1405 |

STOMACH CANCER

| Product Name | Sponsor | Indication | Development Status |
|--|---|---|--------------------------------------|
| rilotumumab | Amgen <i>Thousand Oaks, CA</i> | gastric cancer (see also brain, colorectal, lung, prostate) | Phase II (800) 772-6436 |
| S-1 | Taiho Pharma USA <i>Princeton, NJ</i> | gastric cancer | Phase III (609) 750-5300 |
| Tasigna® nilotinib (Orphan Drug) | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | GIST (see also leukemia, skin) | Phase III (888) 669-6682 |
| telatinib (Orphan Drug) | ACT Biotech <i>San Francisco, CA</i> | late-stage gastric cancer (see also colorectal) | Phase II (415) 230-3900 |
| tesetaxel (Orphan Drug) | Genta <i>Berkeley Heights, NJ</i> | advanced gastric cancer (Fast Track) (see also bladder, breast, prostate, skin) | Phase II (908) 286-9800 |
| TNFerade™ golnerminogene pradenovec | GenVec <i>Gaithersburg, MD</i> | esophageal cancer (see also colorectal, head/neck, pancreatic, skin) | Phase II completed (240) 632-0740 |
| tremelimumab (CP-675206) | Pfizer <i>New York, NY</i> | gastrointestinal cancer (see also kidney, pancreatic, skin, other) | Phase II (860) 732-5156 |
| Tykerb® lapatinib | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | gastric cancer (see also breast, head/neck) | Phase III (888) 825-5249 |

CANCER/CHEMOTHERAPY-RELATED CONDITIONS

| Product Name | Sponsor | Indication | Development Status |
|--|---|--|---|
| Acapodene® toremifene | GTx <i>Memphis, TN</i> | complications from androgen deprivation therapy (see also prostate) | application submitted (901) 523-9700 |
| ACE-011 (sotatercept) | Acceleron Pharma <i>Cambridge, MA</i> Celgene <i>Summit, NJ</i> | chemotherapy-induced anemia (see also other) | Phase II/III (617) 649-9200 (908) 673-9000 |
| AG013 | ActoGeniX <i>Zwijnaarde, Belgium</i> | mucositis | Phase I www.actogenix.com |
| ARX-02 (sufentanil sublingual) | AcelRx Pharmaceuticals <i>Redwood City, CA</i> | cancer breakthrough pain | Phase II (650) 216-3500 |
| Campath® alemtuzumab (intravenous) | Genzyme <i>Cambridge, MA</i> | chronic graft-versus-host disease | Phase I (617) 252-7500 |
| CB1400 | Canopus BioPharma <i>Studio City, CA</i> | mucositis (prevention) | Phase II (818) 980-5008 |
| Emend® for Injection fosaprepitant | Merck <i>Whitehouse Station, NJ</i> Fate Therapeutics <i>San Diego, CA</i> | chemotherapy-induced nausea and vomiting (CINV) in adolescents, children and infants | Phase I (800) 672-6372 |

CANCER/CHEMOTHERAPY-RELATED CONDITIONS

| Product Name | Sponsor | Indication | Development Status |
|--|---|---|--|
| Ereska™ ketamine intranasal | Javelin Pharmaceuticals <i>Cambridge, MA</i> | cancer pain | Phase III (617) 349-4500 |
| fentanyl sublingual spray | INSYS Therapeutics <i>Phoenix, AZ</i> | cancer pain | Phase III (602) 910-2617 |
| FT1050 (Orphan Drug) | Fate Therapeutics <i>San Diego, CA</i> | hematopoietic stem cell support in patients with hematological malignancies | Phase I (858) 875-1800 |
| golotimod | SciClone Pharmaceuticals <i>Foster City, CA</i> | chemotherapy-induced stomatitis (prevention) | Phase II (650) 358-3456 |
| morphine intranasal | Marina Biotech <i>Bothell, WA</i> | cancer pain | Phase II (425) 908-3600 |
| MRX-1024 | Molecular Therapeutics <i>Ann Arbor, MI</i> | mucositis | Phase I (734) 259-4574 |
| nabiximols | Otsuka America Pharmaceutical <i>Rockville, MD</i> | advanced cancer pain | Phase II (800) 438-6124 |
| Nasalfent® fentanyl intranasal | Archimedes Pharma <i>Reading, United Kingdom</i> | cancer pain | application submitted |
| norepinephrine topical | ProCerus BioPharm <i>Madison, WI</i> | prevention of radiodermatitis in patients undergoing radiation therapy | Phase I/II (608) 273-8862 |
| | | prevention of oral mucositis in patients undergoing radiation therapy | Phase I/II (608) 273-8862 |
| | | prevention of chemo- and radio- therapy-induced alopecia | Phase I/II (608) 273-8862 |
| NP-2 gene therapy (intradermal) | Diamyd Medical <i>Pittsburgh, PA</i> | cancer pain | Phase II (412) 770-1310 |
| Nplate™ romiplostim | Amgen <i>Thousand Oaks, CA</i> | chemotherapy-induced thrombocytopenia (see also leukemia) | Phase II (800) 772-6436 |
| orBec® beclometasone (Orphan Drug) | Soligenix <i>Princeton, NJ</i> Sigma-Tau Pharmaceuticals <i>Gaithersburg, MD</i> | graft-versus-host disease (Fast Track) | Phase III (609) 538-8200 (800) 447-0169 |
| | | graft-versus-host disease (prevention) | Phase II (609) 538-8200 (800) 447-0169 |
| | | acute radiation enteritis (Fast Track) | Phase I/II (609) 538-8200 (800) 447-0169 |
| PF-4383119 (tanezumab) | Pfizer <i>New York, NY</i> | cancer pain | Phase II (860) 732-5156 |

CANCER/CHEMOTHERAPY-RELATED CONDITIONS

| Product Name | Sponsor | Indication | Development Status |
|--|---|--|---|
| PHY-906 | PhytoCeutica <i>New Haven, CT</i> | chemoprotection | Phase I/II (203) 777-3462 |
| Prochymal® remestemcel-L (Orphan Drug) | Osiris Therapeutics <i>Columbia, MD</i> | graft-versus-host disease (Fast Track) | Phase III (443) 545-1800 |
| Promacta® eltrombopag | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | chemotherapy-induced thrombocytopenia | Phase II (888) 825-5249 |
| Reviroc™ (Orphan Drug) | Kiadais Pharma <i>St. Laurent, Canada</i> | bone marrow transplant rejection | Phase II/III (514) 336-4886 |
| | | graft-versus-host disease | Phase I/II (514) 336-4886 |
| rolapitant | TESARO <i>Waltham, MA</i> | chemotherapy-induced nausea and vomiting | Phase II completed (339) 970-0900 |
| SAR411298 (FAAH inhibitor) | sanofi-aventis <i>Bridgewater, NJ</i> | cancer pain | Phase I (800) 633-1810 |
| tapentadol controlled-release | Grunenthal <i>Aachen, Germany</i> Johnson & Johnson Pharmaceutical Research & Development <i>Raritan, NJ</i> | cancer pain | Phase II (800) 817-5286 |
| Tavocept™ dimesna | BioNumerik Pharmaceuticals <i>San Antonio, TX</i> | chemoprotection (Fast Track) (see also lung) | Phase III (210) 614-1701 |
| TH-9402 | Kiadis Pharma <i>Amsterdam, The Netherlands</i> | graft-versus-host disease | Phase I/II www.kiadis.com |
| TXA127 | Tarix Pharmaceuticals <i>Brookline, MA</i> | chemotherapy-induced thrombocytopenia | Phase II (617) 827-6824 |
| Voraxaze® glucarpidase (Orphan Drug) | Protherics <i>Brentwood, TN</i> | chemoprotection | application submitted (615) 327-1027 |
| Xen2174 | Xenome <i>Queensland, Australia</i> | cancer pain | Phase II www.xenome.com |

OTHER CANCERS

| Product Name | Sponsor | Indication | Development Status |
|--------------|---|---|---------------------------|
| 8H9 mAb | United Therapeutics <i>Silver Spring, MD</i> | peritoneal cancer (see also brain, sarcoma) | Phase I (301) 608-9292 |
| Å6 | Angstrom Pharmaceuticals <i>Solana Beach, CA</i> | advanced gynecological cancer (see also ovarian) | Phase I (858) 314-2356 |
| ABT-348 | Abbott Laboratories <i>Abbott Park, IL</i> | hematological malignancies (see also solid tumors) | Phase I (847) 937-6100 |

OTHER CANCERS

| Product Name | Sponsor | Indication | Development Status |
|--|--|--|--|
| ABT-888 (veliparib) | Abbott Laboratories <i>Abbott Park, IL</i> | fallopian tube cancer, peritoneal cancer (see also brain, breast, colorectal, ovarian, prostate, skin) | Phase II (847) 937-6100 |
| ACE-011 (sotatercept) | Acceleron Pharma <i>Cambridge, MA</i> Celgene <i>Summit, NJ</i> | cancer metastases (see also cancer/chemotherapy) | Phase II (617) 649-9200 (908) 673-9000 |
| AEG-41174 | Aegera Therapeutics <i>Montreal, Canada</i> | hematological malignancies | Phase I (514) 288-5532 |
| AEW541 | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | hematological malignancies (see also solid tumors) | Phase I (888) 669-6682 |
| Afinitor [®] everolimus | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | neuroendocrine tumors (see also breast, kidney, liver, lymphoma, pancreatic, stomach) | application submitted (888) 669-6682 |
| | | urogenital cancer | Phase I (888) 669-6682 |
| AlloStim [™] | Immunovative Therapies <i>Shoham, Israel</i> | hematological malignancies | Phase I/II www.immunovative.co.il |
| AMG 319 | Amgen <i>Thousand Oaks, CA</i> | hematological malignancies | Phase I (800) 772-6436 |
| AMG 386 | Amgen <i>Thousand Oaks, CA</i> | fallopian tube cancer, peritoneal cancer (see also breast, colorectal, kidney, liver, ovarian, stomach) | Phase III (800) 772-6436 |
| AMG 479 (ganitumab) | Amgen <i>Thousand Oaks, CA</i> | neuroendocrine tumors (see also breast, colorectal, lung, pancreatic, sarcoma) | Phase II (800) 772-6436 |
| antineoplaston- AS2-1 oral | Burzynski Research Institute <i>Houston, TX</i> | cancer metastases | Phase II (713) 335-5697 |
| AR-67 | Arno Therapeutics <i>Parsippany, NJ</i> | myelodysplastic syndromes (see also brain) | Phase II (862) 703-7170 |
| ARQ-197 | ArQule <i>Woburn, MA</i> Daiichi Sankyo <i>Parsippany, NJ</i> | germ cell and embryonal neoplasms (see also colorectal, kidney, liver, lung, pancreatic, sarcoma, solid tumors) | Phase II (781) 994-0300 (973) 944-2600 |
| AS703026 | EMD Serono <i>Rockland, MA</i> | hematological malignancies | Phase I/II (800) 283-8088 |
| ATI-BC-1 | Algeta <i>Oslo, Norway</i> Bayer Healthcare Pharmaceuticals <i>Wayne, NJ</i> | bone metastases | Phase III (888) 842-2937 |
| Avastin [®] bevacizumab | Genentech <i>South San Francisco, CA</i> | high-risk carcinoid tumors (see also brain, breast, colorectal, lung, ovarian) | Phase III (650) 225-1000 |

OTHER CANCERS

| Product Name | Sponsor | Indication | Development Status |
|--|---|---|--|
| axitinib | Pfizer New York, NY | thyroid cancer (see also kidney, lung) | Phase II (860) 732-5156 |
| AZD1152 (aurora kinase inhibitor) | AstraZeneca Wilmington, DE | hematological malignancies | Phase II (800) 236-9933 |
| AZD1480 | AstraZeneca Wilmington, DE | myeloproliferative diseases (see also solid tumors) | Phase I (800) 236-9933 |
| Azedra™ iodine-labeled metaiodobenzyl- guanidine (Orphan Drug) | Molecular Insight Pharmaceuticals Cambridge, MA | paraganglioma, pheochromocytoma (Fast Track) (see also brain) | Phase II (617) 492-5554 |
| BAY 94-9392 | Bayer HealthCare Pharmaceuticals Wayne, NJ | diagnosis of cancer | Phase I (888) 842-2937 |
| belinostat | Spectrum Pharmaceuticals Irvine, CA TopoTarget USA Rockaway, NJ | cancer of unknown primary site | Phase II (949) 788-6700 (973) 895-6900 |
| Bonefos® clodronic acid | Bayer HealthCare Pharmaceuticals Wayne, NJ | cancer metastases | application submitted (888) 842-2937 |
| BP-100-1.01 | Bio-Path Ogden, UT | hematological malignancies | Phase I (801) 580-2326 |
| cabozantinib (XL-184) (Orphan Drug) | Exelixis South San Francisco, CA | medullary thyroid cancer (see also lung) | Phase III (650) 837-7000 |
| CAT-8015 (anti-CD22 recombinant immunotoxin) | AstraZeneca Wilmington, DE MedImmune Gaithersburg, MD | hematological malignancies | Phase I (800) 236-9933 (301) 398-0000 |
| catumaxomab | Fresenius Biotech North America Waltham, MA | malignant ascites (see also ovarian) | Phase II www.fresenius-biotech.com |
| CDB-4124 | Repros Therapeutics The Woodlands, TX | uterine leiomyoma | Phase I/II (281) 719-3400 |
| cell therapy | Cell Medica London, United Kingdom Center for Cell and Gene Therapy Houston, TX | cancer-associated with Epstein-Barr virus infections | Phase II www.cellmedica.co.uk (713) 798-1246 |
| CLT-008 | Cellerant Therapies San Carlos, CA | hematological malignancies | Phase I (650) 232-2122 |
| CNTO 328 (siltuximab) | Centocor Ortho Biotech Horsham, PA | giant lymph node hyperplasia (see also multiple myeloma, prostate) | Phase II (800) 457-6399 |
| CPI-613 | Cornerstone Pharmaceuticals Cranbury, NJ | hematological malignancies (see also pancreatic) | Phase I (609) 409-7050 |

OTHER CANCERS

| Product Name | Sponsor | Indication | Development Status |
|---|--|---|--------------------------------------|
| CS-7017 (efatutazone) | Daiichi Sankyo <i>Parsippany, NJ</i> | thyroid cancer (see also colorectal, lung) | Phase I/II (973) 944-2600 |
| CX-4945 | Cylene Pharmaceuticals <i>San Diego, CA</i> | giant lymph node hyperplasia (see also multiple myeloma, solid tumors) | Phase I (858) 875-5100 |
| dalotuzumab | Merck <i>Whitehouse Station, NJ</i> | neuroendocrine tumors (see also breast, lung, pancreatic) | Phase II completed (800) 672-6372 |
| DCVax®-L ovarian cancer vaccine | Northwest Biotherapeutics <i>Bothell, WA</i> | peritoneal cancer (see also ovarian) | Phase I/II (425) 608-3000 |
| DM-CHOC-PEN | Dekk-Tec <i>New Orleans, LA</i> | central nervous system cancer | Phase I (504) 583-6135 |
| E7050 | Eisai <i>Woodcliff Lake, NJ</i> | squamous cell carcinoma (see also liver, stomach) | Phase I/II (888) 422-4743 |
| EC-20 | Endocyte <i>West Lafayette, IN</i> | diagnosis of folate receptor- positive cancers | Phase II (765) 463-7175 |
| EC-145 | Endocyte <i>West Lafayette, IN</i> | endometrial cancer (see also lung, ovarian) | Phase II (765) 463-7175 |
| EGEN 001 | EGEN <i>Huntsville, AL</i> | recurrent fallopian tube cancer, recurrent peritoneal cancer (see also ovarian) | Phase II (356) 512-0077 |
| ELND002 | Elan <i>Dublin, Ireland</i> | hematological malignancies | Phase I www.elan.com |
| ENMD-2076 | EntreMed <i>Rockville, MD</i> | refractory metastatic late-stage cancer (see also multiple myeloma, ovarian) | Phase I (240) 864-2600 |
| Femara® letrozole | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | endometrial cancer | Phase II (888) 669-6682 |
| FP-1039 | Five Prime Therapeutics <i>San Francisco, CA</i> | endometrial cancer (see also solid tumors) | Phase II (415) 365-5600 |
| ganetespib | Synta Pharmaceuticals <i>Lexington, MA</i> | hematological malignancies (see also breast, colorectal, lung, stomach) | Phase I/II (781) 274-8200 |
| GSK2110183 (AKT protein kinase inhibitor) | GlaxoSmithKline <i>Rsch. Triangle Park, NC</i> | hematological malignancies | Phase I (888) 825-5249 |
| HQK-1004 | HemaQuest <i>Seattle, WA</i> | Epstein-Barr virus-related lymphoid malignancies | Phase II (206) 682-1233 |
| IPI-493 | Infinity Pharmaceuticals <i>Cambridge, MA</i> | hematological malignancies (see also solid tumors) | Phase I (617) 453-1000 |
| Ixempra® ixabepilone | Bristol-Myers Squibb <i>Princeton, NJ</i> | endometrial cancer (see also breast, lung, stomach) | Phase II (212) 546-4000 |
| KB004 | KaloBios Pharmaceuticals <i>South San Francisco, CA</i> | hematological malignancies | Phase I (650) 243-3100 |

OTHER CANCERS

| Product Name | Sponsor | Indication | Development Status |
|--|---|---|---|
| lenvatinib (E7080) | Eisai <i>Woodcliff Lake, NJ</i> | thyroid cancer (see also brain, kidney, liver, skin) | Phase III (888) 422-4743 |
| | | endometrial cancer | Phase II (888) 422-4743 |
| MEDI-551 (anti-CD19 mAb) | AstraZeneca <i>Wilmington, DE</i> MedImmune <i>Gaithersburg, MD</i> | hematological malignancies | Phase I (800) 236-9933 (301) 398-0000 |
| MER-101 (oral zoledronic acid) | Merrion Pharmaceuticals <i>Wilmington, NC</i> | bone metastases | Phase II (910) 799-1847 |
| mesenchymal stem cell therapy (implant) | Cephalon <i>Frazer, PA</i> Mesoblast <i>New York, NY</i> | for bone marrow regeneration in patients undergoing bone marrow transplantation in hematological malignancies | Phase II (610) 344-0200 (212) 880-2060 |
| Mirena [®] levonorgestrel-releasing intrauterine system | Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> | endometrial cancer | Phase II (888) 842-2937 |
| MK-2206 | Merck <i>Whitehouse Station, NJ</i> | neuroendocrine tumors (see also breast, colorectal) | Phase II (800) 672-6372 |
| MLN4924 | Millennium Pharmaceuticals <i>Cambridge, MA</i> | hematological malignancies (see also solid tumors) | Phase I (800) 390-5663 |
| MLN8237 | Millennium Pharmaceuticals <i>Cambridge, MA</i> | hematological malignancies (see also solid tumors) | Phase II (800) 390-5663 |
| MLN9708 | Millennium Pharmaceuticals <i>Cambridge, MA</i> | hematological malignancies (see also solid tumors) | Phase I (800) 390-5663 |
| NBI-56418 (elagolix) | Abbott <i>Abbott Park, IL</i> Neurocrine Biosciences <i>San Diego, CA</i> | uterine leiomyoma | Phase I (847) 937-6100 (858) 617-7600 |
| Nexavar [®] sorafenib | Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> Onyx Pharmaceuticals <i>Emeryville, CA</i> | thyroid cancer (see also breast, colorectal, kidney, liver, lung, ovarian) | Phase III (888) 842-2837 (510) 597-6500 |
| NTX-10 | Neotropix <i>Malvern, PA</i> | neuroendocrine tumors (see also lung) | Phase I (617) 460-1200 |
| octreotide implant | Endo Pharmaceuticals <i>Chadds Ford, PA</i> | malignant carcinoid syndrome | Phase II (610) 558-9800 |
| Opaxio [™] paclitaxel poliglumex | Cell Therapeutics <i>Seattle, WA</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i> | peritoneal cancer (see also lung, ovarian) | Phase III (800) 215-2355 (888) 669-6682 |
| OSI-906 (linsitinib) | OSI Pharmaceuticals <i>Melville, NY</i> | adrenocortical carcinoma (see also lung, ovarian) | Phase III (631) 962-2000 |

OTHER CANCERS

| Product Name | Sponsor | Indication | Development Status |
|---|--|--|--|
| panobinostat (LBH589) | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | hematological malignancies (see also lymphoma, multiple myeloma) | Phase II (888) 669-6682 |
| pasireotide (SDM230) | Novartis Pharmaceuticals <i>East Hanover, NJ</i> | neuroendocrine tumors | Phase III (888) 669-6682 |
| | | meningioma | Phase II (888) 669-6682 |
| PF-04449913 | Pfizer <i>New York, NY</i> | hematological malignancies | Phase I (860) 732-5156 |
| PHA-848125 | Nerviano Medical Sciences <i>Nerviano, Italy</i> | inoperable/unresectable thymoma | Phase II www.nervianoms.com |
| phenoxodiol | Marshall Edwards <i>San Diego, CA</i> | fallopian tube cancer (see also ovarian, prostate) | Phase I/II (858) 792-6300 |
| PM-00104 | PharmaMar USA <i>Cambridge, MA</i> | endometrial cancer (see also cervical) | Phase II (617) 868-3797 |
| PTC299 | PTC Therapeutics <i>South Plainfield, NJ</i> | central nervous system cancer in children (see also breast, skin, solid tumors) | Phase I (908) 222-7000 |
| Quadramet [®] samarium sm-153 lexidronam injection | EUSA Pharma <i>Langhorne, PA</i> | bone metastases (see also multiple myeloma, prostate, sarcoma) | Phase III (800) 833-3533 |
| quarfloxin | Cylene Pharmaceuticals <i>San Diego, CA</i> | neuroendocrine tumors | Phase II (858) 875-5100 |
| R763 | Rigel Pharmaceuticals <i>South San Francisco, CA</i> | hematological malignancies | Phase I (650) 624-1100 |
| RG7112 | Roche <i>Nutley, NJ</i> | hematological malignancies (see also solid tumors) | Phase I (973) 235-5000 |
| SAR245408 (XL-147) | Exelixis <i>South San Francisco, CA</i> sanofi-aventis <i>Bridgewater, NJ</i> | endometrial cancer | Phase II (650) 837-7000 (800) 633-1810 |
| SAR650984 (anti-CD38 naked mAb) | sanofi-aventis <i>Bridgewater, NJ</i> | hematological malignancies | Phase I (800) 633-1810 |
| seliciclib | Cyclacel Pharmaceuticals <i>Short Hills, NJ</i> | nasopharyngeal cancer | Phase II (973) 847-5955 |
| Somatuline Autogel [®] lanreotide | Tercica <i>Brisbane, CA</i> | neuroendocrine tumors | Phase III (650) 624-4900 |
| S-PRAnt | Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> | uterine leiomyoma | Phase I (888) 842-2937 |

OTHER CANCERS

| Product Name | Sponsor | Indication | Development Status |
|---|---|--|--|
| StemEx® carlecortemcel-L (Orphan Drug) | Gamida Cell <i>Jerusalem, Israel</i> Teva Pharmaceuticals USA <i>North Wales, PA</i> | hematological malignancies (Fast Track) | Phase II/III (215) 591-3000 |
| TAK-901 | Millennium Pharmaceuticals <i>Cambridge, MA</i> | hematological malignancies (see also solid tumors) | Phase I (800) 390-5663 |
| Tarceva® erlotinib | Genentech <i>South San Francisco, CA</i> OSI Pharmaceuticals <i>Melville, NY</i> | gynecological cancer, squamous cell cancer (see also bladder, brain, breast, colorectal, head/neck, leukemia, liver, lung) | Phase II (650) 224-1000 (800) 572-1932 |
| terameprocol (intravenous) | Erimos Pharmaceuticals <i>Houston, TX</i> | hematological malignancies (see also brain, cervical, head/neck, solid tumors) | Phase I (713) 541-2000 |
| testosterone vaginal | Columbia Laboratories <i>Livingston, NJ</i> | uterine leiomyoma | Phase I (866) 566-5636 |
| TG-02 | S*Bio <i>Redwood City, CA</i> | hematological malignancies | Phase I (650) 730-2860 |
| tremelimumab (CP-675206) | Pfizer <i>New York, NY</i> | genitourinary cancer (see also kidney, pancreatic, skin, stomach) | Phase II (860) 732-5156 |
| V503 | Merck <i>Whitehouse Station, NJ</i> | vulvovaginal cancer prevention (see also cervical) | Phase III (800) 672-6372 |
| vandetanib | AstraZeneca <i>Wilmington, DE</i> | medullary thyroid cancer (Fast Track) | application submitted (800) 236-9933 |
| VB-111 | VBL Therapeutics <i>Or Yehuda, Israel</i> | thyroid cancer (see also brain) | Phase II www.vblrx.com |
| volasertib | Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i> | urogenital cancer | Phase II (800) 243-0127 |
| Xgeva™ denosumab | Amgen <i>Thousand Oaks, CA</i> | prevention of bone metastases in breast cancer | Phase III (800) 772-6436 |
| | | prevention of bone metastases in prostate cancer | Phase III (800) 772-6436 |
| Zolinza® vorinostat | Merck <i>Whitehouse Station, NJ</i> | gynecological cancer, peritoneal cancer (see also breast, multiple myeloma) | Phase I/II (800) 672-6372 |
| Zybrestat™ fosbretabulin (Orphan Drug) | OXIGENE <i>South San Francisco, CA</i> | thyroid cancer (combination therapy) (Fast Track) (see also lung, ovarian) | Phase II/III (650) 635-7000 |

UNSPECIFIED CANCERS

(DRUGS THAT HAVE POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)

| Product Name | Sponsor | Indication | Development Status |
|--|--|------------|---|
| AFX-9901 | Afecta Pharmaceuticals <i>Irvine, CA</i> | | in clinical trials (949) 253-4688 |
| AGS-6MF | Agensys <i>Santa Monica, CA</i> Astellas Pharma US <i>Deerfield, IL</i> | | Phase I (800) 695-4321 |
| AMG 337 | Amgen <i>Thousand Oaks, CA</i> | | Phase I (800) 772-6436 |
| antineoplaston-A10 IV | Burzynski Research Institute <i>Houston, TX</i> | | Phase II (713) 335-5697 |
| antineoplaston-A10 oral | Burzynski Research Institute <i>Houston, TX</i> | | Phase II (713) 335-5697 |
| ANX-514 (docetaxel emulsion) | ADVENTRX Pharmaceuticals <i>San Diego, CA</i> | | Phase I (858) 552-0866 |
| ARRY-300 | Array BioPharma <i>Boulder, CO</i> Novartis Pharmaceuticals <i>East Hanover, NJ</i> | | Phase I (303) 381-6600 (888) 669-6682 |
| AVL-292 | Avila Therapeutics <i>Waltham, MA</i> | | Phase I (781) 891-0086 |
| B7-2/GM-CSF cancer gene therapy | NuVax Therapeutics <i>Tustin, CA</i> | | Phase I (714) 505-4461 |
| BMS-663513 (anti-CD137) | Bristol-Myers Squibb <i>Princeton, NJ</i> | | Phase I (212) 235-5000 |
| CA-18C3 | Xbiotech <i>Austin, TX</i> | | Phase I (512) 386-2900 |
| cancer compound | Eli Lilly <i>Indianapolis, IN</i> | | Phase I (800) 545-5979 |
| cancer compound | Eli Lilly <i>Indianapolis, IN</i> | | Phase I (800) 545-5979 |
| cancer compound | Eli Lilly <i>Indianapolis, IN</i> | | Phase I (800) 545-5979 |
| cancer compound | Eli Lilly <i>Indianapolis, IN</i> | | Phase I (800) 545-5979 |
| cancer vaccine (oral) | Immunitor USA <i>College Park, MD</i> | | Phase I/II (301) 476-0930 |
| carboxy-amidotriazole orotate (CTO) | Tactical Therapeutics <i>New York, NY</i> | | Phase I (212) 651-9653 |

UNSPECIFIED CANCERS

(DRUGS THAT HAVE POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)

| Product Name | Sponsor | Indication | Development Status |
|--|---|------------|--|
| chidamide | HUYA Bioscience International San Diego, CA Quintiles Rsch. Triangle Park, NC | | Phase I (858) 798-8800 (919) 998-2003 |
| cixutumumab | Eli Lilly Indianapolis, IN ImClone Systems New York, NY | | Phase II (800) 545-5979 (212) 645-1405 |
| CNDO-101 | Coronado Biosciences New York, NY | | Phase I (212) 332-1665 |
| crenolanib (CP-868-596) | AROG Pharmaceuticals Dallas, TX | | Phase I (214) 593-0500 |
| docetaxel nanopharmaceutical | BIND Biosciences Cambridge, MA | | Phase I (617) 419-3400 |
| E7016 | Eisai Woodcliff Lake, NJ | | Phase I (888) 422-4743 |
| E6201 | Eisai Woodcliff Lake, NJ | | Phase I (888) 422-4743 |
| EC-0225 | Endocyte West Lafayette, IN | | Phase I completed (765) 463-7175 |
| EVO 011 | Evolve Oncology New York, NY | | in clinical trials (646) 723-8941 |
| EVO 044 | Evolve Oncology New York, NY | | in clinical trials (646) 723-8941 |
| FANG TM vaccine (autologous tumour cell vaccine) | Gradalis Carrollton, TX | | Phase II (214) 442-8100 |
| fenretinide intravenous (4-HPR) | CerRx Lubbock, TX | | Phase I www.cerrx.com |
| GI-6207 | Globelmmune Louisville, CO | | Phase I (303) 625-2700 |
| GSK2126458 (PI3 kinase inhibitor) | GlaxoSmithKline Rsch. Triangle Park, NC | | Phase I (888) 825-5249 |
| GSK2586881 | GlaxoSmithKline Rsch. Triangle Park, NC | | Phase I (888) 825-5249 |
| hTERT cancer vaccine (human telomerase reverse transcriptase) | Merck Whitehouse Station, NJ Vical San Diego, CA | | Phase I (800) 672-6372 (858) 646-1100 |
| HuCAL-derived antibody | Centocor Ortho Biotech Horsham, PA MorphoSys Munich, Germany | | Phase I (800) 457-6399 |

UNSPECIFIED CANCERS

(DRUGS THAT HAVE POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)

| Product Name | Sponsor | Indication | Development Status |
|--------------------------------------|---|------------|--|
| IMC-3G3 (olaratumab) | Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i> | | Phase II (800) 545-5979 (212) 645-1405 |
| IMC-18F1 (icrucumab) | Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i> | | Phase II (800) 545-5979 |
| ISIS-EIF4ERx (eIF-4E ASO) | Eli Lilly <i>Indianapolis, IN</i> Isis Pharmaceuticals <i>Carlsbad, CA</i> | | Phase II (800) 545-5979 (760) 931-9200 |
| ixabepilone (oral formulation) | Bristol-Myers Squibb <i>Princeton, NJ</i> | | Phase I/II (212) 546-4000 |
| LY2090314 | Eli Lilly <i>Indianapolis, IN</i> | | Phase II (800) 545-5979 |
| LY2157299 (TGF β inhibitor) | Eli Lilly <i>Indianapolis, IN</i> | | Phase I (800) 545-5979 |
| LY2181308 (survivin ASO) | Eli Lilly <i>Indianapolis, IN</i> Isis Pharmaceuticals <i>Carlsbad, CA</i> | | Phase II (800) 545-5979 (760) 931-9200 |
| LY2334737 (Gem prodrug) | Eli Lilly <i>Indianapolis, IN</i> | | Phase I (800) 545-5979 |
| LY2523355 (Eg5 inhibitor) | Eli Lilly <i>Indianapolis, IN</i> | | Phase I (800) 545-5979 |
| LY2584702 | Eli Lilly <i>Indianapolis, IN</i> | | Phase I (800) 545-5979 |
| LY2603618 (ChK-1 inhibitor) | Eli Lilly <i>Indianapolis, IN</i> | | Phase II (800) 545-5979 |
| LY2606368 | Eli Lilly <i>Indianapolis, IN</i> | | Phase I (800) 545-5979 |
| LY2624587 | Eli Lilly <i>Indianapolis, IN</i> | | Phase I (800) 545-5979 |
| LY2780301 | Eli Lilly <i>Indianapolis, IN</i> | | Phase I (800) 545-5979 |
| LY2801653 | Eli Lilly <i>Indianapolis, IN</i> | | Phase I (800) 545-5979 |
| LY2874455 | Eli Lilly <i>Indianapolis, IN</i> | | Phase I (800) 545-5979 |
| LY2875358 | Eli Lilly <i>Indianapolis, IN</i> | | Phase I (800) 545-5979 |
| LY2940680 | Eli Lilly <i>Indianapolis, IN</i> | | Phase I (800) 545-5979 |

UNSPECIFIED CANCERS

(DRUGS THAT HAVE POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)

| Product Name | Sponsor | Indication | Development Status |
|------------------------------------|---|------------|--|
| MK-4101 | Merck <i>Whitehouse Station, NJ</i> | | Phase I (800) 672-6372 |
| MK-8033 | Merck <i>Whitehouse Station, NJ</i> | | Phase I (800) 672-6372 |
| MPC-3100 | Myrexix <i>Salt Lake City, UT</i> | | Phase I (801) 214-7800 |
| notch signalling pathway inhibitor | Eli Lilly <i>Indianapolis, IN</i> | | Phase I (800) 545-5979 |
| NRX-4204 | NuRx Pharmaceuticals <i>Irvine, CA</i> | | Phase I (949) 336-7111 |
| OPB-31121 | Otsuka America Pharmaceutical <i>Rockville, MD</i> | | Phase I (800) 562-3974 |
| OPB-51602 | Otsuka America Pharmaceutical <i>Rockville, MD</i> | | Phase I (800) 562-3974 |
| OVI-237 | OncoVista <i>San Antonio, TX</i> | | Phase II (210) 677-6000 |
| oxaliplatin liposomal | Mebiopharm <i>Tokyo, Japan</i> | | Phase I/II www.mebiopharm.com |
| PBI-05204 | Phoenix Biotechnology <i>San Antonio, TX</i> | | Phase I (877) 593-8945 |
| PF-00562271 | Pfizer <i>New York, NY</i> | | Phase I (860) 732-5156 |
| PF-03084014 | Pfizer <i>New York, NY</i> | | Phase I (860) 732-5156 |
| PF-04554878 | Pfizer <i>New York, NY</i> | | Phase I (860) 732-5156 |
| PF-05212384 (PKI-587) | Pfizer <i>New York, NY</i> | | Phase I (860) 732-5156 |
| PRT062607 | Portola Pharmaceuticals <i>South San Francisco, CA</i> | | Phase I (650) 246-7000 |
| QBI-139 | Quintessence Biosciences <i>Madison, WI</i> | | Phase I (608) 441-2950 |
| SAR153192 (anti-DLL4 mAb) | Regeneron Pharmaceuticals <i>Tarrytown, NY</i> sanofi-aventis <i>Bridgewater, NJ</i> | | Phase I (914) 345-7400 (800) 833-1610 |
| SAR245409 (XL765) | Exelixis <i>South San Francisco, CA</i> sanofi-aventis <i>Bridgewater, NJ</i> | | Phase II (650) 837-7000 (800) 633-1810 |

UNSPECIFIED CANCERS

(DRUGS THAT HAVE POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)

| Product Name | Sponsor | Indication | Development Status |
|--|---|------------|---|
| SAR307746 (REGN910) | Regeneron Pharmaceuticals <i>Tarrytown, NY</i> sanofi-aventis <i>Bridgewater, NJ</i> | | Phase I (914) 345-7400 (800) 833-1610 |
| SB1578 | S*Bio <i>Redwood City, CA</i> | | Phase I (650) 730-2860 |
| tasisulam | Eli Lilly <i>Indianapolis, IN</i> | | Phase II (800) 545-5979 |
| TL32711 | TetraLogic Pharmaceuticals <i>Malvern, PA</i> | | Phase I/II (610) 889-9900 |
| V930/V932 (hTERT cancer vaccine) | Merck <i>Whitehouse Station, NJ</i> Vical <i>San Diego, CA</i> | | Phase I completed (800) 672-6372 (858) 646-1100 |
| VTX-2337 | VentiRx Pharmaceuticals <i>San Diego, CA</i> | | Phase I completed (858) 436-1530 |
| XL999 | Symphony Evolution <i>Rockville, MD</i> | | Phase I www.symphony evolution.com |
| ZYC 300 | Eisai <i>Woodcliff Lake, NJ</i> | | Phase I (888) 422-4743 |

The content of this report has been obtained through industry sources and the Adis "R&D Insight" database based on the latest information. **Report current as of March 18, 2011.** The information may not be comprehensive. For more specific information about a particular product, contact the individual company directly or go to www.clinicaltrials.gov. The entire series of *Medicines in Development* is available on PhRMA's web site.

A publication of PhRMA's Communications & Public Affairs Department. (202) 835-3460

www.phrma.org | www.innovation.org | www.pparx.org | www.buysafedrugs.info

Provided as a Public Service by PhRMA. Founded in 1958 as the Pharmaceutical Manufacturers Association.

Copyright © 2011 by the Pharmaceutical Research and Manufacturers of America. Permission to reprint is awarded if proper credit is given.

actinic keratoses—Roughness and thickening of the skin caused by over-exposure to the sun's ultraviolet rays. It can degenerate into a skin cancer called squamous cell carcinoma.

adenocarcinoma—Malignant tumor derived from a gland or glandular tissue.

adjunctive treatment—An auxiliary treatment that is secondary to the main treatment.

adjuvant—A substance or drug that aids another substance in its action.

allogeneic—Refers to having cell types that are distinct and cause reactions in the immune system.

application submitted—An application for marketing has been submitted by the company to the Food and Drug Administration (FDA).

ascites—Excess fluid in the space between the tissues lining the abdomen and abdominal organs (the peritoneal cavity).

basal cell cancer—Cancer of the lower layers of the skin.

B-cell—A class of white blood cells important to the body's immune system.

biliary—Relating to bile.

carcinoma—A malignant tumor that arises from epithelial tissues, such as skin.

cervical—Relating to the neck of the uterus.

chemoprotection—A therapeutic technique in which bone marrow cells are removed from an individual with cancer and are genetically modified to withstand higher doses of chemotherapy before being returned to the donor.

cholangiocarcinoma—A malignancy of the biliary duct system that may originate in the liver and extrahepatic bile ducts. More than 90 percent are **adenocarcinomas**, and the remainder are squamous cell tumors. Cholangiocarcinomas tend to grow slowly and to infiltrate the walls of the ducts. Each year, approximately 2,500 cases

occur, and the average incidence is 1 case per 100,000 people per year.

cutaneous—Pertaining to the skin.

dysplasia—Abnormal tissue development.

gastric—Of or relating to the stomach.

GISTs—Gastrointestinal stromal tumors are uncommon tumors of the GI tract. Not all GISTs are cancerous; some are benign. Although these cancers can arise anywhere in the GI tract, they occur most often in the stomach (60% to 70%) and less commonly in the small intestine (20% to 30%). The rest are found in the esophagus, large intestine, rectum, and anus. About 80% of people diagnosed with GIST are older than 50. It is slightly more common in men. Blacks are more likely to develop GISTs than whites.

glioblastoma—A fast growing and highly malignant type of brain tumor arising from glial (supporting) cells within the brain. There are about five to 10 new cases per million population per year in the United States, and the cause is unknown.

glioma—A type of brain tumor arising from the supporting glial cells within the brain. Gliomas make up about 60 percent of all primary brain tumors and are frequently malignant.

graft-versus-host disease (GVHD)—A complication in bone marrow transplants where immune system cells attack the transplant recipient's tissues.

head and neck cancer—The term given to a variety of malignant tumors that develop in the mouth, throat, paranasal sinuses, nasal cavity, larynx, and salivary glands. Many authorities also include skin tumors of the face and neck and tumors of the cervical lymph nodes. There are more than half a million survivors of oral, head, and neck cancer living in the United States today.

hematological malignancies—Cancers of the blood or blood-forming tissues, such as **leukemia**, **Hodgkin's** and **non-Hodgkin's lym-**

phomas, AIDS-related malignancies, **multiple myeloma**, myelodysplasia and myeloproliferative disorders.

hepatocellular cancer/carcinoma—A cancer that begins in the liver cells.

hyperuricemia—An abnormally high uric acid level in the blood.

imaging agent—A substance used to enhance x-ray images of organs and spaces in the body.

intraepithelial neoplasia, anal (AIN) & cervical (CIN)—AIN is a consequence of chronic human papillomavirus infection in the anal canal and appears to be driven by high viral loads of human papillomavirus. What is known of its natural history resembles that of cervical intraepithelial neoplasia. **Dysplasia** and cervical intraepithelial neoplasia (CIN) are different terms or names for the same condition—it is a precursor to **cervical cancer**. CIN may be mild, moderate or severe.

Kaposi's sarcoma—A rare, malignant skin tumor that occurs in some AIDS patients. It can be accompanied by fever, enlarged lymph nodes and gastrointestinal problems.

leiomyoma—A benign neoplasm derived from smooth muscle.

leukemia—A form of cancer in which abnormally growing white blood cells are scattered throughout the body and bone marrow. They can take over the marrow and prevent it from making enough normal blood cells (white, red and platelets), leaving the patient highly susceptible to serious infections, anemia and bleeding episodes. The cells can also spill into the blood, infiltrating and interfering with the function of other organs. The four main types of leukemia are: **acute lymphoblastic leukemia (ALL)**, **acute myeloid leukemia (AML)**, **chronic lymphocytic leukemia (CLL)**, and **chronic myeloid leukemia (CML)**. The acute types have a rapid onset, and overwhelming infection or blood loss can cause death. The chronic forms progress much more slowly.

lung cancer—The leading cause of cancer deaths in both men and

women. There are several types of lung cancer, the most common being squamous cell carcinoma, small (oat) cell carcinoma, adenocarcinoma and large cell carcinoma. Each has a different growth pattern and response to treatment. The squamous cell, small cell and large cell types are all strongly associated with tobacco abuse.

lymphoma—Cancers in which the cells of lymphoid tissue, found mainly in the lymph nodes and spleen, multiply unchecked. Lymphomas fall into two categories: Hodgkin disease, characterized by a particular kind of abnormal cell, and **non-Hodgkin lymphomas**, which vary in their malignancy according to the nature and activity of the abnormal cells. **Mantle cell lymphoma** is a type of non-Hodgkin lymphoma.

macroglobulinemia—A disorder in which plasma cells produce an excessive quantity of macroglobulins (large antibodies) that accumulate in the blood. It results from a group of abnormal, cancerous lymphocytes and plasma cells. Men are affected more often than women, and the average age at onset is 65.

mastocytosis—A condition characterized by infiltration of mast cells into the tissues of the body. Mast cells are connective tissue cells which release chemicals including histamine that are very irritating and cause itching, swelling, and fluid leakage from cells.

medullary—Relating to the medulla (any soft marrow-like structure, especially the innermost part) or marrow.

melanoma—A cancer made up of pigmented (usually brown-colored) skin cells anywhere in the body.

mesothelioma—A tumor of the lining of the lung and chest cavity (the pleura).

metastases/metastatic—Areas of secondary cancer that have spread from the primary or original cancer site.

mucositis—The swelling, irritation, and ulceration of the mucosal cells that line the digestive tract. Mucositis

can occur anywhere along the digestive tract from the mouth to the anus. It can be a very troublesome and painful side effect of chemotherapy.

multiple myeloma—A malignant condition of middle to old age, characterized by the uncontrolled proliferation and disordered function of plasma cells in the bone marrow. The condition, which makes the patient particularly prone to infection, is rare, with about three new cases annually per 100,000 population.

myeloablation—A severe form of myelosuppression, a condition in which bone marrow activity is decreased, resulting in fewer red blood cells, white blood cells, and platelets. It is a side effect of some cancer treatments.

myelodysplastic syndromes (MDS)—Blood disorders that ultimately are fatal. Patients usually succumb to infections or bleeding. The term “preleukemia” has been used to describe these disorders.

neoadjuvant therapy—Chemotherapy, radiation therapy, or hormone therapy given before the primary or main treatment. Neoadjuvant therapy, like chemotherapy and radiation therapy, is often given before surgery to reduce the size of a tumor or to make surgery less complicated.

neuroblastoma—A tumor of the adrenal glands or sympathetic nervous system (the part of the nervous system responsible for certain automatic body functions, such as the control of heart rate). Neuroblastomas are the most common extracranial (outside the skull) solid tumors of childhood.

osteosarcoma—Cancer of the bone that occurs predominantly in adolescents and young adults. It accounts for 5 percent of cancer in children

peritoneal—Relating to the peritoneum, the membrane that lines the abdominal cavity and covers most of the abdominal organs.

Phase 0—First-in-human trials conducted in accordance with FDA’s 2006 guidance on exploratory Investigational New Drug (IND) studies designed to speed up development of promising drugs by establishing very early on whether the agent behaves in human subjects as was anticipated from preclinical studies.

Phase I—Safety testing and pharmacological profiling of new drugs in small numbers of humans.

Phase II—Effectiveness testing and identification of side effects of new drugs in humans.

Phase III—Extensive clinical trials in humans to verify effectiveness and monitor adverse reactions of new drugs.

prolactinoma—A noncancerous pituitary tumor that produces a hormone called prolactin, which results in too much prolactin in the blood.

refractory—Resistant to treatment or cure.

sarcoma—A malignant tumor that arises from deep body tissues, such as muscle, bone or fibrous tissue.

T-cell—One of two main classes of white blood cells called lymphocytes, which are important to the body’s disease-fighting immune system.

thrombocytopenia—A reduction in the number of platelet cells in the blood, which causes a tendency to bleed, especially from the smaller blood vessels.

thymoma—Although rare, thymomas are the most common tumor of the thymus, a small organ located in the upper chest just below the neck that produces certain types of white blood cells (lymphocytes) before birth and during childhood. Thymomas arise from thymic epithelial cells, which make up the covering of the thymus. Up to 40 percent of thymomas are invasive. They affect men and women equally and are usually diagnosed between the ages of 40 and 60. Thymomas are uncommon in children.

unresectable—Unable to be removed (resected) by surgery.

SELECTED FACTS ABOUT CANCER IN THE UNITED STATES

Overview¹

- In 2010, more than 1.5 million new cancer cases were expected to be diagnosed. The National Cancer Institute estimates that approximately 11.4 million Americans with a history of cancer were alive in January 2006. The 5-year relative survival rate for all cancers diagnosed between 1999 and 2005 is 68 percent, up from 50 percent in the mid-70s.
- Men have a little less than a 1 in 2 lifetime risk of developing cancer, and for women, the risk is a little more than 1 in 3. About 78 percent of all cancers are diagnosed in people ages 55 and older.
- Scientific evidence suggests that about one-third of the cancer deaths expected this year will be related to overweight or obesity, physical inactivity, and nutrition, and thus could be prevented.
- Cancer is the second leading cause of death by disease—1 of every 4 deaths—in the United States, exceeded only by heart disease. This year, an estimated 569,490 are expected to die of cancer, more than 1,500 people a day.

Costs¹

- The National Institutes of Health estimates overall costs for cancer in 2010 at \$263.8 billion: \$102.8 billion for direct medical costs (total of all health expenditures); \$20.9 billion for indirect morbidity costs (e.g., cost of lost productivity due to illness); and \$140.1 billion for indirect mortality costs (cost of lost productivity due to premature death).

Pain

- **Pain**, which can be caused by the disease itself or by treatments, is common in people with cancer, although not all people with cancer will experience pain. Approximately 30 percent to 50 percent of people with cancer experience pain while undergoing treatment, and 70 percent to 90 percent of people with advanced cancer experience pain.²
- Breakthrough **cancer pain** is common among people with cancer-related pain. It occurs in 50 percent – 90 percent of oncology inpatient settings, 89 percent of home care and inpatient hospice settings, 74 percent of U.S. pain clinics, and 33 percent of community-based oncology practices.³
- Breakthrough **cancer pain** is associated with higher costs for people who suffer from it compared to those who do not, for example, higher hospitalization rates (36.9 percent compared to 22.5 percent) and higher estimated annual costs of care (\$1.7 million compared to \$192,000).³

SELECTED FACTS ABOUT CANCER IN THE UNITED STATES

New Cancer Cases/Deaths¹

| Cancer Type | Estimated 2010 New Cases | Estimated 2010 Deaths |
|----------------------------|--------------------------|-----------------------|
| All Sites | 1,529,560 | 569,490 |
| Male | 789,620 | 299,200 |
| Female | 739,940 | 270,290 |
| Acute Lymphocytic Leukemia | 5,330 | 1,420 |
| Male | 3,150 | 790 |
| Female | 2,180 | 630 |
| Acute Myeloid Leukemia | 12,330 | 8,950 |
| Male | 6,590 | 5,280 |
| Female | 5,740 | 3,670 |

SELECTED FACTS ABOUT CANCER IN THE UNITED STATES

New Cancer Cases/Deaths¹ (continued)

| Cancer Type | Estimated 2010 New Cases | Estimated 2010 Deaths |
|---|--------------------------|-----------------------|
| Bladder Cancer | 70,530 | 14,680 |
| Male | 52,760 | 10,410 |
| Female | 17,770 | 4,270 |
| Bone Cancer (and joints) | 2,650 | 1,460 |
| Male | 1,530 | 830 |
| Female | 1,120 | 630 |
| Brain Cancer (and other nervous system) | 22,020 | 13,140 |
| Male | 11,980 | 7,420 |
| Female | 10,040 | 5,720 |
| Breast Cancer | 209,060 | 40,230 |
| Male | 1,970 | 390 |
| Female | 207,090 | 39,840 |
| Cervical Cancer/Uterine Cancer | 55,670 | 12,160 |
| Male | — | — |
| Female | 55,670 | 12,160 |
| Chronic Lymphocytic Leukemia | 14,990 | 4,390 |
| Male | 8,870 | 2,650 |
| Female | 6,120 | 1,740 |
| Chronic Myeloid Leukemia | 4,870 | 440 |
| Male | 2,800 | 190 |
| Female | 2,070 | 250 |
| Colorectal Cancer | 142,570 | 51,370 |
| Male | 72,090 | 26,580 |
| Female | 70,480 | 24,790 |
| Esophageal Cancer | 16,640 | 14,500 |
| Male | 13,130 | 11,650 |
| Female | 3,510 | 2,850 |
| Kidney Cancer (and renal pelvis) | 58,240 | 13,040 |
| Male | 35,370 | 8,210 |
| Female | 22,870 | 4,830 |
| Leukemia (all types) | 43,050 | 21,840 |
| Male | 24,690 | 12,660 |
| Female | 18,360 | 9,180 |
| Liver Cancer | 24,120 | 18,910 |
| Male | 17,430 | 12,720 |
| Female | 6,690 | 6,190 |

SELECTED FACTS ABOUT CANCER IN THE UNITED STATES

New Cancer Cases/Deaths¹ (continued)

| Cancer Type | Estimated 2010 New Cases | Estimated 2010 Deaths |
|----------------------------|--------------------------|-----------------------|
| Lung Cancer (and bronchus) | 222,520 | 157,300 |
| Male | 116,750 | 86,220 |
| Female | 105,770 | 71,080 |
| Lymphoma (all types) | 74,030 | 21,530 |
| Male | 40,050 | 11,450 |
| Female | 33,980 | 10,080 |
| Lymphoma (non-Hodgkin's) | 65,540 | 20,210 |
| Male | 35,380 | 10,710 |
| Female | 30,160 | 9,500 |
| Melanoma-Skin Cancer | 68,130 | 8,700 |
| Male | 38,870 | 5,670 |
| Female | 29,260 | 3,030 |
| Multiple Myeloma | 20,180 | 10,650 |
| Male | 11,170 | 5,760 |
| Female | 9,010 | 4,890 |
| Ovarian Cancer | 21,880 | 13,850 |
| Male | — | — |
| Female | 21,880 | 13,850 |
| Pancreatic Cancer | 43,140 | 36,800 |
| Male | 21,370 | 18,770 |
| Female | 21,770 | 18,030 |
| Prostate Cancer | 217,730 | 32,050 |
| Male | 217,730 | 32,050 |
| Female | — | — |
| Stomach Cancer | 21,000 | 10,570 |
| Male | 12,730 | 6,350 |
| Female | 8,270 | 4,220 |

Sources:

1. *Cancer Facts & Figures 2010*, American Cancer Society (www.cancer.org)
2. Lesage P. and Portenoy RK. Cancer Control; *Journal of the Moffitt Cancer Center* 1999;6(2):136-145.
3. American Pain Foundation (www.painfoundation.org)

THE DRUG DISCOVERY, DEVELOPMENT AND APPROVAL PROCESS

It takes 10-15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000 compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved.

| Discovery/ Preclinical Testing | | Clinical Trials | | | FDA | Phase IV |
|-----------------------------------|--|--------------------------------------|--|--|--------------------------------|---|
| | | Phase I | Phase II | Phase III | | |
| Years | 6.5 | 1.5 | 2 | 3.5 | 1.5 | |
| Test Population | Laboratory and animal studies | 20 to 100 healthy volunteers | 100 to 500 patient volunteers | 1,000 to 5,000 patient volunteers | Review process/ approval | Additional post- marketing testing required by FDA |
| Purpose | Assess safety, biological activity and formulations | Determine safety and dosage | Evaluate effectiveness, look for side effects | Confirm effectiveness, monitor adverse reactions from long-term use | | |
| Success Rate | 5,000 compounds evaluated | 5 enter trials | | | 1 approved | |

THE DRUG DEVELOPMENT AND APPROVAL PROCESS

The U.S. system of new drug approvals is perhaps the most rigorous in the world.

It takes 10-15 years, on average, for an experimental drug to travel from lab to U.S. patients, according to the Tufts Center for the Study of Drug Development, based on drugs approved from 1994 through 1998. Only five in 5,000 compounds that enter preclinical testing make it to human testing. And only one of those five is approved for sale.

On average, it costs a company \$1.3 billion to get one new medicine from the laboratory to U.S. patients, according to a 2007 study by the Tufts Center for the Study of Drug Development.

Once a new compound has been identified in the laboratory, medicines are developed as follows:

Preclinical Testing. A pharmaceutical company conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the compound is evaluated for safety.

Investigational New Drug Application (IND). After completing preclinical testing, a company files an IND with the U.S. Food and Drug Administration (FDA) to begin to test the drug in people. The IND shows results of previous experiments; how, where and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. All clinical trials must be reviewed and approved by the Institutional Review Board (IRB) where the trials will be conducted. Progress reports on clinical trials must be submitted at least annually to FDA and the IRB.

Clinical Trials, Phase I. These tests usually involve

about 20 to 100 normal, healthy volunteers. The tests study a drug's safety profile, including the safe dosage range. The studies also determine how a drug is absorbed, distributed, metabolized, and excreted as well as the duration of its action.

Clinical Trials, Phase II. In this phase, controlled trials of approximately 100 to 500 volunteer patients (people with the disease) assess a drug's effectiveness and determine the early side effect profile.

Clinical Trials, Phase III. This phase usually involves 1,000 to 5,000 patients in clinics and hospitals. Physicians monitor patients closely to confirm efficacy and identify adverse events.

New Drug Application (NDA)/Biologic License Application (BLA). Following the completion of all three phases of clinical trials, a company analyzes all of the data and files an NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness. The applications contain all of the scientific information that the company has gathered. Applications typically run 100,000 pages or more. The average review time for the 25 new therapeutics approved by the FDA in 2009 was 13.3 months.

Approval. Once FDA approves an NDA or BLA, the new medicine becomes available for physicians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials (Phase IV) to evaluate long-term effects.

Discovering and developing safe and effective new medicines is a long, difficult, and expensive process. Pharmaceutical companies invested an estimated \$67.4 billion in research and development in 2010.

TRACKING THE BIOPHARMACEUTICAL RESEARCH PIPELINE

Today, more than 3,000 new medicines are in development in the United States. Many of these potential new medicines will fail in clinical trials, but some may represent tomorrow's new treatments. Bringing each new medicine to patients will require, on average, 10 to 15 years of testing and review.

PhRMA publishes several reports that track the biopharmaceutical research pipeline for many diseases, including the leading causes of death among Americans—heart disease, cancer, and stroke. The reports include medicines currently in clinical trials or at the U.S. Food and Drug Administration (FDA) for review. Below is a summary of our most popular reports.

- **Cancer**—There are few things that cause patients more fear and uncertainty as a cancer diagnosis. Yet today—because of a steady stream of new and improved medicines and treatments—cancer can increasingly be managed and even beaten. *The 2010 report found 887 medicines in the pipeline.*
- **Heart Disease and Stroke**—Keeping up the momentum of drug discovery that has helped cut deaths from heart disease and stroke in half in the past three decades, biopharmaceutical companies are working on new medicines for these diseases. *The 2011 report found 299 medicines in the pipeline.*
- **Diabetes**—Approximately 4,110 people are diagnosed with diabetes every day. To help fight this disease, pharmaceutical and biotechnology researchers are working on new medicines to treat it and related conditions. *The 2010 report found 235 medicines in the pipeline.*
- **Mental Illnesses**—Pharmaceutical and biotechnology researchers are testing many new medicines to help the more than 450 million people worldwide who suffer from some form of mental illness. *The 2010 report found 313 medicines in the pipeline.*
- **Biotechnology**—Millions of people have already benefited from medicines and vaccines developed through biotechnology, and a new report offers hope that many more will benefit in the future. *The 2008 report found 633 medicines in the pipeline.*
- **Children**—Biopharmaceutical researchers are testing medicines to meet the special needs of children. These medicines offer hope that the significant improvements achieved in children's health over the past few decades will continue and even accelerate. *The 2010 report found 234 medicines in the pipeline.*
- **Infectious Diseases**—Throughout history, infectious diseases have taken a devastating toll on the lives and well-being of people around the world. Today, vaccines and antibiotics have proven to be effective treatments in many cases, but infectious diseases still pose a very serious threat to patients. Infectious diseases may never be eradicated. But, new knowledge, new technologies, and a huge commitment of resources by America's biopharmaceutical research companies and the government can help meet the continuing—and ever-changing—threat from infectious diseases. *The 2010 report found 395 medicines in the pipeline.*



New Medicines. New Hope.®

Pharmaceutical Research and Manufacturers of America
950 F Street, NW
Washington, DC 20004